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Abstract
Aminoglycoside related nephrotoxicicty in cystic fibrosis mil
MohamedAl-Aloul
The last few years witnessed increasing interest in renal function of CF patients.
The CFTRis expressedin all parts of the kidney, but traditional views were that,
apart from nephrolithiasis, no specific pathology resulted and deranged renal
function wasrare.
The P. aeruginosa Liverpool Epidemic Strain (LES) is endemic in our clinic and often
only predictably sensitive to aminoglycosides (tobramycin) and polymyxins
(colistin), both potentially nephrotoxic agents. Several reports of drug-related acute
renal failure in CF were cited. | present our own case series, the first to be
published in the adult CF literature: all were related to IV aminoglycoside therapy.
Subsequently, in a cross sectional survey of 80 consecutive stable patients
attending the outpatient clinic, | identified a high level (42%) of previously
unrecognised background renal impairment using CCl as an estimate of GFR from
24-hour timed urine collections. This was significantly associated with lifetime
exposure to IV aminoglicosides. IV colistin, at recommended doses, did not appear
to be independently nephrotoxic but potentiated the cumulative renal injury of
aminoglycosides in combination. Due to practical shortfalls with urine collections,
use of formulae to estimate GFR is advocated. Several are employed in chapter 6;
they correlate to varying degrees with CCl measurement but uniformly tended to
overestimate GFR in the subgroup with impaired renal function, limiting their
practical utility as a screening tool for renal dysfunction in this patient group.
The primary toxic effect of aminoglycosides and polymixins is on the proximal
tubular epithelium. Release of tubular enzymes and proteins in urine is a sensitive
method of quantifying acute subclinical structural and functional changes due to
drug-induced tubular injury and monitoring its recovery. Using these assays | was
able to confirm that frequent aminglycoside exposure, without sufficient time for
complete tubular recovery, is one plausible mechanism underlying the cumulative
toxicity documentedearlier. In contrast patients whose tubules recover fully before
subsequent drug challenge are likely to handle re-exposure with less incremental
injury. “Aminoglycoside-holidays” are proposed but the limited antibiotic choice
available to treat LES creates a need for other renal sparing startegies. TOBI, a
nebulised formulation of tobramycin delivers the drug directly to the site of
infection whilst minimising systemic bioavailabilty. FOM, a unique antibiotic with
antipseudomonal properties, is shown in animal models to protect against
aminoglycoside induced disruption of the proximal tubular lysosomal system.
Compared with IV TOB and COL combination in randomised crossovertrials, | was
able to demonstrate similar clinical responses in the treatment of acute pulmonary
exacerbations with a combination of either TOBI and IV COL or IV TOB, COL and
FOM with the added benefit of attenuated acute renal injury, reflected in lower
levels of enzymuria and proteinuria. The potential for long term nephroprotection
with these approaches needs further examination with longitudinal multicentre
trials employing sensitive and specific renal tubular assays.
CHAPTER ONE
Introduction
1.1 CYSTIC FIBROSIS (CF)
Cystic fibrosis (CF) is an autosomal recessive disorder and the most common
inherited lethal disease of Caucasian populations, with an incidence of about 1 in
2500live births and a carrier frequency of 1 in 25 (Bye et al, 1994). The disease
affects approximately 30,000 individuals in the U.S. and 60,000 individuals
worldwide (Gibson et al, 2003a). The clinical picture is dominated by disease in the
respiratory, gastrointestinal and reproductive tracts. The main characteristics of CF
are recurrent bacterial infections in the lower respiratory tract, malabsorption due
to exocrine pancreatic insufficiency, and male infertility due to absence or stenosis
of the vas deferens (Koch and Hoiby, 1993). Pulmonary disease is responsible for
most of the morbidity in CF and is the cause of death in over 90% of patients
(Davies, 2002). The quality oflife and life expectancy of patients with CF have been
greatly enhanced over past decades due to better notions of symptomatic
treatment strategies and as a result, patients with the disease now oftenlive
beyond the third decade. However, life with CF is still shadowed by the prospect of
premature death due to respiratory failure resulting from recurrent bacterial
infections.
1.2 THE MOLECULARBASIS OF CF
Cystic fibrosis is caused by mutations in the CF gene which has been identified,
cloned and sequenced, andits protein product has been analysed (Kerem et al,
1989; Riordan et al, 1989; Rommensetal, 1989; Zielenski et al, 1991). The geneis
250 kb long, identified in the q21-31 region of the long arm of chromosome7, and
encodes a multifunctional transmembraneprotein of 165-kD containing 1480 amino
acids termed the cystic fibrosis transmembrane conductance regulator (CFTR) and
expressed in a variety of secretory as well absorptive epithelia including renal
tubules (Rommensetal, 1989; Berger et al, 1991; Riordan, 1993).
In the apical plasma membrane, CFTR is part of a multiprotein assembly consisting
of two transmembrane (anchoring) domains (TMDs) and two nucleotide-binding
domains (NBDs), separated by a larger regulator domain (RD) containing multiple
phosphorylation sites (figure 1.6.1) (Riordan, 1993; Foskett, 1998). It is now
established that CFTR functions as a 3’5’-cyclic monophosphate (cAMP)-activated CI
channel that modulates a series of intracellular functions by a complex process
involving both phosphorylation by 3’5’cAMP-dependentprotein kinase A (PKA) and
the interactions of ATP with the nucleotide binding domain (Anderson and Welsh,
1992; Morales et al, 1999). The CFTRalso has a voltage dependent low conductance
for Cl (9pS)(Bergeret al, 1991).
The carboxyl terminal (TRL) of CFTR is anchored in the cytoskeleton, in close
proximity to a number of important proteins such as signal transduction proteins
and other ion channels (Riordan, 1993; Foskett, 1998; Roweet al, 2005). On one
hand, these associated proteins influence CFTR functions and are potential
modifiers of the CF phenotype which varies substantially among patients with the
same mutations in CFTR. Reciprocally, and through interaction with these
neighbouring protein complexes, CFTR plays an important role in intracellular
vesicular acidification (Barasch et al, 1991), exocytosis, protein processing and
traffic (Morris and Frizzell, 1994), secretion of ATP (Winter et al, 1994), down
regulation of transepithelial sodium transport through the epithelial Na channel
(ENaC), regulation of calcium-activated chloride channels and potassium channels
[the outwardly rectifying Cl channel (ORCC) and the renal secretory K channel
(ROMK-2)] (Schwiebert et al, 1995; Stutts et al, 1995; Ismailov et al, 1996;
McNicholaset al, 1996).
Over 1000 mutationsin this gene have been described so far. These mutations can
be classified on the basis of the mechanism by which they are believed to cause
disease into six classes: absence of synthesis (class I), defective protein maturation
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and premature degradation (class II), disordered regulation (class Ill), defective
chloride conductance (class IV), reduced number of CFTR transcripts due to a
promoteror splicing abnormality (class V), and defective CFTR stability at the cell
surface (class VI) (Rowe et al, 2005). The most common mutation worldwide,
termed AF508, is categorised as a class Il defect. CFTR with the AF508 mutation
lacks a phenylalanine residue at position 508. The defective protein is rapidly
recognised as misfolded and is degraded shortly after synthesis before it can reach
its site of action at the cell surface. It is present in approximately 70% of defective
CFTRalleles and in 90% of patients with CF in the United States (Rowe et al, 2005),
but its frequency varies between ethnic groups from 30% in Ashkenazi Israeli
patients to 88% of Danish (Koch and Hoiby, 1993).
With the description of so many varied mutations in CFTR, attention was drawn to
the relation between genotype and the phenotypic manifestations of the disease.
Generally, class I-IIl mutations, which are the most common,are associated with
pancreatic insufficiency, whereas patients with rarer class IV-VI mutations typically
do not haveinsufficiency (Ratjen and Doring, 2003). Although several mutations are
known to be associated with less severe pancreatic disease, the association of
genotype with the severity of lung disease is less clear. No relation between
genotype and the course of lung disease was found in a study that included eight
CFTR mutations occurring in 72% of patients with CF from 14 countries. The A455E
mutation (class IV), a common mutation causing CF in the Netherlands, has been
found to correlate with mild pulmonary disease, probably due to residual CFTRion-
channelactivity (Gan et al, 1995). In Denmark, more aggressive pulmonary disease
wasfound in patients who were homozygousfor AF508 than in patients who were
compound — i.e., who had AF508 on one chromosomeand another rarer mutation
on the other (Johansen et al, 1991). In a retrospective cohort study that included
approximately 18,000 patients using the US Cystic Fibrosis Foundation National
Registry, the mortality rates for the 11 most common genotypes heterozygousfor
AF508 was compared with those homozygousfor AF508. Distinct genetic subgroups
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were found to be associated with mild clinical manifestations and low mortality
(McKoneet al, 2003). However, substantial differencesin clinical severity are often
observed in patients with the same CFTR mutations. For example, the course of
pulmonary disease often differs strikingly among CF siblings, and the progression of
disease is highly dependent on treatment, which can vary from one CF centre to
another (Koch and Hoiby, 1993). The wide phenotypic variation in patients
homozygous for AF508, and differences in chloride conductance between
monozygous and dizygous twins, suggest that environmental factors and/or genes
other than CFTR, modify progression and severity of the disease (Ratjen and Doring,
2003).
There is widespread agreement that defective ion transport, salt homeostasis, or
both, due to the absence of normal functioning CFTR are intimately linked to organ
damagein CF. The precise molecular mechanism, however, is unknown. Different
models have been proposed to explain the salt and fluid metabolism abnormalities
observed in the CF lung (Gibson et al, 2003a; Roweetal, 2005). In the “low-volume
model”, the absence of CFTR leads to overactivity of sodium absorption through
epithelial sodium channels (ENaC) and chloride absorption continues through non-
CFTR pathways. The resulting sodium and water hyperabsorption causes the
dehydration of airway surfaces, defective mucociliary transport and accumulation
of thick mucus leading to airway obstruction. Similar mechanisms explain the
increase in sweat Cl concentration and thick secretions in the bowel lumen and
the pancreatic ducts result in intestinal obstruction and pancreatic insufficiency
(Davis et al, 1996). In the “high-salt model”, the absence of CFTR restricts
reabsorption of chloride, the transepithelial potential difference becomes
hyperpolarised and there is elevated amountofsalt in the airway-surface liquid. It
has been suggested that the raised luminal salt concentration would inactivate
endogenous antimicrobial peptides and thereby predispose patients to bacterial
infections (Smith et al, 1996). Regardless of which model better explains the
pulmonary complications in CF, there is a strong consensus that the airways lack
the normal ability to secrete chloride through CFTR (Roweetal, 2005).
1.3 CFTR IN THE KIDNEY
In mammals, the kidneys are responsible for the maintenance of extracellular
sodium chloride (NaCl) concentration which in turn regulates the extracellular fluid
volume (ECFV) and blood pressure. Na’ and CI are reabsorbed along the nephron,
reaching over 99% of the filtered load under low salt diets. Cl, the predominant
anion in the glomerular ultrafiltrate, is reabsorbed along the nephron either by
trans- or para-cellular pathways (Berry and Rector, 1991). Trans-cellular transport of
Cl involves several membraneproteins and channels including the CFTR.
In spite of the injury in several organs, patients with CF do not develop major renal
dysfunction although they have reduced renal excretion of NaCl and decreased
capacity to dilute and concentrate urine (Stenvinkel et al, 1991; Donckerwolcke et
al, 1992). These patients also have an enhanced excretion of penicillins and
aminoglycosidesin urine (Strandvik et al, 1989; Bates et al, 1997). The impairedsalt
reabsorption by the kidney could be related to changes in ECFV caused by excessive
losses of NaCl in sweat and faeces. However, decreased NaCl renal excretion might
also result from a primary defect in renal tubular function caused by mutationsin
CFTR.
Several studies have demonstrated the presence of CFTR in the kidney, and its
mRNA has been detected in all nephron segments by reverse transcription PCR
(Riordan et al, 1989; Morales et al, 1996). CFTR was detected in proximal tubule,
thin limb of Henle’s loop, the lumenal membraneofdistal tubule, cortical collecting
duct, and the inner medullary collecting duct by immunocytochemistry (Crawford et
al, 1991). Patch clamp analysis has also confirmed its presence in proximal and
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distal tubules and in cortical and inner medullary collecting ducts (Husted et al,
1995; Letz and Korbmacher, 1997). CFTR is highly expressed during the early stages
of kidney development. At gestational age 12 weeks kidney CFTRis confined to the
apical membraneof the ureteric bud-derived collecting tubules, and its presence in
proximal tubule cytoplasmis first seen at 16 weeks gestation (Devuyst et al, 1996).
1.3.1 CFTR in proximal tubule
Although immunolocalisation studies indicate an apical expression of CFTR in the
proximal tubules (Crawford et al, 1991), patch clamp studies localise its activity at
the basolateral membrane (Rubera et al, 1998; Simpsonet al, 2005). The function of
CFTR in the proximal tubules is uncertain because the reabsorption of NaCl in this
segment of the nephron is increased in CF, rather than decreased as would be
expected if CFTR mediates Cl absorption (Stenvinkel et al, 1991; Bates et al, 1997).
The increase in CF kidney Cl reabsorption could be associated with the reduced
ECFV or with a reduced NaCl reabsorption in the thick ascending limb of Henle and
distal tubule, both found in CF (Strandvik et al, 1989; Donckerwolckeet al, 1992).
On the other hand, in CF the defective CFTR channel causes an increasein penicillin
and aminoglycosides excretion in the proximal tubule. One hypothesis for this
phenotypeis that the abnormal CFTR decreases Cl reabsorption, which increases Cl
in the tubular lumen. This Cl will move into the cell in exchange for those drugs,
which increases their clearance (Woodlandetal, 1998).
1.3.2 CFTR in Henle’s loop and distal nephron segments
The mRNA for CFTR wasfoundin the thin ascending limb of Henle’s loop, but no
protein was identified in this nephron segment by immunolocalisation or patch
clamp studies (Crawford et al, 1991; Devuyst et al, 1996). The CFTR protein has not
been detected in the thick ascending limb of Henle’s loop by immunocytochemistry,
although in patch clamp studies a Cl channel with a low conductance (9pS),
dependent on ATP and Mg””wasfoundin the basolateral membrane(Bergeretal,
1991). This channel was nominated pseudo CFTR,sinceit is still functional in CFTR
knockout mice (Marvaoetal, 1998).
Distal convoluted tubule CFTR was detected by immunolocalisation and patch
clamp studies in the apical membrane (Rubera et al, 1998; Barriere et al, 2003).
Probably Cl is secreted into the luminal fluid through CFTR in response to the
electrochemical gradient generated by the Na‘/Cl co-transporter. CFTR in this
segment may also facilitate HCO3 secretion by mediating the recycling of CI
through the Cl/HCO3 exchanger in the apical membrane(Tauc et al, 1996; Rubera
et al, 1999). CFTR protein was not found in the collecting tubule, in the a and B
intercalated cells of collecting ducts or in the outer medullary collecting duct
(OMCD) (Crawford et al, 1991; Todd-Turla et al, 1996).
1.3.3 CFTR in collecting ducts
In cortical collecting ducts (CCD) the CFTR protein was only identified in the apical
membrane of the principal cells (Huber et al, 1998; Bens et al, 2001). There is
experimental evidence that Cl absorption in this nephron segmentis through the
paracellular pathway following the electrochemical gradient (Koeppen and Stanton,
1992). However, depending on the electrochemical driving force for Cl movement
across the apical membrane CFTR channel, this ion could either be absorbed or
secreted (Ling et al, 1994). This Cl movement is dependent on Na” absorption
through the ENaC channel and may be controlled by hormoneslike aldosterone and
arginine-vasopressin (Duong Van Huyenetal, 1998).
In the inner medullary collecting duct (IMCD) CFTR plays an intriguing role. The CFTR
channel is expressed at the apical membrane in this nephron segment, but an
alternative splice form of this molecule, the TNR-CFTR wasalso found (Moraleset
al, 1996). Electrophysiological studies support the view that CI secretion through
the CFTR follows the electrochemical driving force across the apical membrane
(Husted et al, 1995; Kizer et al, 1995). The Cl secretion occurs by a two step
process, first involving the uptake of Cl across the basolateral membrane by CI
/HCO3 exchange and Na‘/K*/2CI co-transport, then the efflux of Cl across the
apical membrane through CFTR channel (Rocha and Kudo, 1990; Kizer et al, 1995;
Moyer et al, 1995; Letz and Korbmacher, 1997). Arginine vasopressin (AVP)
stimulates Cl secretion in IMCD by increasing 3’5’-cAMP whichactivates PKA which
in turn activates CFTR channel (Moyeret al, 1995). The role of AVP on CIsecretion
may be related to the fact that Na’ secretionfollows that of CI, inducing natriuresis
and chloruresis to maintain a normal plasma osmolality during dehydration, as
observedin vivo in rats (Luke, 1973).
1.3.4 TNR-CFTR, the renal splice variant of CFTR
TNR-CFTR, a splice variant isoform of CFTR geneis associated with specific small
endosomal populations highly expressed in the renal medulla (Moraleset al, 1996).
Functional studies with TNR-CFTR, expressed in Xenopus oocytes or mammalian
cells, showed cAMP-dependantsingle Cl channel properties like those of the wild
type CFTR, but with lowerefficiency (Morales et al, 1996). In medullary collecting
ducts the TNR-CFTR protein and mRNAexpression is present during embryoniclife,
increasing during fetal kidney development and reaching the highest level at birth
(Devuyst et al, 1996). The specific function of the TNR-CFTR is not clear and does
not seem to be related to Cl secretion. Because it is found in abundance in
intracellular vesicles in the cytoplasmic compartment, it may be involved in
vesicular trafficking.
1.3.5 CFTR and polycystic kidney disease (PKD)
CFTR expression and chloride channel function is normal in PKD, an autosomal
dominant genetic disease (Hanaoka et al, 1996; Sullivan et al, 1998). This renal
disorder is characterised by the presence of multiple epithelial cysts with epithelial
cell proliferation and apical fluid secretion. The cyst enlargement in PKD kidneyis
thought to involve inappropriate polarized secretion of Na’ ions into the tubule
lumen due to the mispolarisation of the (Na’ + K")-ATPase pumpin the cyst apical
membrane (Wilson, 1997). Na’ and CI contents in cyst fluid are abnormally high,
and addition of cAMPto PKDcyst epithelia in culture increases fluid secretion and
ATPrelease into the cyst fluid. These findings could be due to the CFTR,sinceit is
well knownthat this channel transports both CI and ATP (Sullivan et al, 1998) and
suggest involvementof CFTR in PKD cyst fluid secretion and enlargement.
1.3.6 CFTR and other conductances
Cl transport by CFTR in renal epithelia represents a high-energy expenditure, since
this channel requires ATP hydrolysis (Winter et al, 1994) and its conductanceis too
low (9pS) to producefast absorptive or secretive fluxes. One possible role for CFTR
in the kidneyis the activation or inhibition of other channels like ORCC, ENaC and
ROMK2 (Schwiebert et al, 1995; Ismailov et al, 1996; Morris, 1999; Wang, 1999). It
has also been shown that AVP produces an increase of Cl secretion due to
transcriptional enhancementin the expression of CFTR and other transportersin rat
cortical collecting duct cells (Djelidi et al, 1999).
Recent studies form Morales’ group showedthat in homozygous Brattlebororats, a
strain of Long-Evansrats carrying an autosomal recessive mutation that results in a
deficiency of AVP secretion in the plasma, the expression of CFTR mRNA waslowin
the renal cortex and medulla but returned to normal after AVP reposition. The
mRNA of CFTR was increased in the medulla of dehydrated Wistar rats and no
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variation was observed in the cortex. The modulation of CFTR by the main hormone
involved in the regulation of fluid osmolality suggests that this Cl channel plays a
role in ECFV regulation (Morales et al, 2001).
In conclusion, the studies discussed above show the importance of the CFTR
channelin the kidney. Besidesits function in Cl transport, CFTR modulatesdifferent
epithelial conductances, such as channels for sodium (ENaC), potassium (ROMK2)
and chloride (ORCC), probably by mediating ATP transport. Although very well
studied in other organs, the function of CFTR is not fully understood in the kidney
and further studies are crucial to understandits role in renal physiology.
1.4 CYSTIC FIBROSIS AND RENALDISEASE
As mentioned above, although the CFTR geneis expressed in all nephron segments
(Morales et al, 2000), clinically significant primary renal disease, with perhaps the
exception of nephrocalcinosis, is not a recognised feature of CF. However, patients
with CF are at risk of developing secondary renal disease either in association with
chronic bronchial sepsis or as a complication of other organ involvement, for
example pancreatic disease resulting in diabetes or, more commonly,as a result of
nephrotoxic medications. As the prognosis of patients with CF improves, renal
complications may become moreprevalent and assume greater importance.
1.4.1 Nephrocalcinosis and nephrolithiasis
CF is associated with an increased risk of nephrocalcinosis and nephrolithiasis. In an
autopsy study of 38 patients with CF, microscopic nephrocalcinosis was presentin
35, including one still-born infant and two neonates(Katz et al, 1988). The incidence
of nephrolithiasis in CF ranges from 3% to 6.3% (Strandvik and Hjelte, 1993;
Chidekel and Dolan, 1996; Matthewset al, 1996; Hoppeet al, 1998; Perez-Brayfield
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et al, 2002; Gibney and Goldfarb, 2003) compared to 1-2% in age-matched controls
without CF (Gibney and Goldfarb, 2003). The majority of renal stones are composed
of calcium oxalate. In a study of 13 CF patients with renal stones, patients presented
at a mean age of 27 years, with flank pain as the presenting symptom in 69% of
cases (Perez-Brayfield et al, 2002).
It is tempting to speculate that the genetic defect in the CFTR protein causes
nephrocalcinosis/nephrolithiasis, particularly since Dent’s disease, an X-linked
proximal renal tubular disorder characterised by hypercalciuria, nephrocalcinosis,
nephrolithiasis and low molecular weight proteinuria, has now beenascribed to a
renal specific Cl channel defect (Lloyd et al, 1996). However, hypercalciuria is not a
universal finding in patients with CF, which implies that stone formation is caused
by factors other than the underlying genetic defect (Matthews et al, 1996;
Gutknecht, 2001). Such factors include low urine volume, hypercalciuria (which is
exacerbated by furosemide therapy, treatment with steroids and prolonged periods
of immobilisation), hypocitraturia (von der Heiden et al, 2003), hyperoxaluria and
hyperuricosuria (Turner et al, 2000; Perez-Brayfield et al, 2002; Terribile et al, 2006).
The data regarding calcium and urate secretion are conflicting. Some authors report
that hypocalciuria is protective against nephrolithiasis in CF patients (Bohles and
Michalk, 1982) and suggest that calcium supplements, given for example for CF-
associated low bone mineral density, may increase the risk of stone formation. A
greater degree of consensus exists for hyperoxaluria and hypocitraturia as risk
factors for renal stones. Hyperoxaluria is often alimentary in origin and is associated
with pancreatic insufficiency and fatty acid malabsorption (Hoppeet al, 2005). It is
aggravated by the reduction or disappearance of oxalate degrading bacteria in the
gut, especially the bacterium Oxalobacter formigenes (Sidhu et al, 1998). In the
latter study 71% of healthy volunteers were colonised with O. formigenes compared
to only 16% of patients with CF. The intensive use of antibiotics in CF care may
induce permanent gut decolonisation with O. formigenes, increased oxalate
absorption and subsequent hyperoxaluria (Hoppeet al, 1998; Hoppeetal, 2005).
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CF patients with urolithiasis warrant detailed metabolic evaluation, as correction of
risk factors may decrease stone recurrence. Pancreatic enzyme dosage should be
reviewed by a specialist dietician. Fluid intake should be increased and
supplemental citrate prescribed for those with a proven history of urolithiasis.
Stones may be passed in the urine with medical intervention or require extra
corporeal shock wave lithotripsy or ureteroscopy with stone extraction (Perez-
Brayfield et al, 2002).
1.4.2 IgA nephropathy
IgA nephropathy, althoughrare, is the most frequently reported glomerulonephritis
in patients with CF (Melzi et al, 1991). In 1999, Stirati reported that four out of five
renal biopsies performed for haematuria, proteinuria or reduced renal function
showed IgA nephropathy (the fifth demonstrated amyloidosis) (Stirati et al, 1999).
The co-existence of CF and IgA nephropathy may be coincidental, since both are
relatively common disorders; however, there may be a real association because
patients with CF have high circulating levels of IgA due to recurrent bacterial
infections which, if deposited in the kidney, may cause a further immune response
resulting in glomerulonephritis.
1.4.3 Vasculitis
Vasculitis, usually antineutrophil cytoplasmic antibody (ANCA) positive, has also
been described in older patients with CF, some of whom havehadclinically evident
nephritis (Finnegan et al, 1989). ANCA has also been foundin children with CF and
recurrent infections but withoutclinical vasculitis or glomerulo-nephritis.
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1.4.4 Amyloidosis
With improvedpatient survival secondary amyloidosis, a sequel of chronic infection,
is being increasingly recognised as a serious complication of CF. In 1986 McGlennen
et al (McGlennen et al, 1986) reviewed the literature and reported their autopsy
findings from 1957 to 1983: there were only 16 cases reportedin the literature but
in their cohort of 33 patients, all older than 15 years at the time of death, 11 had
evidence of systemic amyloidosis including renal involvement. Only onepatient had
presented clinically and the diagnosis was made on renal biopsy prior to death
(which was dueto renal failure) (McGlennen et al, 1986). Since then there have
been several reports of patients with CF presenting with nephrotic syndrome due to
amyloidosis (Gaffney et al, 1993; Waz et al, 1995). If this occurs, the prognosisis
poorwith nearly all dying within a yearof clinical presentation, although there have
been encouraging results in two patients treated with colchicine (Kuwertz-Broking
et al, 1995).
1.4.5 Diabetic nephropathy
More than 30% of CF patients have insulin-dependent CF related diabetes (CFRD) by
early adult life (Brennan et al, 2004). Although there is probably a lower prevalence
of renal complications in patients with CFRD compared with non-CF patients with
other forms of diabetes (Schwarzenberg et al, 2007), it is estimated that 30-50% of
those with CFRDM will progress to diabetic nephropathy within 5-10 years of
diagnosis, with a proportion ultimately requiring renal replacement therapy
(Sullivan and Denning, 1989; Magryta et al, 1999). It is therefore inevitable that with
prolonged survival more patients with CF will develop diabetic nephropathy with
the characteristic histological changes of nodular glomerulosclerosis.
The combination of long-standing diabetes mellitus, poor glycaemic control, plus
pathophysiological features specific to CF (though not yet elucidated) may
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contribute to the development of microangiopathy (Sullivan and Denning, 1989).
Indeed, Westall et al (Westall et al, 2004) described 3 adult CF patients with renal
dysfunction, who on renal biopsy had histological changes characteristic of diabetic
nephropathy (Kimmelstiel-Wilson nodules) in the absence of abnormal glucose
metabolism (using standard biochemical diagnostic criteria: all patients had normal
fasting plasma glucose levels, oral glucose tolerance tests and measurements of
HbA1c). They speculated that the pro-inflammatory cytokine profile, typical of CF,
predisposesto the lesions described. Furthermore, Van den Berget al (van den Berg
et al, 2008) reported, in a case control study, that despite a similar overall burden of
microangiopathic complications in patients with CFRD and non-CF type 1 insulin-
dependent diabetics, there was a higher prevalence of microalbuminuria in the
CFRD group evenafter correcting for blood pressure and level of glycaemic control
(21% vs. 4%, P=0.003). This mayreflect the influence of other CF-related factors on
renal function.
Diabetic microangiopathy causessignificant morbidity in patients with multisystem
involvement, including blindness, glaucoma, hypertension, and renal failure
(Sullivan and Denning, 1989; Magryta et al, 1999). In a non-transplanted cohort of
CF diabetics (median duration of CFRD of 20 years) nine out of 29 patients had
hypertension, three had microalbuminuria, and one had elevated creatinine. None
had macroalbuminuria (Andersen et al, 2006). The presence of fasting
hyperglycaemia increases the risk of microalbuminuria (Schwarzenberg et al, 2007)
and the whole spectrum of renal abnormalities attributable to CFRD is more
common in CF diabetics who also receive lung transplantation (Andersen et al,
2006). In another case control study, the microvascular complications shown by
patients with CFRD weresimilar to those seen in patients with type 1 diabetes but
with a lower prevalence of retinopathy and a higher prevalence of
microalbuminuria. The latter may reflect the influence of other cystic fibrosis-
related factors on renal function (van den Berget al, 2008).
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These observations suggest that routine screening for diabetes and_ its
microangiopathic complications in the population with CF, as well as optimal control
of hyperglycaemia, is warranted (Brennan et al, 2004). Although not yet adoptedin
all CF clinics, diabetologists are increasingly engaged in the multidisciplinary
approach to managementof people with CF (Andersenet al, 2006; van den Berg et
al, 2008).
1.4.6 Drug-related nephrotoxicity
Nephrotoxic drugs are the commonest cause of renal injury in patients with CF.
Potential nephrotoxicity may be exacerbated by combination drug therapy and by
salt depletion (Bennett, 1997).
1.4.6.1 Aminoglycosides
Aminoglycoside antibiotics have an important role in the treatment of
Pseudomonasaeruginosainfections. In common with otherrenally excreted drugs,
serum concentrations of aminoglycosides are reduced in patients with CF, who
consequently require high doses to achieve therapeutic drug levels and ensure
clinical efficacy. Woodland (Woodland et al, 1998) has proposed that disordered
CFTR expression at the apical surface of proximal tubular epithelial cells results in
decreased Cl reabsorption from the proximal renal tubular fluid. This is
compensated by increased exchange of Cl for organic anions thereby increasing
tubular secretion of these organic anions including anionic drugs (Woodland et al,
1998). Aminoglycoside nephrotoxicity typically presents with non-oliguric acute
renal failure and minimal abnormalities on urinalysis. It is thought to be caused by
the accumulation of drug within the lysosomes of proximal renal tubular cells and
results in acute tubular necrosis (ATN). It is reversible once aminoglycoside therapy
has been discontinued, although tubular damage may continue for several days
after cessation because of continued high parenchymal levels. Aminoglycoside
nephrotoxicity is related to the dose and duration of therapy, as well as the level of
renal function before and during treatment. CF patients are therefore at particular
risk for aminoglycoside toxicity since they require high doses of antibiotics to
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achieve therapeutic drug levels and often for prolonged courses. It is therefore
essential that trough and peak serum drug levels are monitored carefully to both
ensure therapeutic adequacy and avoid nephron-and oto-toxicity. Levels should be
monitored until the correct drug dosage has been established. Drug levels should be
repeated and renal function checkedif there is any deterioration in the patient’s
condition.
1.4.6.2 Non-steroidal anti-inflammatory drugs
NSAIDS are used in CF for the managementof CF-related arthropathy and chronic
chest/back pain related to abnormal posture, chronic cough and chronic pleurisy.
NSAID-induced renal dysfunction is rare in otherwise well individuals, but patients
with CF are at increased risk because of chronic salt depletion and particularly if
acutely dehydrated. This is because NSAIDS inhibit the enzyme cyclo-oxygenase
thus blocking the production of vasodilator prostaglandins, causing renal
vasoconstriction and acute renal dysfunction. It is therefore essential to monitor
renal function in patients with CF taking NSAIDS, particularly if they are unwell
(Orme, 1986; Lang et al, 1991; Lafrance and Miller, 2009).
1.4.6.3 Drug-induced nephrocalcinosis
As noted above, nephrocalcinosis and nephrolithiasis may be drug related. Loop
diuretics (which may be used to treat right-sided heart failure in CF) and
corticosteroids (which may be used in the management of chronic inflammatory
lung disease) both increase calcium excretion and may cause or exacerbate
nephrocalcinosis and nephrolithiasis (Randall et al, 1965; Barilla et al, 1978).
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1.4.7 Tubulointerstitial nephritis (TIN)
TIN may complicate CF as an allergic reaction to drugs (including a large numberof
antibiotics) or to infection (for example, streptococcal infections). There are
sometimes accompanying signs of systemic allergy such as rash or pain at a drug
injection site. Non-specific symptoms such as malaise, fever, nausea and vomiting
may be present and are occasionally misattributed to the underlying infection.
These changes are also important since they may lead to dehydration, which
increases the chances of nephrotoxicity due to aminoglycosides.
Laboratory findings in TIN include elevation of plasma urea and creatinine that may,
in the early stages, be accompanied by hypokalaemia and hypophosphataemia (due
to tubular dysfunction) and sometimes, a peripheral blood and / or urinary
eosinophilia (Baker, 2002; Patzer, 2008; John and Herzenberg, 2009). Urinalysis will
often reveal haematuria and proteinuria in addition to glycosuria. Ultrasonography
usually reveals large, bright kidneys and renal biopsy, which is necessary to confirm
the diagnosis, reveals a predominantly T cell interstitial infiltrate sometimes with
tubular dilatation and areas of tubulointerstitial fibrosis(Sierra et al, 2007).
The treatment of TIN is primarily supportive, with dialysis therapy as indicated. Any
suspected causative medication, which in a CF patient is most likely to be an
antibiotic and most usually a B-lactam (Alexopoulos, 1998) antibiotic or a NSAID,
should be discontinued. The use of corticosteroids in the managementof acute TIN
remains controversial but is probably justified, particularly in dialysis-dependent
patients since, anecdotally, its use has been associated with rapid recovery of renal
function. In infection-related acute TIN, specific treatment of the underlying
infection is also indicated. It should be noted that in patients receiving combination
drug therapy, such as a B-lactam antibiotic or a NSAID and an aminoglycoside, TIN-
induced renal impairment will result in increased aminoglycoside levels and
exacerbate aminoglycoside-related nephrotoxicity.
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1.4.8 Lung transplantation
Lung transplantation predisposes patients with CF to renal disease (Schindler etal,
2001). There is an accelerated loss in the glomerular filtration rate compared to
lung transplants for other pulmonary diseases (Broekroelofs et al, 2000; Hmielet al,
2005). This post operative decline in lung function suggests that the patients’ renal
reserve may be impaired pre surgery. The patients are at risk of a further decline in
renal function from the nephrotoxic effects of the postoperative
immunosuppressive drug regimens. As post-transplant survival continues to
improve, renal physicians will be faced with an increasing numberof patients with
renal failure requiring dialysis or kidney transplant.
In conclusion, as the prognosis for CF patients continues to improveit is likely that
renal complications will become more common. There may also be more subtle
primary abnormalities of renal function, perhaps with long term consequences,
resulting from abnormal expression of CFTR in the kidneys. This is a potentially
fruitful area for further research.
1.5 USE OF ANTIBIOTICS IN CF
1.5.1 Respiratory infections including P. aeruginosa
Although in the early stages of CF there may be few or no clinical abnormalities,
bronchoscopy studies have documented respiratory infection and inflammation in
well infants (Armstrong et al, 1995; Khan et al, 1995; Armstrong et al, 1996;
Rosenfeld et al, 2001b).
Viral and bacterial infections with Staphylococcus aureus and Haemophilus
influenzae predominate in younger patients. Chronic infection with P. aeruginosa
used to be commonin most patients by their late teens. This is no longer true. Lee
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at al reported less than 20% of the paediatric and around 55% of the adult
population attending the Leeds CF unit had chronic P. aeruginosa infection (Lee et
al, 2004). The impact of this epidemiological change can be seen in the need to
segregate cohorts into different clinics based on the colonising agent. Chronic
infection can be preventedor at least substantially delayed by intensive treatment
of the first P. aeruginosa isolate, using an eradication regimen of antibiotics, often
comprising combinations of nebulised, oral and / or IV antibiotics (Vazquez etal,
1993; Frederiksen et al, 1997; Ratjen et al, 2001; Taccetti et al, 2005; Lebecqueetal,
2006). The most effective regimen is still uncertain (Conway et al, 2003). It is
critically important to offer this treatment to all patients because chronic P.
aeruginosa infection results in worseclinical status, lower respiratory function,
lower weight, height and BMI, more hospital admissions and increased treatment
costs (Konstan et al, 1999; Emerson et al, 2002; Taccetti et al, 2005). In the majority
of patients, chronic P. aeruginosa infection is with the mucoid form of the bacteria.
This defends itself against innate immunity and phagocytosis by producing large
amounts of a protective alginate-based biofilm (Lyczak et al, 2002). Alginate also
protects P. aeruginosa against the activity of antibiotics (Aaron et al, 2002). The
huge numbers of peripheral blood leucocytes which congregate in the lung in an
attemptto kill these bacteria release powerful enzymes, directed at the pathogens
but also damaging to the lung itself. These fuel a self-perpetuating inflammatory
processin the lungs, the end result of which is destruction of lung tissue (Venaille et
al, 1998). Following repeated respiratory tract infectionsit is the body’s response to
P. aeruginosa infection which is largely responsible for progressive lung damage
(Heeckeren et al, 1997; Konstan and Berger, 1997).
1.5.2 Antibiotics and eradication of early or recurrent P. aeruginosa infection
Chronic P. aeruginosa infection is associated with the mucoid phenotype of P.
aeruginosa (Lyczak et al, 2002), a more rapid decline in lung function and a worse
prognosis. Strategies aimed at preventing or delaying progression from initial
acquisition of P. aeruginosa to chronic infection are an essential part of CF
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management and have proved highly effective. Recent data suggest that the
window ofopportunity for such strategies may be quite large (Li et al, 2005). Whilst
acquisition of P. aeruginosa may occur quite early in life, the transition from the
non-mucoid to the mucoid phenotype maytakeseveral years.
Evidence from several studies has shown that early administration of antibiotics,
once colonisation with P. aeruginosa has been identified, significantly reduces the
risk of chronic infection (Littlewood et al, 1985; Valerius et al, 1991; Frederiksen et
al, 1997; Ratjen et al, 2001; Gibson et al, 2003b; Taccetti et al, 2005; Lebecqueetal,
2006). A common feature of these trials is the use of aerosolised antibiotics.
Conversely, trials using intravenous antibiotics for early eradication therapy have
been disappointing (Steinkampet al, 1989).
In the study by Valerius et al, 26 patients received PO ciprofloxacin plus nebulised
colistin twice daily for 3 weeks or no treatment, in responseto an initial isolation of
P. aeruginosa. After 27 months of the trial significantly fewer patients who had
received treatment were positive for P. aeruginosa (14% vs. 58%) (Valerius et al,
1991). This protocol was further refined by the Copenhagen groupto increase the
duration of treatment with oral ciprofloxacin and aerosolised colistin to three
months. Follow up after three and a half years revealed that only 16% of treated
patients developed chronic P. aeruginosa infection in comparison to 72% of
untreated historical controls (Frederiksen et al, 1997). Ratjen et al gave 15 patients
aerosolised tobramycin 80 mgdaily for 12 monthsin responsetoinitial isolation of
P. aeruginosa (Ratjen et al, 2001). After one year follow up, 14/15 patients
remained negative for P. aeruginosa. Gibson et al randomised 21 children under the
age of six years who became positive for P. aeruginosa to receive 300 mg
Tobramycin Solution for Inhalation (TOBI) or placebo twice daily for 28 days (Gibson
et al, 2003b). At the end of treatmentall eight children who received TOBIvs one of
13 who received placebo (P<0.0001) were negative for P. aeruginosa.
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Early eradication therapy is believed to be a major reason for the increased survival
of patients with CF, mainly as a result of reduction in the prevalence of chronic P.
aeruginosainfection (Johansen et al, 2004; Lee et al, 2004).
There have been no studies comparing colistin with TOBI for early eradication of
new P. aeruginosa isolates. While there is evidence for the efficacy of TOBI, the
cheaper alternative, colistin, has been extensively used and has proved highly
effective when combined with oral ciprofloxacin in preventing, or at least
substantially delaying, chronic infection after the first P. aeruginosa isolate (Valerius
et al, 1991; Frederiksen et al, 1997).
Eradication therapy is usually well tolerated. Absorption of nebulised tobramycin
does not reachsufficient levels in the majority of patients to adversely affect renal
function. A retrospective review of children with CF receiving inhaled gentamicin
showedsignificantly raised N-acetyl-B-D glucosaminidase (NAG) activity indicating
renal tubular damage compared to control children who had neverreceived inhaled
gentamicin or who had discontinued the drug at least three months previously. The
long term clinical implications of these findings remain uncertain as urinary NAG
activity returned to normalat the end of treatment.
There has been no evidence to suggest significant increases in antimicrobial
resistance during eradication therapy, even after multiple repeat courses (HO etal,
2004). Aerosolised antibiotics and oral ciprofloxacin have been associated with an
increased risk of colonisation with Stenotrophomonas maltophilia (Denton et al,
1996a), Aspergillus species (Bargon et al, 1999), and MRSA (Nadesalingam etal,
2005).
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1.5.3 Antibiotics and treatment of chronic P. aeruginosa infection
1.5.3.1 Intravenous antibiotics
There are four main indicationsfor IV antibiotic therapy:
i.
ii.
iil.
To eradicate P. aeruginosa infection
a. As an alternative to combined oral and nebulised antibiotic
treatment e.g. when treating an infant or youngchild
b. As a prelude to the standard oral and nebulised antibiotic
regimen whena new P. aeruginosaculture is associated with new
respiratory symptoms
c. Whena standard eradication regimen has failed
To treat a new cough that has not settled with the addition of an oral
antibiotic
If new respiratory symptoms do not settle after two different oral
antibiotics, or if there are significant continuing symptomsafter a single
oral antibiotic course, treatment with oral antibiotics is recommended.It
is important to rememberthat significant new infection may be present
even whencareful auscultation does not reveal new added sounds and
in the absence of new radiological changes. There may only be a
persistent or new cough. It is the general experience that the persistent
coughdries up within a few daysof starting IV antibiotics. The antibiotic
prescribed will depend on previous respiratory cultures for the patient.
To treat a respiratory exacerbation
Respiratory exacerbations are loosely defined in terms of more
breathlessness, increased cough, change in sputum colour or volume,
changeson chest radiographs, deteriorating respiratory function and loss
of appetite and weight. An increased severity of two or more lower
respiratory tract symptomsand a fall of 10% or more from baseline FEV1
or FVC were suggested to best reflect a new respiratory exacerbation
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(Kanga et al, 1999; Dakin et al, 2001; Rosenfeld et al, 2001a). It is
recommended that respiratory exacerbations are treated with two
intravenous antibiotics to minimise the risk of antibiotic resistance
developing (Cheng et al, 1996; Denton et al, 1996b). Combined therapy
may also have an additive or synergistic effect. The duration of a course
of IV therapy varies but is usually 2-3 weeks. Usually an aminoglycoside
(e.g. gentamicin or tobramycin) is combined with a beta-lactam (e.g.
ceftazidime, tazocin, meropenem or aztreonam) as recommendedby the
CF trust guidelines (Cystic Fibrosis Trust Antibiotic Group 2002). Colistin,
a polymyxin, is often used as a second line agent, for example if there
are concernsoverallergy or bacterial aminoglycoside resistance (Conway
et al, 1997; Littlewood et al, 2000). However, in certain centres such as
ours, the emergence and spread of transmissible and multiresistant P.
aeruginosa strains has dictated a greater utility for this old antibiotic
(Ledson et al, 1998). The individual patient’s history of antibiotic
hypersensitivity reactions is taken into account when deciding
treatment.
The initial choice of antibiotics still depends on the bacterial sensitivity
pattern, although there is dispute over whether the laboratory-deduced
sensitivities are of any relevance in vivo. The reliability of susceptibility
testing of P. aeruginosa isolated from chronic infections in CF is
uncertain. Foweraker et al showed that standard laboratory protocols
often under-represented the complexity of resistance patterns and this
contributed to widespread inter-laboratory variability in determining
susceptibility patterns (Foweraker et al, 2005). Further evidence also
suggests that the susceptibility pattern in chronic P. aeruginosa infection
is poorly predictive of clinical response. As a result, an argument has
been madeto reduce the numberof routine sensitivity tests done in CF
clinics. Isolates of P. aeruginosa obtained from patients with CF and
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chronic infection are only routinely tested if they have not been checked
in the previous three months, or if obtained from a sample taken at the
commencement of IV antibiotics, or if the patient is failing on their
current antibiotic regimen (Etherington et al, 2008). Clinical
improvement may reflect the drug’s anti-inflammatory and/or anti-
oxidant effects, or activity against P. aeruginosa virulence factors such as
exotoxin A, total protease, elastase, phospholipase C, lipase and
lecithinase, rather than its bactericidal effect (Adeboyeku et al, 1999;
Ledsonet al, 1999; Davey et al, 2000).
It is generally accepted that once-daily tobramycin is as effective and
safe as thrice-daily administration (Master et al, 2001; Whitehead etal,
2002; Smyth et al, 2005; Smyth and Tan, 2006). Most patients find once-
daily dosing more convenient. Trough drug levels should be monitored
before the second dose and on day eight (although CF unit protocols
vary) and should be <1 mg/l. In a small number of patients, toxicity may
still occur despite trough levels of < 1 mg/I (Coulthard et al, 2007).
Further monitoring may involve taking two blood samples at one and
eight hours post dose.
Improvement during a course of IV treatment can be demonstrated by
performing regular respiratory function tests and carefully assessing
other symptomsandsigns including body weight.
As a routine three-monthly treatment for patients with chronic P.
aeruginosa infection
This regimen was recommended by the Copenhagengroupin 1989. They
demonstrated a significantly better five year survival when patients with
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chronic P. aeruginosa infection were treated with IV anti-pseudomonal
antibiotics every three months irrespective of their clinical condition
(Jensen et al, 1989; Frederiksen et al, 1996). This is now more debatable
as the general picture of CF has changed and manyCFphysicians believe
that only patients requiring this frequency of treatment to maintain their
clinical stability should be so treated. For other patients, the risk of this
“one prescription for all” approach in terms of inducing toxic effects on
renal function, hearing and balance has not been fully quantified or
understood but may outweigh the possible benefits of this treatment
regimen (Ciofu et al, 1994; Elborn et al, 2000; Breen and Aswani, 2001).
The physical status of patients with CF in 2009is totally different to that
in 1989 and most patients will keep well without resort to four IV
antibiotic courses annually. Moreover, patients are living much longer
and therefore the potential for serious adverse events from lifetime of
frequent antibiotic treatments is significantly increased (though not
previously reported in a quantitative manner). A greater frequency of
antibiotic use also increases the risk of patients developing
hypersensitivity reactions to these medications (Koch et al, 1991;
Burrowsetal, 2007).
Finally, there is the cost of treatment to the hospital and health service
and the extra costs incurred by hospitalisation for the patients and their
carers.
1.5.3.2 Antibiotic treatment for multi-resistant organisms
Multiresistant isolates of P. aeruginosa are an increasing problem (Pitt et al, 2003).
Innately resistant organisms such as BCC, Stenotrophomonas maltophilia and
Achromobacter xylosoxidans are becoming more prevalent (Moore et al, 2001).
MRSAis also a growing problem (Nadesalingam et al, 2005; Sawicki et al, 2009).
These changing patterns probably result from greater patient longevity and
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increased antibiotic use for acute exacerbations and maintenancecare. The optimal
treatmentfor these resistant bacteria is not known (Conwayetal, 2003).
Multiresistant P. aeruginosa infection may be treated successfully by using two
antibiotics with different mechanismsof action. In practice antibiotic choices have
usually been made on a best-guessbasis. It had been hoped that better directed
therapy could have been achieved throughthe application of multiple combination
bactericidal testing (MCBT) (Lang et al, 2000). This systematically tests isolates
against different combinations of antibiotics to determine optimal sensitivity
patterns. However, a follow up study showedthat clinical outcomes were not
significantly improved when using regimens selected on the basis of MCBT
comparedto standard susceptibility tests (Aaron et al, 2005).
The selection of antibiotics for pan-resistant bacteria is problematic. In practice,
they should be treated with the antibiotics that by experience have produced the
best clinical response in that individual patient. Combination antibiotic therapyis
recommended(Cystic Fibrosis Trust Antibiotic Group 2002; Fowerakeret al, 2005),
but the choice of regimen should always be guided bytheclinical response.
Resistanceto colistin is rare and interest in this antibiotic has therefore increased in
recent years (Ledsonetal, 1998; Littlewood et al, 2000; Kasiakou et al, 2005). Some
believe it is a valuable second line IV drug to be reserved for multiresistant P.
aeruginosa (Conway et al, 1997; Conwayet al, 2000; Falagas et al, 2009). Aerosol
delivery of tobramycin solution for inhalation (TOBI) achieves high endobronchial
concentrations that may overcome bacterial resistance as defined by standard
laboratory criteria for IV therapy (Saiman et al, 1996; Lang et al, 2000). Its
application in the treatment of CF acute pulmonary exacerbationsis an attractive
proposition, but whether this can be carried out successfully and safely is an
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unanswered question. Mechanisms of antibiotic delivery (timing, dosage, infusion
rate) should be reviewed to achieve optimal bactericidal effect. There is also a need
to evaluate the efficacy of new antibiotic groups such as the macrolides.
1.5.3.3 Nebulised antibiotics
The advantages of nebulised antibiotic therapy for P. aeruginosa infection in CF
have been recognised for over 30 years (Mearns, 1970). An antibiotic delivered
directly to the site of infection should be most effective. The altered lung
environment consequent on inadequate CFTR protein function may reduce drug
accumulation by the bacteria, and aminoglycoside concentrations may be reduced
by binding to the excess extracellular neutrophil DNA (Levy et al, 1983). Sputum
concentrations 25 times greater than the minimum inhibitory concentration (MIC)
may be necessary to achieve a bactericidal effect (Mendelman et al, 1985). These
levels can not be reached by IV administration without unacceptable risks of
systemic toxicity, but can be realised by inhalation of aerosolised antibiotics which,
because of their minimal systemic absorption,are less likely to cause ototoxicity or
nephrotoxicity (Smith et al, 1989).
Tobramycin crosses the placenta and thereis a theoretical risk of damageto the VIII
cranial nerve and of nephrotoxicity. Avoidance of parenteral administration is
recommended during pregnancy but the risks from nebulised administration are
much less. A decision whether or not to continue nebulised antibiotic treatment
during pregnancy should be made onanindividual basis and consultation with the
patient. The minimal theoretical risk to the baby of continued treatment should be
weighed against the risks to the mother’s health of stopping treatment.
28
Clinical indications for nebulised antibiotics:
ii.
Delay or prevention of chronic P. aeruginosa infection (see above)
Prevention of clinical deterioration in patients chronically infected with P.
aeruginosa
Regular nebulised antibiotics reduce the rate of decline of respiratory
function in patients chronically infected with P. aeruginosa. In 1981
Hodson et al. compared six months of treatment with twice daily
nebulised gentamicin (80mg) and carbenicillin (1gm) vs. placebo (Hodson
et al, 1981). Treated patients had significantly improved respiratory
function and a non-significant trend towards fewer hospital admissions.
Follow up studies confirmed the benefits of treatment for chronic P.
aeruginosa infection: improved lung function, a slower decline in lung
function, fewer hospital admissions, better clinical scores and weight,
and decreased P. aeruginosa density and production of virulence factors
(Conway, 1999). There was no renal toxicity, ototoxicity or increase in
bacterial resistance (Touw et al, 1995; Mukhopadhyayetal, 1996).
Low systemic and high local concentrations of colistin after nebulised
delivery (Ratjen et al, 2006), and a randomised double blind study of
TOBI (Ramsey et al, 1999) support their use in patients with chronic P.
aeruginosa infection. In the TOBI study, the first cycle of treatment
produced a 12% increase in FEV1 which was maintained through the
study. There wasalso a significant fall in colony forming units per gram
of sputum, and patients required fewerIV antibiotic treatments. Sputum
drug concentrations greater than 25 times the MIC value were seen in
95% of patients. Adolescent patients responded particularly well with
14% improvement in FEV1 compared 1.8% for controls (Moss, 2002).
Increasing P. aeruginosa tobramycin resistance was not associated with
reduced clinical efficacy (Ramsey et al, 1999). There was no increased
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isolation of intrinsically tobramycin-resistant microorganisms (Burns et
al, 1999).
Colistin resistance is rare (Denton et al, 2002; Govan, 2002; Landman et
al, 2008) and there is general consensus that sensitivity returns when
colistin inhalation and IV use are suspended for six months (Landman et
al, 2008). A comparative study of twice daily nebulised TOBI (300 mg)
and nebulised colistin (1 megaunit), at present the only antibiotics
licensed in the UK for nebulisation in CF, showed that both treatments
reduced the bacterial content of the sputum significantly. FEV1
increased by 6.7% with TOBI and 0.37% with colistin (Govan, 2002;
Hodsonetal, 2002).
The Cochrane review found insufficient evidence to claim superiority for
either TOBIorcolistin. Eleven trials met the inclusion criteria. The review
concluded that nebulised antibiotic treatment improves lung function
and reduces the frequency of pulmonary exacerbations. There was no
evidenceofclinically important adverse events (Ryanet al, 2003).
Long term treatment with nebulised antibiotics is effective with patients
having fewer hospital admissions and IV antibiotic use and better
preservation of respiratory function (Moss, 2001). Long term treatment
is generally safe but patients show an unpredictable range of systemic
antibiotic absorption. The possibility of toxic drug levels resulting from
nebulised antibiotic delivery should be remembered. Acuterenal failure
after one week of TOBI and concurrent ciprofloxacin, and reversible
vestibular dysfunction due to inhaled tobramycin in a patient receiving
haemodialysis have been reported (Hoffmann et al, 2002; Edsonetal,
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fii.
2004). Following inhaled gentamicin children showedsignificantly raised,
but reversible, urinary NAG activity indicating renal tubular damage,
compared to control children who had never received gentamicin
inhalation or who had discontinued the drug at least three months
previously. There was a positive correlation between NAGlevels and
cumulative antibiotic dose (Ring et al, 1998).
Otheruses of nebulised antibiotics
a.
b.
Acuterespiratory exacerbations
There are no trials showing that nebulised antibiotics are as
effective as IV antibiotics for treating infective exacerbations, or
that they are useful adjuncts to IV therapy (Stephenset al, 1983;
Schaad et al, 1987; Semsarian, 1990).
Nonetheless, clinicians may wish to use TOBI for the treatment of
exacerbations associated with multiresistant P. aeruginosa
because of the high endobronchial antibiotic levels achieved. The
high sputum drug concentrations may render the usual
laboratory breakpoints meaningless (Saiman et al, 1996; Lang et
al, 2000).
To prevent P. aeruginosainfection
Twice daily inhaled gentamicin in a small group of very young
children prevented chronic infection for a mean of 78 months
(Heinzl et al, 2002). Regular use of nebulised TOBI, colistin,
injectable forms of tobramycin or amikacin are associated with a
chronic P. aeruginosa infection rate of <3% in Belgian children
(Lebecque et al, 2006). There are however important negative
effects to be considered before adopting this proactive approach.
These include the increased risks of bacterial resistance, the risk
of emergence of fungal organisms, the potential toxicity of
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treatment and the impact on daily life of long-term nebulised
antibiotic treatments. Chronic infection can also be preventedin
the majority of children with less invasive protocols aimed at
eradicating new P. aeruginosainfection.
c. Treatment of nontuberculous mycobacterial infection
Treatment should be considered for patients who are smear
positive, and for those with persistent positive cultures and
symptomsdespite routine antibiotic treatment.
Nebulised amikacin is part of the complex and long term
antibiotic regimens for the treatment of the rapid growers, such
as M. abscessus (Cullen et al, 2000). There is no evidence base for
dosage but 500mg bd is recommended. This may need reducing
to 250mgbd in youngerchildren.
d. Nebulised vancomyin for the treatment of MRSA
1.5.3.4 Long term oral azithromycin (see above undertubulointerstitial nephritis)
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1.6 FIGURES
Figure 1.6.1 - Predicted two-dimensional structure of the CFTR protein
 
The CFTR domains shownare: TMD1 and TMD2-transmembrane spanning domains 1 and 2,
respectively; R domain-regulatory domain; NBD1 and NBD2-nucleotide binding domains 1
and 2, respectively. The most common mutation, AF508,is found in NBD1.
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CHAPTER TWO
Aim and outline of this study
34
2.1 AIM OF THE PRESENT STUDY
It is obvious from the literature review presented in chapter one that CF patients
are exposed to a high burden of potentially nephrotoxic therapy to manage both
their day-to-day stability and as rescue treatment for pulmonary exacerbations. The
aim of this study was to search for and quantify any resulting impairment in their
renal reserve, evaluate different methods of assessing renal function in this patient
population, and examinein prospective trials measures aimed at kidney protection
in the face of ongoing obligatory need for nephrotoxins.
2.2 OUTLINE OF THE PRESENT STUDY
In Chapter 4, | describe a prospective cross sectional study in which creatinine
clearance was measured in stable adult CF patients attending our regional
outpatient clinic. The study aimed to identify those with impaired renal function
and examine potential association with prior exposure to different classes of
nephrotoxic antibiotics.
As the lower limit of normal GFR is set at 80 ml/min, impaired renal function
encompassesa wide range of reduced GFR values. The study in chapter4 identified
many patients with only mild renal dysfunction. However, the relevance of this
finding to clinical practice is highlighted by a case series of acute renal failure
detailed in chapter 5.
So, what can we do aboutit?
Before changesto our antibiotic policies could be proposed in order to extend the
renal reserve of our patient, a key question to address is how best to assess renal
function in CF. This includes:
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1. Means of screening for background levels of reduced GFR in the clinic
population
Ds Methods to quantify the magnitude of acute renal toxicity related to a
current course of antibiotics
For the former, chapter 6 summarises a comparison of the performance of 8
formulae developed for estimation of GFR vs direct measurement of CCl from 24
hour urine collections. For the latter, urine proteins and enzymesare used as early
biomarkers of renal tubulotoxicity. These are employed in chapter 7 to examine
possible mechanisms of cumulative tubular injury with repeated exposure to
nephrotoxic antibiotics.
Chapters 8 and 9 subsequently apply these sensitive urinary biomarkers in
prospective cross over trials, wherein alternative potentially nephroprotective
antibiotic strategies are compared with standard therapy for acute pulmonary
exacerbations. The studies presented assess efficacy and safety of the different
antibiotic combinations including their impact on GFR as well as tubular structural
integrity and function.
Some of the conclusions reached in the above studies have led to a natural change
in our antibiotic policies and these, along with other general recommendations
aimed at protecting renal function in C F patients, are discussedin the final chapter.
Proposals for future researchin this field are also presented.
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CHAPTER THREE
General laboratory methods
37
3.1 SPIROMETRY
Lung function was measured by qualified lung function physiologists (BSc in Clinical
Physiology and the Association for Respiratory Technology and Physiology
professional qualifications) on a standard volumetric spirometer (Vitalograph, Ennis,
Ireland) with the patient in erect position. Tests were performed to standardsof the
joint American Thoracic Society/European Respiratory Society guidelines (Miller et
al, 2005). Flow was calibrated twice daily using a 3-litre syringe with accepted
tolerance of +/- 3%. The best of three measurements was recorded; forced expired
volumein one second (FEV1) and forced vital capacity (FVC) were noted.
3.2 SERUM AND URINE CREATININE
Serum and urine creatinine concentrations were measured according to the Jaffe
reaction, using a standard alkaline picrate assay through a Roche clinical chemistry
autoanalyzer.
3.3 MEASURED CREATININE CLEARANCE(mCCl)
This wasassessed in every patient by comparing the urinary creatinine (UCr) cleared
over 24 hr with a paired spot serum creatinine (SCr) obtained after an 8 hour fast at
the end of each 24-hr collection period.
The renal clearance of endogenous creatinine was determinedby the formula:
mCCl= UCr * urine volume/SCr
and expressed as ml/min adjusted, where appropriate, for body surface area
(CCI/1.73 m’).
3.4 SERUM TOBRAMYCIN
Serum tobramycin concentrations were measured in the hospital clinical
biochemistry laboratory using TDxFLx assay (Abbott Laboratories; lower limit of
quantitiation 0.2 mg/l).
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3.5 URINE PROTEINS AND ENZYMES
In the studies where proteinuria and enzymuria were measured, urine was collected
in standard containers, kept in an opaque sheath on ice at the patient’s bed side.
For each 24 hour urine collection, the total urine volume was recorded and an
aliquot of 20 ml frozen at -80°C until assayed.
3.5.1 Urine total protein and albumin
Total protein in urine was measured by a turbidimetric method in a Roche Clinical
Chemistry Analyser (Wako, Japan). The sample is preincubated in an alkaline
solution of sodium hydroxide, 530 mmol/l, containing EDTA-Na at 74 mmol/l, which
denatures the protein and eliminates interference from Mg"* ions. Benzothonium
chloride is then added, producing a turbidity that is read at 505 nm. The lower
detection limit (the lowest measurable analyte level that can be distinguished from
zero) for this method is 40 mg/l. The local laboratory reference value is < 150 mg/l
or < 200 mg/24 hours(Junge et al, 2006).
Urinary albumin was quantified by by an immunoturbidimetric assay in a Roche
analyser. This uses sheep polyclonal anti-human albumin antibodies in TRIS buffer:
100 mmol/l, at pH 7.2 and 25°C. The lower detection limit is 3 mg/l and the local
laboratory reference is < 2.5 mg albumin/mmol creatinine for males and < 3.5
mg/mmolfor females in random samples and < 30 mg/24 hour urine collections.
3.5.2 Urinary N-acetyl-B-D glucosaminidase (NAG)
NAG (Yuen et al, 1982; Marchewka and Dlugosz, 1998) was measured using a
commercially available assay kit [PPR Diagnostics, London] optimised for use in 96-
well plate format. 8,l of urine was added to 120ul of substrate (2-methoxy-4-(2'-
nitrovinyl)-phenyl 2-acetamido-2deoxy-f-D-glucopyranoside) in a citric acid
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/phosphate buffer and incubated for 30 minutes at 37°C. Production of the
coloured product 2-methoxy-4-(2'-nitrovinyl)-phenol by NAG hydrolysis was
measured at 505nM after addition of 40ul of KCI/KH2PO, buffer at pH 9.5.
Calibration was achieved by reference to a standard curve of bovine kidney NAG of
defined activities. The effects of varied urine concentration were minimised by
expressing NAG level as a ratio of urine creatinine. Results are reported as
units/mmolcreatinine.
3.5.3 Urinary alanine aminopeptidase (AAP)
AAP (expressed as units/mmolcreatinine) was measured using a modification of a
procedure described by Jung and Scholz (Jung and Scholz, 1980). Urine samples
were prepared using PD10 desalting columns [Amersham Biosciences, Bucks, UK].
In 96 well microplates, 30! of desalted urine was added to 150! of 59mM tris/HCL
buffer (pH 7.8) and allowed to equilibrate at 37°C for 15 minutes. The reaction was
started with the addition of 30uL of substrate alanine-4-nitroanilide hydrochloride
(26mM in tris buffer). The reaction was monitored over 5 minutes and the changein
absorbance at 410nm calibrated by reference to a standard curve of known
concentration of p-nitroaniline product.
3.5.4 Urinary B2-microglobulin (B2M)
B2M (Herber, 1984) (expressed as mcg/mmolcreatinine) was measured from spot
urines collected at 14:00 hours. Samples were immediately buffered to a pH of 7.0
and frozen at -80°C until analysed with a solid immunoradiometric assay [Euro/DPC,
Llanberis, UK].
For all urine enzymes and proteins, the effects of varied urine concentration were
minimised by expressing levels of the substance of interest as a ratio of urine
creatinine.
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CHAPTER FOUR
Renal impairment in CF patients due to repeated
intravenous aminoglycoside use
41
4.1 INTRODUCTION
Although cystic fibrosis (CF) is a multisystem disorder, the only abnormalities
traditionally associated with the renal tract are an increased incidence of
nephrolithiasis (Hoppe et al, 1998; Perez-Brayfield et al, 2002) and more recently,
mechanical urological problems associated with coughing (Orr et al, 2001). Several
cases of acute renal failure were noted in patients attending the adult CF unit in
Liverpool which wereassociated with the concurrent use of potentially nephrotoxic
antibiotics, and this was also reported elsewhere (Kovesi et al, 1998; Drew etal,
2002). The increasing prevalence of antibiotic multiresistance in P. aeruginosa
strains in CF patients (Pitt et al, 2003; Spencker et al, 2003), and in particular that
associated with epidemic strains (Chenget al, 1996; Jones et al, 2001), may increase
the requirements for nephrotoxic antibiotics. Indeed, the most prevalent epidemic
strain in the United Kingdom (UK) (the Liverpool epidemic strain; LES) (Scott and
Pitt, 2003) is commonin my CF unit andis frequently sensitive only to tobramycin
and colistin sulphomethate (Mirakhur et al, 2003), both of which are potentially
nephrotoxic (Price and Graham, 1970; Bennett, 1983). Although other workers
reported acute changes in markers of renal tubular function during courses of
intravenous (IV) aminoglycoside therapy (Reed et al, 1981; Steinkampet al, 1986),|
was not aware of any studies documenting the level, if any, of background renal
impairment in CF patients. | hypothesized that cumulative IV aminoglycoside and
colistin exposure may adversely affect creatinine clearance, a measure of
glomerular filtration rate (GFR) and hencerenal function. To explore this further,|
prospectively recorded GFR in a group of adult CF patients who had no history of
renal problems, using both measured (24-hr urine collection) and calculated
(formula of Cockcroft and Gault (Cockcroft and Gault, 1976)) creatinine clearance,
and compared it with their lifetime use of these potentially nephrotoxic
antipseudomonal antibiotics.
42
4.2 PATIENTS AND METHODS
4.2.1 Study population
Eighty consecutive CF outpatients chronically infected by P. aeruginosa (defined as
three or more positive sputum cultures within a 6-month period) and who werein a
stable clinical state formed the study population [mean age: 24.2 years (SD 7.6;
range 16-56), mean forced expired volumein 1 sec (FEV1) % predicted: 63 (SD 24.6;
range 16-117), and mean body mass index (BMI) 20.9 (SD 3.3; range 14—29.5), 40
male]. Patients co-infected with the Burkholderia cepacia complex were excluded.
Twenty-three had CF-related diabetes mellitus (CFRDM), and 11 had liver disease.
No patient had undergone transplantation or was taking immunosuppressive
therapy knownto cause renal disease. All patients gave informed consent, and the
local ethics committee approved the study. All patients had previously required
courses of intravenous antibiotics, and all had been treated with IV aminoglycosides
and/or colistin. Colistin was given at a dose of 2 megaunits tds in the adult
population and at 75,000 unit/kg/day in 3 divided doses in childhood. According to
local protocols, aminoglycoside levels had been measured and the dose adjusted at
the fourth administration to achieve a trough level of <1.0 mg/I and a peak level of
6-10 mg/l. No patient had any previous history of renal problems, including acute
drug-related nephrotoxicity. In addition, 49 patients (61%) had a recent negative
urinalysis, and all had normal renal ultrasound scans at annual screening.
4.2.2 Assessmentof renal function
4.2.2.1 Measured Creatinine Clearance (mCCI)
See chapter 3 (General laboratory methods) for measurements of serum and urine
creatinine and subsequentcalculation of mCCI. A total of 163 24-hr urine collections
were obtained (mean:2 collections per patient; range: 1-5).
Twenty-four-hour urine collections were validated according to the method of
Thakur et al (Thakur et al, 1997). Briefly, the mean urinary creatinines for men
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(0.193 (SD: 0.047) mmol/kg) and women (0.138 (SD: 0.043) mmol/kg) were
calculated separately, and all 24-hr urine collections that had values within 1 SD of
these respective means were considered valid and were included for further
evaluation. Using this validation method, 135 collections (83%) were suitable for
further study. Each patient had at least one valid specimen, and in patients where
more than one 24-hr collection wasvalid, the best (highest) measured creatinine
clearance (mCClI) was chosenforanalysis.
4.2.2.2 Estimated Creatinine Clearance (eCCl)
This was calculated using the formula of Cockcroft and Gault (Cockcroft and Gault,
1976) where serum creatinine is adjusted for age, sex, and body massto estimate
the creatinine clearance:
eCCl= (140 - age) * weight [kg]/72 * SCr [mg/dl] * (0.85 forfemales)
The minimum value for normal creatinine clearance in our laboratory is set at 80
ml/min/1.73 m’.
4.2.3 Assessment of aminoglycoside and colistin use
Hospital and central home care records were examined to ascertain the total
numberof IV courses of aminoglycosides and colistin each patient received up to
the point of urine collection. To ensure that assessmentof lifetime use of these
therapies was complete, records from referring paediatric clinics to the Liverpool
adult CF unit were retrieved and examined for data regarding IV antibiotics.
In line with the UK CF Trust guidelines (Cystic Fibrosis Trust Antibiotic Group 2002) a
minimum of two antipseudomonal antibiotics were used to treat pulmonary
exacerbations. In the Liverpool adult CF unit, IV quinolones are not administered
and oral ciprofloxacin is reserved for outpatient treatment. Nebulised antibiotics
are discontinued during IV therapy. Table 4.7.1 summarizes the numberof courses
of different combinations of antipseudomonal agents used intravenously. The
median length of IV antibiotic courses was 14 days; the range was 7-49.
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4.2.4 Statistical methods
The relationship between renal function and IV antibiotic use was examined with a
multiple linear regression model, with CCl as the dependent variable and the
number of IV courses of aminoglycoside + B-lactam, colistin + B-lactam, and
aminoglycoside + colistin as the independent variables. Age, CFRDM, BMI,
supplemental feeding, FEV1 (% predicted), and the use of azithromycin and
nonsteroidal anti-inflammatory agents (NSAIDs) were considered potential
confounders.
Pearson’s correlation was calculated for the comparison of mCCl and eCCl.
Proportions were compared with a x’ test. P<0.05 was consideredstatistically
significant. Analysis was carried out with StatsDirect, version 2.3.
4.3 RESULTS
All patients had blood urea and serum creatinine values within normal range (mean
4.6 mmol/l (SD: 1.7) and 84.2 (SD: 16.7) umol/I, respectively). The mean creatinine
clearance using either technique waswithin normal range (mCCI: 84.6 ml/min/1.73
m? (SD: 25.6); eCCl: 89.5 (SD: 23.2) ml/min) (P=NS). However, 34 patients (42.5%)
had a mCCI<80 ml/min/1.73 m2 (mean: 61.8 (SD: 12.3) ml/min/1.73 m’), indicating a
degreeof renal impairment. Similarly, the eCCl was abnormalin 25 patients (31.3%)
(mean: 64.4 (SD: 16.4) ml/min). The two measures of renal function correlated
significantly (r=0.59, P<0.001; Figure 4.8.1). The degree of diminished creatinine
clearance in affected patients is shown in Table 4.7.2.
There was an inverse relationship between creatinine clearance and the total
numberof IV aminoglycoside and IV colistin courses (Figure 4.8.2). Compared with
eCCl, 24-hr urine based measurements displayed a stronger correlation with IV
antibiotic use (eCCl: r= -0.40, P<0.0001, vs. mCCl, r= -0.65, P<0.00001). In the
multiple regression analysis model, increasing lifetime use of aminoglycosides
administered with nonnephrotoxic antibiotics displayed a significant association
with declining creatinine clearance. However, when administered with
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nonnephrotoxic antibiotics alone, colistin was not associated with loss of renal
function per se but enhanced the apparent nephrotoxicity of aminoglycosides when
the two antibiotics were coadministered (Table 4.7.3). In this regression model, the
described interactions between CCI and antibiotic use were independentof patient
age, CFRDM status, BMI, supplemental feeding, FEV1 (% predicted), and
azithromycin and NSAIDsuse (P=NS,forall interactions).
The prevalence of diabetes did not differ between those with and without renal
impairment (11/34 vs. 12/46, x =0.37, P=0.54), nor was there a difference in serum
urea levels (mean: 4.80 (SD: 1.96) mmol/l vs. 4.38 (SD: 1.37) mmol/l, P=0.35).
4.4 DISCUSSION
Traditional indices of assessing renal function, including urinalysis and
measurement of blood urea and serum creatinine, are insensitive and unreliable
markers of early renal disease. Excretory renal function depends on the glomerular
filtration rate (GFR), for which in healthy subjects there is an enormous reserve
capacity, and serum urea and creatinine do not rise above normal range until at
least 60% of GFR is lost (Baker, 2002). Indeed, using these parameters, gross
nephrotoxicity was not detected in any of the studied patients despite 30-40% of
the cohort having impaired renal function. This is in keeping with previous data
251]iothalamate clearance, proteinuria and/orfrom smaller studies that used [
enzymuria as markers of renal function (Reed et al, 1981; Steinkamp et al, 1986;
Godsonet al, 1988). Hence, when the serum urea and creatinine are within normal
range, the measurement of GFR is essential to assess renal function. In normal
individuals, renal removal of endogenous creatinine produced by muscle cell
turnover is a reasonably accurate measure of GFR, and a comparison of serum and
urine creatinine (creatinine clearance) is readily available in clinical practice
(Bannister and Field, 1996). | therefore used this as a measureof renal function in
my patients. However, poor patient compliance can lead to collection errors, and
such a method maybedifficult in a paediatric setting. In this study, | aimed to use
more than one urine collection per patient to reduce compliance errors.
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Furthermore, repeated samples were validated according to the method described
by Thakur et al (Thakur et al, 1997) to ensure that only correctly collected
specimens wereincluded. One is therefore confident that this technique reflected
the measured creatinine clearance as accurately as_ practically possible.
Nevertheless, it has been suggested that when muscle creatinine output is reduced
(e.g., low muscle mass, malnutrition), serum and therefore urinary creatinine will be
low, such that this method may underestimate GFR and give a false indication of
renal disease (Tan et al, 2003). CF patients may fall into the group who have low
muscle mass.
In order to addressthis, several formulae were created to assess CCI by comparing
serum creatinine with the predicted creatinine production, based on an estimation
of muscle mass. The most widely used of these is that produced by Cockcroft and
Gault (Cockcroft and Gault, 1976), and this was validated in several patient groups
(Sampson and Drury, 1992; Thakur et al, 1997). However, the Cockcroft-Gault
formula should be used with caution, since it was generated not to estimate GFR
but to predict creatinine production from serum creatinine by factoring in weight,
sex, and age. Using creatinine production as an estimate of urinary creatinine
clearance assumes that the renal handling of creatinine is both normal and
constant. This does not apply to patients with damaged renal function and can
result in a gross overestimation of GFR, especially when the true GFR is <80 ml/min
(Thakur et al, 1997; Alcanatra et al, 1998). Indeed, it was shownthat the Cockcroft-
Gault formula will overestimate GFR by 71% in patients with reduced renal
clearance (Guasch etal, 1996). Althoughits application in CF patients was recently
recommended(Tanet al, 2003), its use has not been provenin this condition, and
the evidence for its validity in low muscle mass patients is also contradictory
(Mirahmadi et al, 1983; Thakur et al, 1997). Nevertheless, in order to circumvent
possible problems associated with either method, | applied both 24-hr urine
collections and the Cockcroft-Gault formula to assess renal function in this patient
group. | also ensured that all patients were clinically stable, such that the potential
confounding effects of acuteillness or a catabolic state would notfalsely lowertheir
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creatinine clearance. In keeping with this, the two methods correlated well, and
adjusting the regression analysis for BMI did not alter the results. One accepts that
an effect of renal nutrition on GFR cannot be entirely excluded, since the lack of
difference in serum urea levels between those with and without renal impairment
suggests that one of the other factors that influence urea (such as the amount or
type of dietary protein) maybe active.
| also adjusted the regressional analysis for most potentially confounding factors.
Althoughciprofloxacin was shownto cause acute renal failure, | did not include this
in the regressional analysis model, since its nephrotoxicity is idiosyncratic
(Lomaestro, 2000) and notrelated to cumulative exposure. Furthermore, in the UK,
community physicians often give such therapy, making assessment of lifetime
exposure impossible.
Nevertheless, using these techniques, this is the first report demonstrating a high
prevalence of abnormal renal function in adult CF patients: 42% by mCCl and 31%
by the Cockroft-Gault formula had a creatinine clearance below the normal range.
Although the threshold | used for this (80 ml/min/1.73 m7) is derived from non-CF
individuals, most published data suggest that GFR in CF patients is similar to age-
matched controls (Assael et al, 1986; Rey et al, 1998) and | therefore believe that
this value is valid in CF.
Furthermore, | was able to demonstrate a strong relationship between degree of
renal impairment and the use of nephrotoxic antibiotics, which appeared to be
associated primarily with the use of aminoglycosides. Nephrotoxicity is a dose-
limiting feature of aminoglycosides, which have a narrow margin of safety, with
toxic levels close to the therapeutic range (Samaniego-Picota and Whelton, 1996).
Renal impairment is associated not only with excess levels of aminoglycosides but
also with cumulative lifetime dose (Pedersen et al, 1987). Acute aminoglycoside-
induced renal injury is believed to be at the proximal tubule, with resultant leak of
serum electrolytes (Akbar et al, 1999) and the appearance of cell-bound enzymes
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and protein in the urine (Reed et al, 1981; Steinkamp et al, 1986; Godson etal,
1988) reflecting early structural and/or functional changes. In keeping with this,
acute tubular necrosis was documented at renal biopsy in CF patients with acute
renal failure caused by aminoglycoside therapy (Drew et al, 2002). The results of
this relatively large cross sectional study also show a further adverse effect on
glomerular filtration with long-term aminoglycoside use.
Although case reports of acute renal failure in CF (Kovesi et al, 1998; Drew etal,
2002) implicated predominantly gentamicin, tobramycin and gentamicin are
thought to be similarly nephrotoxic (Burkle, 1986) and | therefore did not attempt
to separate the effects of these two agents. Furthermore, a recent study suggested
that aminoglycosides may be less nephrotoxic when given oncedaily (Smyth etal,
2005). However,all patients in the Liverpool adult CF unit have experienced variable
dosing regimens overtime, and | was therefore unable to differentiate this effect in
the study group.
In this study, the nephrotoxic effect of aminoglycosides was potentiated by the
coadministration of colistin, while the use of colistin without aminoglycosides butin
conjunction with other antibiotics did not appear to be nephrotoxic. Interestingly,
although the developmentof severe (sometimesirreversible) renal failure was one
of the reasons the polymyxin family of antibiotics fell out of favour in the early
1970s, the doses used were very high (Price and Graham, 1970). The study
presented herein suggests that colistin used in moderate doses is not nephrotoxic,
but must only be coadministered with aminoglycosides with caution. Unfortunately,
many CF patients in Liverpool are colonized by a highly multiresistant strain of P.
aeruginosa (the Liverpool epidemic strain; LES) that is frequently sensitive only to
tobramycin and colistin (Mirakhur et al, 2003). Thus, many of these patients will
have been coadministered courses of these two antibiotics repeatedly for good
clinical reasons.
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The emergence of these multiresistant P. Aeruginosa strains in CF has resulted in
the repeated use of a limited number of antibiotics to which the organisms are
sensitive, increasing the risk of toxic effects. Colonization by multiresistant strains
may occurin two ways.First, the repeated use of antibiotics will select out resistant
strains, and the practice of routine 3-monthly IV antibiotic therapy in some
paediatric centres may exacerbate this (Ciofu et al, 1994). Furthermore, compared
| “4with conventional “on demand” treatment, this practice confers no advantagein
pulmonary function (Elborn et al, 2000; Breen and Aswani, 2001) and may be
associated with higher mortality (Elborn et al, 2000). Indeed, many patients in the
present study had received such prophylactic IV therapy in childhood before
transfer to the adult CF unit after adolescence. Any apparent short-term benefit of
such a policy must therefore be weighed against the possibility of renal damage in
the long term. The adult CF physicians in Liverpool are now unable to use these
powerful antibiotics in some of their patients because of their compromised renal
function, and have had to modify the dosage regimensin other patients with careful
monitoring of parameters of renal function. Second, epidemic P. aeruginosa strains
tend to be multiresistant (Cheng et al, 1996; Jones et al, 2001) and there is evidence
that such strains are becoming moreprevalent in CF clinics (Armstrong et al, 2002;
Scott and Pitt, 2003) possibly due to a lack of effective segregation policies.
In summary,this study showed that cumulative aminoglycoside use in CF patientsis
associated with long-term renal impairment. Furthermore, although this effect is
potentiated by the coadministration of IV colistin, this therapy on its own in
moderate doses does not appearto be nephrotoxic. Further research is required to
define the mechanism of renal damage due to these therapies, and to explore
potential renoprotective strategies. We recommendthatall CF patients who require
such antibiotic therapy undergo surveillance at least annually for renal impairment.
In the paediatric sector, this may require the use of formulaeto calculate creatinine
clearance, while in adult patients, measured creatinine clearance at the time of
annual screening may be more appropriate.
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CHAPTERFIVE
Acute renalfailure in CF patients chronically infected
by the Liverpool epidemic P. aeruginosa strain
57
5.1 INTRODUCTION
Cystic fibrosis patients chronically infected with P. aeruginosa often require
repeated courses of intravenous antibiotics, many of which may be nephrotoxic. In
keeping with this, | have already demonstrated that a significant proportion of adult
CF patients have renal impairment due to cumulative life time exposure to such
antibiotics (Chapter 4). Although there have been recent reports of episodes of
acute renal failure in children with CF (Kovesi et al, 1998; Drew et al, 2002; Drew et
al, 2003), there are no reported cases in the adult CF population. | now present 8
cases of acute renal failure (ARF) in patients attending the Liverpool Adult CF Unit
(clinic population at the time of completing this study was 185), all of which
occurred in relation to the use of intravenous aminoglycosides for pulmonary
exacerbations caused by chronic infection with the Liverpool epidemic P.
aeruginosa strain (LES), which is frequently multiresistant. Other potential
contributory factors are discussed. Demographic datais given in table 5.11.1.
The CF unit did not adopt once daily aminoglycoside dosing at the time. Local
protocols required measurement of aminoglycoside levels pre and one hour post
the fourth administration and dose adjustment to achieve a troughlevel of < 2.0
mg/I and a peak level of 6-10 mg/l. Subsequently, trough and peak levels were re-
measured 24 hours after any dose adjustment, weekly thereafter and as neededin
response to changes in the patient’s condition to ensure therapeutic serum
concentrations. Consistent with general experience (Tan et al, 2002a), adherence to
this monitoring protocol was less than ideal during home-based IV antibiotic
therapy.
5.2 CASE 1
Case 1 presented in April 2000 with a chest exacerbation with associated
musculoskeletal chest wall pain requiring diclofenac. Admission serum urea,
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creatinine and electrolytes (U&E) were normal and he was commencedonhis usual
dose of IV tobramycin 180 mgtds (9.4 mg/kg/day) and IV colomycin 2 megaunits
tds. Tobramycin levels estimated pre and one hour post the fourth dose were
within the protocol range (<1 mg/l and 7.8 mg/l respectively). His chest improved
but after 16 days, routine tobramycin assay revealed trough and peak levels of 18
and 30 mg/l respectively. Urea was raised at 16.8 mmol/l and creatinine at 231
umol/I. Antibiotics and diclofenac were stopped and IV hydration commenced.
There was no evidence of urinary infection and renal ultrasound was normal. Renal
function continued to deteriorate until day 20 (peak creatinine 331 pmol/l). U&E
slowly returned to normal over the next three weeks but CCI six months later
remained reduced at 58 ml/min (lower limit of normal range = 80).
5.3 CASE 2
Case 2 presented in June 2003 with a pulmonary exacerbation associated with
pleuritic chest pain. U&E were normal. Spirometric measurement was impossible
because of a longstanding Bells Palsy. He was given IV tobramycin 160 mgtds (9.8
mg/kg/day, his usual dose), IV co-trimoxazole (1.44 g bid) (for co-existing
longstanding Burkholderia cenocepacia infection), IV colomycin (2 megaunits tds)
and diclofenac for his pain. Trough and peak tobramycin levels around the fourth
dose weresatisfactory. On day 10 he complained of dizziness, ataxia and tinnitus.
Aural examination was normal. Trough tobramycin level was 8.9 mg/I and renal
function was impaired (urea 23.4 mmol/l, creatinine 300 mol/l). Urine wassterile.
Renal USS showed normal size kidneys. Tobramycin and diclofenac were
discontinued and IV rehydration commencedwith good effect. Serum U&E returned
to normal by 21 days, but CCl four months later was only 63 ml/min. CCl had
previously been measuredin July 2002 whenhe wasclinically stable at 86 mls/min.
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5.4 CASE 3
Case 3 was maintained on azithromycin as an anti-inflammatory agent. In
November 2003 she started home IV antibiotics (tobramycin 120 mg tds [8
mg/kg/day] and colomycin 2 megaunits tds) for a pulmonary exacerbation. Baseline
U&E were normal. Serum tobramycin levels pre and one hour post the fourth dose
were appropriate (0.4 and 9.3 mg/I respectively). On day 12 she developed flu-like
illness and widespread inflammatory arthropathy (mainly wrists, fingers and knees).
Simple analgesia was ineffective and Ibuprofen was commenced. On day 15 she
developed vomiting, dyspepsia, reduced oral intake and a 3 kg weight loss was
noted. A random tobramycin level was 14.8 mg/l and urea and creatinine were
elevated (16 mmol/I and 265 pmol/I respectively). MSU was negative and renal USS
showed normal kidneys with no obstruction.
Ibuprofen, azithromycin and antibiotics were discontinued and IV rehydration
commenced. Serum creatinine peaked at 289 pmol/l on day 17 before gradually
returning to normal on day 25 (107 pmol/l), at which point CCl was 37 mls/min.
5.5 CASE 4
Case 4 waslisted for pulmonary transplantation, and required prolonged courses of
IV antibiotics, often carried out at home, to achieve a clinical effect. In October
2000 U&E were normal. In December 2000 she undertook a course of home IV
tobramycin (160 mg tds: 10.3 mg/kg/day — her usual dose) andIV ceftazidime (3 g
tds) and serum tobramycin levels around the fourth dose were normal (0.9 and 8.3
mg/l respectively). By day 18 there had beenlittle clinical change and sputum
cultures suggested reduced susceptibility of her P. aeruginosa isolate to
ceftazidime, which wasaccordingly changed to IV colomycin 2 megaunits tds. At day
25, azithromycin was added in and the intravenous antibiotics continued
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unchanged. Tobramycin levels remained in the therapeutic range. By day 39, FEV1
had improved but she complained of nausea, headache, dizziness and widespread
arthralgia; BP rose to 180/95, renal function deteriorated (urea 42.1 mmol/l and
creatinine 394 umol/I) and a random tobramycin level was high at 39 mg/l. She was
admitted to hospital, IV antibiotics and azithromycin stopped, and rehydration
started. Investigation of the renal tract was unhelpful except for microscopic
haematuria. Marked peripheral blood eosinophilia (16%) was noted. Serum
creatinine peaked at 465 umol/I on day 46, when the CCI was only 11 ml/min. By
day 59 she was normotensive and the U&E had returned to normal, but two months
later CCl was only 51 ml/min and was still reduced at 58 mls/min twoyearslater.
5.6 CASE 5
Case 5 wasa late diagnosis at age 51 years having been treated for asthma and
bronchiectasis in a general chest clinic. Awaiting transplant assessment, she was
commencedon nebulised tobramycin (TOBI) and azithromycin.
In February 2004, she was hospitalised for a respiratory exacerbation. TOBI’ was
replaced with IV tobramycin (120 mg tds: 9 mg/kg/day) and IV colomycin 2
megaunits tds. Pre treatment renal function was normal. Although trough and peak
tobramycin levels on days 2 and 4 weresatisfactory (1.1 and 9.1; 1.3 and 8.4 mg/l
respectively), by day 9 they were elevated (12.3 and 29.1 mg/l) and renal function
was abnormal(Cr 285 pmol/l). Renal tract investigations were normal, except for
urine and peripheral blood eosinophilia. Antibiotics and azithromycin were stopped
and she was treated conservatively with IV hydration. Three days later random
serum tobramycin was 1.1 mg/I. Recovery of renal function was slow and 24 days
later CCl was 41 ml/min. Due to her severe respiratory morbidity nebulised TOBI
and azithromycin were restarted four weeks later without immediate adverse
effects on renal function.
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5.7 CASE 6
Case 6 was admitted in May 2001 for an exacerbation and treated for two weeks
with meropenem, colomycin (2 megaunits tds) and tobramycin (120 mg tds: 6.5
mg/kg/day; her usual dose is 140 mg tds). Tobramycin levels were 2.3 and 9.0 mg/|
pre and post the fourth dose respectively. Tobramycin dose was not adjusted, and
U&E remained normal. In June 2001 she had a further exacerbation, treated at
homewith tobramycin (120 mg tds), colomycin (2 megaunits tds) and ceftazidime(3
g tds). On day 4 she became pyrexial and developed a widespread macular rash.
Trough and peak tobramycin levels were 6.0 and 18 mg/l respectively. Urea was
10.5 mmol/l and creatinine 318 mol/l. There was no evidence of a urinary tract
infection and renal USS was unremarkable. A blood eosinophilia of 11% and
haematuria and eosinophilia in the urine sediment suggested a drug-induced
allergic reaction. Antibiotics were stopped and she insisted on discharge. U&E
returned to normal after two weeks, although on day 19 CCl was only 60 ml/min.
5.8 CASE 7
Case 7 wastaking azithromycin as an anti-inflammatory agent. In June 2000 she was
treated at home with gentamicin (120 mg tds: 6.6 mg/kg/day) and meropenem (1 g
tds). Gentamicin levels were within the therapeutic range (trough 1.0 and peak 8.3
mg/l) and U&E were normal. She did not improve and on day 10 washospitalised.
At day 15 gentamicin levels were 6.0 and 9.4 mg/I pre and post dose respectively,
on unchanged medication. Creatinine rose to 144 umol/I. Gentamicin was stopped
and subsequently restarted (she would not accept an alternative in view of previous
allergic reactions or intolerance to many antibiotics) at 120 mg bid with satisfactory
levels thereafter. She was discharged with clinical improvement and normal U&Eat
day 31. She represented two weeks later with a further exacerbation. On this
occasion she was treated with tobramycin (140 mg tds: 7.6 mg/kg/day) and
meropenem (1 mgtds): pre and post fourth dose tobramycin levels were 7.9 and
16.8 mg/l respectively and tobramycin was omitted for several doses and then
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recommenced at 80 mgbid on day 7. Subsequently tobramycin levels remained in
the therapeutic range (pre dose <1 and post dose 8.7-10.1 mg/l) for multiple assays
taken between days 8 and 22. Thefirst abnormal creatinine was noted on day 8
(157 mol/l) and reverted to normal by day 14. Investigation of the renal tract failed
to provide an alternative explanation. Furthermore, on day 22 she complained of
dizziness, tinnitus, and deafness, and ENT review revealed disequilibrium and high
tone sensorineural deafness in keeping with aminoglycoside toxicity. Tobramycin
treatment was withdrawn.
5.9 CASE 8
Case 8 underwent ureteric reimplantation for  pelvi-ureteric juction
obstruction/strictures and had recurrent urinary tract infections as a youngchild,
but had no episodes of renal dysfunction as an adult. In October 2000 she received
two weeks of IV tobramycin (160 mg tds) and colomycin (2 megaunits tds) at home
for a pulmonary exacerbation with good effect and no adverse reactions. The same
treatment was repeated five weeks later for a second exacerbation. Peak
tobramycin levels > 10 mg/I on days 2 and 5 resulted in the dose being reduced in a
stepwise fashion to 100 mg tds. A trough tobramycin assay of 2.9 mg/I on day 10 led
to further reduction in dose to 100 mg bid. U&E remained normal throughout. By
day 14 herrespiratory symptoms and FEV1 had improved but she complained of
lethargy, nausea, vomiting, fever, rigors and cloudy urine. She was immediately
admitted to hospital and the first abnormal U&E recorded (urea 12.2 mmol/l;
creatinine 190 mol/l). Despite abundant puscells in the urinary sediment, MSU
and blood cultures weresterile. A small calculus was projected over the lower pole
of the left kidney on a plain abdominal x ray. USS showed both kidneys to be of
normal size without significant scarring or obstruction but the appearances of the
parenchymawere in keeping with bilateral pyelonephritis. Immunology screen was
negative. She was rehydrated with IV fluids and tobramycin was replaced with
meropenem. Her symptomssettled and U&E returned to normal over the next 7
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days, although CCl was reduced to 12 ml/min. Renal impairmentwasstill evident 27
monthslater (CCI 48 ml/min).
5.10 DISCUSSION
The potential for aminoglycosides to cause renal damagewasfirst described in 1945
(Hinshaw and Feldman, 1945). In commonwith other renally excreted drugs, their
serum concentrations are reduced in patients with CF (Rey et al, 1998), who
subsequently require high doses to achieve therapeutic levels often over prolonged
courses. CF patients are therefore at particular risk of aminoglycoside toxicity.
Surprisingly however, there are few reports of renal disease in CF, and acuterenal
failure has only recently been described in children in association with gentamicin
(Drew et al, 2002; Drew et al, 2003). This report is the first to describe
aminoglycoside toxicity in adult CF patients, mainly in association with tobramycin
whichis, traditionally, thought to be one of the less nephrotoxic aminoglycosides
(Burkle, 1986; Pedersenet al, 1987).
Aminoglycosides have a narrow therapeutic range, and require careful monitoring
of serum levels to prevent acute toxic effects. Such toxicity results from a
proportion of the administered dose accumulating in the epithelial cells of the
proximal renal tubules, causing a stepwise alteration of cell function ultimately
leading to acute tubular necrosis (Mingeot-Leclercq and Tulkens, 1999). Advancing
toxicity is characterised by increased electrolyte leak and finally renal failure is
manifest by uraemia and high serum creatinine concentration. In clinical practice,
oliguric or anuric renal failure is rare. Tubular damage may continue for several days
after cessation of aminoglycoside therapy due to high parenchymal levels
(Mingeot-Leclercq and Tulkens, 1999). Indeed serum creatinine continuedtorise for
a few days after aminoglycoside withdrawal in cases 1, 3 and 4 in this series, and in
some recovery was protracted. None of the patients presented here had
oliguria/anuria, abnormal serum electrolyte concentration or evidence of
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glomerulonephritis, and renal biopsy was not performedsince all cases recovered
without the need for dialysis. However, all were left with reduced creatinine
clearance (mean 52 mls/min [range 37-63]; mean interval from episode of ARF 9
months [range 1-27]). In every case, serum urea and creatinine levels recovered to
normalafter the acute event, highlighting the insensitivity of these routine serum
markers for monitoring long term changein renal function.
Aminoglycosides are powerful antipseudomonalagents, and have an importantrole
in the treatment of patients with CF, especially where multiresistant strains are
present. In this series, all patients were chronically infected by such a multidrug
resistant transmissible strain (the Liverpool epidemic strain) that is generally only
sensitive to tobramycin and colomycin (Mirakhur et al, 2003). However, the reasons
why these patients developed acute renal toxicity related to aminoglycoside use
after many previous courses are unclear. Risk factors for aminoglycoside toxicity
include cumulative exposure, high dosage, prolonged therapy, dehydration,
concurrent nephrotoxic medication and pre-existing renal disease. All patients
presented here had previously received many courses of IV aminoglycosides
without overt ill effect (mean 6.8 courses in the preceding 2 years [range 4-11]), and
their dosage had been correctly monitored (average 10 satisfactory paired serum
tobramycin levels per patient [range 6-18]). Their pulmonary function and
nutritional state did not change significantly over this period. Also, the dosages of
aminoglycoside were within the UK CF Trust guidelines (Cystic Fibrosis Trust
Antibiotic Group 2002) (mean 8.8 mg/kg/day, [range 6.5-10.3]), and with the
exception of case 4 (duration 39 days), none were subjected to unusually prolonged
treatment (mean 9.8 days [range 4-16] at diagnosis of acute renal toxicity). The
close proximity of 2 courses in cases 6, 7 and 8 may have played a part in
precipitating renal injury. Only one patient had evidence of pre-existing renal
anomaly and none had features of obstructive uropathy or connective tissue
disorder/vasculitis.
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There are several possible contributory factors potentiating the development of
acute renal failure in this series of patients. All patients were on combination
antibiotic therapy in keeping with current best practice for CF (Cystic Fibrosis Trust
Antibiotic Group 2002), and B-lactam antibiotics have been implicated in drug
induced acute tubulo-interstitial nephritis (TIN) (Pusey et al, 1983). In theory, acute
TIN may complicate CF as a result of an allergic reaction to many drugs (Stephens
and Rigden, 2002), but there is only one report of this complication in CF patients,
in relation to the use of ceftazidime (Drew et al, 2002). In my study cohort, review
by a senior renal specialist concluded that the substitution of ceftazidime for
meropenem (case 6) and the introduction of azithromycin (cases 4 and 5) may be
relevant: these cases developed peripheral blood eosinophilia and renal sediments
in keeping with drug induced TIN (Pusey et al, 1983). Azithromycin, a macrolide
antibiotic increasingly used for its immune modulatory effect in CF, has also been
shownto precipitate TIN (Mansoor et al, 1993), but this has not been previously
described in CF patients. Also, there are no reports of an interaction between
azithromycin and aminoglycosides, and the pharmacokinetics of azithromycin are
not significantly altered in patients with mild to moderate renal insufficiency
(Hoffler et al, 1995). None of my patients taking azithromycin were onstatins,
cyclosporin or other immunosuppressive therapy, as interactions with these agents
have been reported to induce ARF (Ljutic and Rumboldt, 1995; Grunden andFisher,
1997). All but two of the cases described above were co-treated with IV colistin.
Although no histological evidence of acute interstital inflammation was seen on
necropsyof six non-CF intensive care unit patients after treatment with large doses
of colistin (26 megaunits per day) (Price and Graham, 1970), suspected acute
interstitial nephritis induced by colistin was more recently reported in a 35 yearold
critically ill non-CF patient upon retreatment with this antibiotic (Kallel et al, 2005) .
The authors proposed that he had developed an allergic reaction to colistin after
the first exposure manifesting as acute renal failure. However, polymyxin-induced
TIN has never been described in the CF literature (Bosso et al, 1991). Obviously, as
TIN-induced renal impairment results in increased serum aminoglycoside levels,it
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will further exacerbate aminoglycoside related nephrotoxicity. TIN is unpredictable
and can happenat any timeafter introduction of the drug (Puseyet al, 1983).
In addition, many of my patients were also receiving concurrent non-steroidal anti-
inflammatory drugs (NSAIDs), which have previously been reportedto interact with
aminoglycosides in CF patients (Kovesi et al, 1998; Scott et al, 2001). These are
frequently administered in adult CF patients, who maypresent with posture-related
musculoskeletal chest or back pain as well as CF-related arthropathy. NSAIDsinhibit
intra-renal production of the vasodilator prostaglandin E2 and prostacyclin, causing
renal vasoconstriction and acute renal dysfunction (Whelton, 1995). This is relevant
only in extracellular volume contracted states, when renal blood flow is dependent
on prostaglandin production. It is therefore essential to monitor renal function in CF
patients taking NSAIDS particularly if they are unwell, dehydrated and receiving IV
aminoglycosides(cases 1, 2 and 3).
Thus, aminoglycoside-induced nephrotoxicity may not be a simple process and can
be influenced by several interrelated factors. Indeed, the development of ARFin
this case series is very likely multifactorial, with dehydration and the co-
administration of several potentially nephrotoxic medicines, such as _anti-
inflammatory agents and antibiotics, making significant contributions.
The cases discussed aboveillustrate one of the difficulties encountered in treating
adult CF patients infected with multiresistant epidemic P. aeruginosa, in particular
the LES. This strain is highly prevalent amongst CF patients in Liverpool, and is
widespread throughoutCF clinics in the UK (Scott and Pitt, 2003). Prevention of the
spread of such organisms within the CF communityis essential, and this can only be
achieved through the implementation of strict segregation policies. Avoidance of
aminoglycosides is rarely an option as the emergence of these resistant strains
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compels their use. Instead, | suggest that emphasis should be on reducing their
harm. For example, compared with the multiple daily dosing schedules of
aminoglycosides that were used in all the cases described in this study, once daily
regimens were recently shown to be equally effective in the treatment of CF
pulmonary exacerbations, with the possible added advantage of reduced
nephrotoxicity (Smyth et al, 2005). However, the renal sparing effects of this
approach wereonly seen in children but not adult CF patients. In fact, CF adults in
this trial displayed a significantly higher serum creatinine after once daily therapy
but the study did not have sufficient power to exclude greater nephrotoxicity in the
adult subgroup (Smyth et al, 2005). The same authors have since demonstrated
reduced tobramycin elimination rate on once daily therapy: this may be explained
by early renal damage caused by the higher tobramycin boluses that could not be
detected by the crude biochemical assays usedin the initial randomised trial (Touw
et al, 2007).
Renoprotective strategies could also include choosing less toxic aminoglycosides
(Tan et al, 2002a), alternating classes of antipseudomonal antibiotics to increase the
interval between course exposuresto allow complete drug clearance, and increased
vigilance when aminoglycosides are used concurrently with other potentially
nephrotoxic drugs. Careful monitoring of drug levels is paramount, particularly if
there is a potentially dehydrating state or pre-existing renal anomaly. | have
previously demonstrated that adult CF patients have occult renal damage
associated with long-term exposure to aminoglycosides (chapter 4). In those
paediatric CF units where routine three monthly IV antibiotic courses are offered
(which has not been shown to be beneficial (Elborn et al, 2000)) aminoglycosides
should be avoided where possible. As survival in CF continues to improve, the
incidence of drug-induced renal injury may increase, strengthening the case for
screening/surveillance for aminoglycoside-induced toxicity (Tan et al, 2002b).
Measurement of creatinine clearance and an assessment of the interval
aminoglycoside exposure at each annual screen maybe a useful aid.
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CHAPTERSIX
Comparison of methods of assessmentof renal
function in CF patients
71
6.1 INTRODUCTION
Although CFTR protein is expressed in the kidney, renal disease is not a primary
complication of the CF state (Morales et al, 2000). Previously, renal stones were a
recognised feature of dehydration due to CF (Perez-Brayfield et al, 2002), and more
recently cases of acute renal failure have been reported in CF children (Kovesietal,
1998; Drewetal, 2003). | have now shownthat acute renal failure can occur in CF
patients undergoing aminoglycoside therapy (Chapter 5), and have demonstrated
an association between the cumulative lifetime use of these nephrotoxic antibiotics
and diminishing renal function in adult CF individuals (Chapter 4). With improving
survival, CF patients will become repeatedly exposed to these renally harmful
antibiotics in the treatment of pulmonary exacerbations and careful monitoring of
renal function is therefore essential.
Renal function depends upon the glomerularfiltration rate, which is most easily
reflected in clinical practice by the ability of the kidney to clear the muscle
breakdownproduct creatinine (the creatinine clearance rate) (Cameron and Greger,
1997). Measurement of this requires comparison of the urinary and serum
creatinine, which in turn depends upon an accurate assessment of urinary
creatinine, best provided by a 24 hour urine collection (Cameron and Greger, 1997).
However, the need for timed urine collections can lead to compliance errors in
adults, and may not bepossible in children.
To circumvent this, formulae (Jelliffe, 1971; Jelliffe, 1973; Cockcroft and Gault,
1976; Lott and Hayton, 1978; Mirahmadi et al, 1983; Salazar and Corcoran, 1988;
Cronberg et al, 1992; Agarwal and Nicar, 1994; Levey et al, 1999; Rule et al, 2004)
based on the serum creatinine (SCr) and physical characteristics of the subject have
been developed to estimate creatinine clearance. They are commonly used in
children and also where drug dosages need to be adjusted according to renal
function. Of these, the Cockcroft-Gault Formula (CGF) (Cockcroft and Gault, 1976)
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and the abbreviated Modification of Diet in Renal Disease formula (aMDRD)(Rule et
al, 2004) are the most widely used in clinical practice. The accuracy of CGF in
different settings (eg, the elderly (Nicoll et al, 1991), diabetics (Sampson and Drury,
1992) and patients with cancer (Davila and Gardner, 1987)) has been documented.
CGF has recently been recommendedforuse in CF patients (Tan et al, 2003) and the
UK Chronic Kidney Disease guidelines (Burden and Tomson, 2005) advocate the use
of aMDRD for automated laboratory reporting of estimated glomerular filtration
rate. However, neither of the two formulae has been validated in the CF population.
To investigate this further, | compared the accuracy of CGF, MDRD, aMDRD and
other formulae with measured creatinine clearance over a range of renal function in
a groupof adult CF patients and also in a control group of non-CF subjects.
6.2 PATIENTS AND METHODS
6.2.1 CF population
Eighty three adult CF patients (FEV1 % predicted: mean 63, standard deviation [SD]
23, range 16-119) attending the outpatient clinic were recruited over a 26 month
period. All patients had a serum creatinine within the normal range (mean 85.5
umol/I, SD 15.8; local laboratory reference range is 50-140 pmol/l). None had
previous history of renal problems, including acute drug-related nephrotoxicity, and
all were in a stable clinical state with no acute antibiotic therapy for at least 12
weeksprior to study. In addition, all had normal renal ultrasound scans at annual
screen.
6.2.2 Control population
The control group consisted of forty age and BMI matched (table 6.5.1) non CF
subjects attending the general medical department for management of
hypertension with stable renal function and a serum creatinine within the normal
range (84.0 umol/I [SD 13.5]). None had severe hypertension, any evidence of end
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organ damage,or weretaking nephrotoxic drugs. Controls wereselected if they had
at least one urine sample for estimation of GFR collected during the same time
interval as that for the CF group.
6.2.3 Measured creatinine clearance (mCCl)
All subjects received routine instructions on howto collect 24 hour urine samples.
CF patients submitted 206 urine collections (median 2 samples per patient; range 1
— 5) compared with 82 collections from controls (median 2 per patient, range 1-3).
Samples of less than 500 ml were excluded. The mean urinary creatinine per
kilogram body weight was calculated separately for men (CF: 0.187 [SD 0.046]
mmol/kg; controls: 0.181 [0.061] mmol/kg) and women (CF: 0.138 [0.040] mmol/kg;
controls: 0.142 [0.044] mmol/kg). As previously described (Thakur et al, 1997;
Chapter 4), all 24-hour urine collections that had creatinine/kilogram within one
standard deviation of these respective means were considered valid and included
for further evaluation. Following validation, 159 (77%) collections from 74 CF
patients and 60 (73%) from 29 controls were used to obtain mCCl. Valid collections
from each patient were averaged to form single data points. SCr was measured
after an 8 hour fast at the end of each collection by standard autoanalyser
technique. The clearance of endogenouscreatinine was determined by the formula
mCCl = Urine Cr * Urine volume / SCr and expressed as ml/min (Cameron and
Greger, 1997). No attempt was madeto convert mCCl in terms of body surface area
(BSA).
6.2.4 Estimated creatinine clearance (eCCl)
The age, sex and weight of each subject were determined. eCCls were calculated
according to the formulae as listed in appendix | (Jelliffe, 1971; Jelliffe, 1973;
Cockcroft and Gault, 1976; Mirahmadi et al, 1983; Salazar and Corcoran, 1988;
Cronberg et al, 1992; Agarwal and Nicar, 1994; Levey et al, 1999; Rule et al, 2004).
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Gendercorrection factors were applied when indicated. If a formula estimated CCI
per 1.73 m* BSA, the estimate was readjusted for the subject’s actual BSA prior to
any analysis. Predictions were made without knowledge of mCCl.
6.2.5 Statistical analysis
Results were expressed as the mean +/- SD. For each formula, mean eCCl and its SD,
Pearson’s correlation coefficient (r), p value, and bias (mean eCCl - mean mCCl) was
determined. Using methods described by Bland and Altman (Bland and Altman,
1986), 95% confidenceinterval for bias and limits of agreement (LOA = bias +/- 2SD)
were computed. In the case of CGF and aMDRD,these values werealso calculated
after splitting the data by sex and the presence of renal insufficiency (mCCI < 80
ml/min). For the linear regression analysis, mCCI was plotted on the x-axis vs eCCl
on the y-axis (figure 6.6.1). Data from non-CF controls were similarly analysed.
To test the variability of the mCCls in subjects who submitted more than one valid
urine collection, a repeated measure ANOVA model was devised, and an F test was
used to comparethe intra-individual variations of CF and non CF subjects.
6.3 RESULTS
Table 6.5.2 lists the formulae in descending order of r value in the CF group.
Defining a better predictor as one with a stronger correlation with the mCCl and a
narrowerrangeof error (LOA), CGF and either variety of MDRD were not found to
be superior to other formulae. Amongst formulae with single digit bias in the CF
group, CGF and Mirahmadi had the narrowest LOA: CGF waslikely to overestimate
mCCl by as much as Mirahmadi waslikely to underestimate it. As CGF and aMDRD
are the most commonly used in clinical practice, they were chosenfor the further
analyses described below.
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WhenCGF eCCl was compared with mCCl in CF subjects, the overall correlation was
significant [r = 0.69, p<0.001 (figure 6.6.1)] but less solid than that in non-CF
controls [r = 0.85, p<0.001]. Similar values were found for aMDRD (0.56 and 0.88
respectively, p<0.001). Both formulae generated greater meanbias (9.7 and 4.9 vs
3.4 and 1.4 ml/min respectively, p<0.05) and wider LOAs (-25 to 44 and -35.3 to
45.1 vs -24 to 31 and -23.6 to 26.4 ml/min respectively) in CF patients compared
with non-CF controls. These are shown as Bland and Altman plots (figure 6.6.2).
Furthermore, the proportion of CGF- and aMDRD-derived eCCl values within 10%,
20%, and 33% of mCCl for CF patients were only 25, 54 and 78% and 27, 56 and77%
respectively compared with 35, 72 and 95% and 62, 85 and 97% for controls (CGF:
p<0.05 and <0.01; aMDRD <0.001 and <0.01 at the 20% and 33% thresholds
respectively, figure 6.6.3). MDRD produced similar results to aMDRD (data not
presented).
Thirty five CF patients had diminished mCCl compared with 8 non CF controls (47%
vs 28%, p<0.01), and significantly more mCCl readings were <80 ml/min in the CF
group (72 out of 159 (45%) vs 13 out of 60 (22%), p<0.01). In CF patients, both CGF
and aMDRDgrossly overestimated CCI in the presence of renal insufficiency (table
6.5.3): the bias was very large (18 and 16 ml/min respectively) and the limits of
agreement were wide (-10 to 46 and -18 to 50 respectively), considering that the
mean mCClIin this subgroup was only 63 ml/min. Conversely, when mCCl was
normal (2 80 ml/min), CGF and aMDRD were much moreaccurate predictors of CCl
(mean bias 1.6 and -5.6 ml/min respectively, p<0.001). In contrast, both formulae
producedverysimilar results for both men and women(table 6.5.4). For the non CF
group,figures were similar to overall CF data summarisedin tables 6.5.3 and 6.5.4.
In both the CF and the control groups the first and subsequent mCCl were not
significantly different from one another and the intra-individual variation of repeat
mCCl wassimilar in both groups (P=NS for both groups).
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6.4 DISCUSSION
With increasing reports of acute drug-related renal injury in CF patients,
surveillance for aminoglycoside nephrotoxicity is advocated (Woodetal, 1996; Tan
et al, 2003; Smyth et al, 2008). How best to monitor renal function in this patient
group is unclear. Serum parametersincluding creatinine and electrolyte levels, such
as magnesium,are bothinsensitive and unreliable (Shemeshet al, 1985; Leveyetal,
1988; Akbar et al, 1999). They may remain within the normal range despite
significant and otherwise undetected loss of glomerular filtration and/or tubular
function. Indeed in this study, all CF patients retained normal serum creatinine
concentrations despite 35 having subnormal mCCl.
Accurate measurementof glomerular filtration relies upon a chemical that is merely
filtered through the glomerulus, without any active tubular reabsorption or
secretion. Inulin is such a compound, and its clearance is considered the “gold
standard” for measuring the glomerular filtration rate (Cameron and Greger, 1997).
However, its use in day to day clinical medicine is impractical. The use of the
endogenous substance creatinine (which has a constant and steady production
from muscle breakdown during periods of stable body weight and dietary protein
intake) is an acceptable alternative, although some active secretion in the tubule
may falsely elevate the creatinine clearance rate above GFR by a factor of 1.1
(Bauer et al, 1982a). This effect is exaggerated as GFR falls and the serum creatinine
rises (Bauer et al, 1982b; Shemesh et al, 1985; Giovannetti and Barsotti, 1991).
Nevertheless, in clinical practice measured creatinine clearance is used in lieu of
inulin clearance to measure GFR. | therefore used this measurement as the
standard against which formulae-derived estimates were judged. Althoughusingit|
showed that up to 40% of the CF group had impaired renal function, the true
numberwith a diminished GFRis likely to be greater. | was therefore assured that
using this method did not overestimate renal problems in my patients.
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One possible criticism of this study is the use of timed urine collection to derive
creatinine clearance, where failure to collect all urine in 24 hours can result in an
underestimate of GFR. To avoid this, only specimens of adequate volume (> 500mls)
were included (Cockcroft and Gault, 1976). | could not find a published reference
range for normal daily creatinine excretion in adult CF patients: to ensure that
outlying creatinine values did not bias the results, | only included samples within
one standard deviation of the mean value, of all pooled samples per gender, for
total 24 hour creatinine excretion corrected for body weight, a method used by
other workers (Thakur et al, 1997). Additionally, thus labelled “valid” specimens
generated reproducible results on repeat measurement. | am therefore confident
that the technique employedin this study for timed urine collection allowed an
accurate measurementofcreatinine clearance, in turn reflecting the GFR.
Nevertheless, this method of measuring creatinine clearance in clinical practice is
cumbersome;in adults poor compliance can lead to collection errors and in children
collection may be difficult. In an attempt to overcome this, several formulae
(Jelliffe, 1971; Jelliffe, 1973; Cockcroft and Gault, 1976; Lott and Hayton, 1978;
Mirahmadi et al, 1983; Salazar and Corcoran, 1988; Cronberg et al, 1992; Agarwal
and Nicar, 1994; Levey et al, 1999; Rule et al, 2004) have been developed that claim
to approximate creatinine clearance from serum creatinine concentrations by
factoring in the patient’s biometric data with a range of constants. Recent
guidelines (K-DOQI (National Kidney Foundation, 2002) and UKCKDG (Burden and
Tomson, 2005)) suggest that such formulae should be used to estimate GFR in
preference to mCCl. All these formulae are predictors of the measured CCl, and
typically generate a range wherein mCClfalls. The more accurate the formula, the
smaller this range: an ideal predictor should have a range equal to zero and a
correlation coefficient (r) equal to one. In practice, however,all known formulae are
associated with someerror, and the aim is to select a predictor that correlates well
with mCCl with the minimum of error. Bland and Altman demonstrated that a
positive correlation does not always translate into a good prediction, nor does a
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high r value alone guarantee an accurate prediction (Bland and Altman, 1986).
Instead, they described a more reliable way of comparing 2 methods of measuring a
clinical variable (Bland and Altman, 1986). They documented the difference
between the predicted value and the measured value and devised limits of
agreement (meandifference +/- 2 SD). Investigators can then decideif this interval
is acceptable within their clinical setting. Using these definitions, the first 7
formulae in table 6.5.2 could be equally applicable in CF patients, and none is
superior to the others.
| paid CGF and aMDRDparticular attention since they are the most commonly used
formulae to estimate eCClin clinical practice. In their original monologue Cockcroft
and Gault demonstrated an r = 0.83, with 67% and 95% of their predictions falling
within 20% and 35% respectively of the mCCI (Cockcroft and Gault, 1976). Other
authors have reproduced similar results, supporting the applicability of these
formulae in several disease groups (Davila and Gardner, 1987; Rhodeset al, 1987;
Nicoll et al, 1991; Sampson and Drury, 1992; Cochran and St John, 1993; Alcantara
et al, 1998) and the use of CGF in assessing renal function in CF was recently
recommended (Tan et al, 2003). In our series however, CGF-derived eCCls
comparedless favourably with those for non-CF controls with a lower correlation
with mCCl (r = 0.69 vs 0.85) and a wider error range (-25 to 44 vs -24 to 31).
Additionally, significantly fewer CF estimates fell within 20% and 33% of mCCl (54%
vs 72% and 78% vs 95%, respectively). The results for aMDRD weresimilar.
There are several possible explanations for the apparent discrepancy between CGF
and aMDRDaccuracy in CF patients compared with that in controls and other
disease groups.
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Firstly, since serum creatinine is dependent upon muscle mass, individuals with a
diminished muscle mass may have lower serum levels, resulting in a falsely high
eCCl and greater bias. This was shown in patients after spinal injury, where
paraplegia causes limited muscle massrelative to total body weight. The use of CGF
in these patients was studied by Mirahmadi et al (Mirahmadi et al, 1983) who found
a large bias of 20 ml/min and suggested a correction factor of 0.8 to accountforthis
overestimation. CF patients may similarly have a reduced muscle mass compared
with weight matched controls due to their nutritional difficulties (Stettler et al,
2000; Groeneweg et al, 2002), a hyper catabolic state from chronic systemic
inflammation (Vinton et al, 1999), and frequently a limited exercise capacity
(Selvadurai et al, 2003). Indeed, The formulas of Cockcroft and Gault, Jelliffe | and
Jelliffe Il all overpredicted creatinine clearance in a previous small study of 18 CF
patients with biases of 19, 24 and 8 ml/min and precisions of 37, 42 and 33 ml/min
respectively (Townet al, 1996).
Secondly, it has been shownthat formulae overestimate creatinine clearance where
there is renal impairment. For example, in a study of the use of CGF in paraplegics,
30% of eCCls were outside 33% of mCCls in the subgroup with renal impairment
(Thakur et al, 1997), and this has been reproduced by other authors (Guaschetal,
1996). Thus, the significantly higher proportion of urine collections generating
subnormal mCCl in my CF patient group than in the control groupor in the study of
Thakur et al (45% vs 22% and 18% respectively, p<0.01) may have contributed to
the overestimation produced by CGF. With as many as 40% of eCClfalling outside
33% of the corresponding mCCl for CGF (and 35% for aMDRD) myresults show that
these formulae are less accurate in predicting creatinine clearance in CF patients
with compromised renal function, the very group in which this prediction is of
greatest importance.
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Thirdly, subtle differences in the renal physiology of CF patients are knowntoexist
but are not well understood (Morales et al, 2000): the enhanced drug clearancein
the CF kidney (Rey et al, 1998) is one suchvariation. It may be that one or more (as
yet unknown) variables or constants specific to the CF condition need to be factored
into such formulaein order to improve the prediction accuracy.
The simplicity of their use makes such formulae attractive tools in daily clinical
practice, but they have one major drawback: the formula is not reliable when serum
creatinine is unstable (Cockcroft and Gault, 1976), thus overestimating GFR when
serum creatinine is rising and vice versa. Hence | ensured that all subjects in this
series were clinically well with stable renal function. The lack of significant
variability on repeat measurementof creatinine clearance further supportsthis.
In summary, although CGF and aMDRDare as effective as other formulae in
estimating GFR in adult CF patients, their accuracy is limited and is not as robust as
the traditional timed urine collection method whencarefully supervised. Formulae
have found a nichein calculating drug dosagein renally impaired patients (Preston
et al, 1995), and recent guidelines have suggested that they are used in preference
to timed urine collections. However, in the context of regular surveillance for
aminoglycoside nephrotoxicity, | believe they should be applied with caution as they
maysignificantly overestimate creatinine clearance and hencerenal function in this
subgroup of CF patients; failing to identify the very patients they are aiming to
detect in clinical practice. As awareness of drug-related renal insufficiency in CF
increases, so does the need for a more accurate predictor of creatinine clearance in
these patients and based on my data | cannot recommend current formulae,
including aMDRD and that described by Cockcroft and Gault, as a substitue to
carefully supervised direct measurement of creatinine clearance at the present
time.
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6.5 TABLES
Table 6.5.1 - Baseline characteristics of the study population
Data presented as means (SD) where appropriate
 
CF patients Non-CFcontrols
N 83 40
M:F 44:39 26:14
Age (yrs) 24.3 (7.5) 26.2 (5.1)
BMI(kg/m?) 21.3 (3.6) 22.5 (4.3)
SCr (umol/1) 85.5 (15.8) 84 (13.5)
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Table 6.5.2 - Formulae derived eCCl (ml/min) and their relationship with mCCl in CF
patients (mean mCCl (SD): 83.1 (22.9) ml/min)
 
Formula Mean eCCl (SD) r Pvalue Bias 95% Cl for Bias LOA
Agarwal 93.9 (21.9) 0.7 <0.001 10.8 6.8 to 14.8 - 23.6 to 45.2
Cronberg 95.2 (20.2) 0.7 <0.001 12.1 8.1 to 16.1 - 21.7 to 45.9
Mirahmadi 74 (16.1) 0.69 <0.001 -9.1 -13 to-5.2 - 42.3 to 24.1
CGF 92.6 (20.1) 0.69 <0.001 9.7 5.5 to 13.5 - 24.9 to 43.9
Jelliffe 2 87 (20.8) 0.67 <0.001 3.9 -0.2 to 8 -31.7 to 39.5
Lott 88.1 (19.3) 0.61 <0.001 5 0.6 to 9.4 - 32.4 to 42.4
MDRD 87.1 (19.2) 0.60 <0.001 4 - 0.5 to 8.3 - 34.3 to 42.3
(6 variable)
Jelliffe 1 82.4 (14.9) 0.57 <0.001 -0.7 - 12 to 10.6 -38.1 to 36.7
aMDRD
88 (19.7) 0.56 <0.001 4.9 0.3 to 9.5 - 35.3 to 45.1
(4 variable)
Salazar 106 (22.9) 0.55 <0.001 22.9 17.9 to 27.9 - 20.7 to 66.5
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6.6 FIGURES
Figure 6.6.1
a) mCCl and eCCl correlation derived from the Cockcroft-Gault formula in CF
patients (r=0.69, P < 0.001; mean bias 9.7 ml/min)
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Figure 6.6.1 continued
b) mCCl and eCCl correlation derived from the Cockcroft-Gault formula in non CF
controls (r=0.85, P<0.001; meanbias 3.4 ml/min)
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Figure 6.6.1 continued
c) mCCl and eCCl correlation derived from aMDRDin CF patients (r=0.57, p<0.001;
meanbias 4.9 ml/min)
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Figure 6.6.1 continued
d) mCCl and eCCl correlation derived from aMDRDin non CF controls (r=0.88,
P<0.001; mean bias 1.4 ml/min)
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Figure 6.6.2
Bland and Altman Plots comparing mCCl with CGF and aMDRDin CFpatients
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Figure 6.6.3
Percentage of eCClresults falling within 10, 20 and 33% of mCCl in CF patients and
non-CF controls. CGF and aMDRD shown.
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CHAPTER SEVEN
Changesin renal tubular function with repeated
exposure to aminoglycosidesin CF patients
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7.1 INTRODUCTION
In chapter 4, | documented cumulative sub-clinical reductions in creatinine
clearance proportionalto life time IV aminoglycoside exposure in a cohort of adult
CF patients attending the Liverpool CF unit. The Leeds CF group also demonstrated
a_ significant association between higher baseline urinary N-acetyl-B-D
glucosaminidase (NAG) and the previous 6-year exposure to tobramycin and colistin
(Etherington et al, 2007).
Tobramycin is primarily a proximal tubular cell toxin. Mechanisms for its toxicity
include binding to cell membrane phospholipids denuding the apical brush border,
sequestration in proximal tubular cell lysosomes and injury to mitochondrial
respiration (Kaloyanides, 1992). Most commonly tobramycin produces relatively
minor proximal tubular dysfunction leading to release from tubular cells and
therefore elevated urinary levels of NAG, a proximal tubular lysosomal enzyme and
alanine aminopeptidase (AAP), a brush border enzyme (Mondorf, 1982; Price,
1982). Both NAG and AAPhave been widely used as markers of subtle renal tubular
damage(Kunin et al, 1978; Diener et al, 1981; Gibey et al, 1981; Davey et al, 1983;
Bosomworthetal, 1999). After repeated intravenous courses more marked tubular
dysfunction leading to hypomagnesaemia (Akbar et al, 1999), aminoaciduria and
glycosuria with loss of urine concentrating capacity can be seen and rarely even
acute, non-oliguric, renal failure may ensue (Prime and Tune, 1981).
To explore possible underlying mechanisms for cumulative aminoglycoside toxicity,
in the study presented in this chapter | examined changes in renal function during
two consecutive CF exacerbations each treated with a standard course of IV
tobramycin using a common UK dosage schedule. Enzymuria and proteinuria were
used to detect minor changes in proximal tubular function. U&E and CCl were used
to gauge moreseverealterations in tubular performance.
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7.2 PATIENTS AND METHODS
7.2.1 Study population
| recruited 40 consecutive adult CF patients [mean (SD) age: 22.1 (4.7) years, FEV1%
predicted: 53 (19) %, BMI: 21.9 (2.4) kg/m’, 18 males] presenting with an acute
pulmonary exacerbation for which IV antibiotic therapy was judged necessary and
whodid not receive IV aminoglycosides or colistin for at least 12 weeks prior to
recruitment.
All patients harboured multiresistant LES P. aeruginosa strains which in vitro were
only predictably sensitive to tobramycin and colistin. Chronic infection was defined
as 3 or morepositive sputum cultures within the previous 12 months (Cystic Fibrosis
Trust Control of Infection Group 2001), and multi-resistance as resistance to at least
2 of the 3 standard antipseudomonal antibiotic classes (Cystic Fibrosis Trust
Antibiotic Group 2002). An exacerbation was defined as worsening respiratory
symptoms accompanied by spirometric reduction (Rosenfeld et al, 2001a). Patients
were excluded if they had known hypersensitivity to aminoglycosides or colistin,
significant haemoptysis or new radiographic changes, a history of Burkholderia
cepacia complex isolation in the preceding 12 months and received any additional
oral antipseudomonal antibiotic or non-steroidal anti-inflammatory therapy in the
two weeks prior to recruitment.
Changes to maintenance therapy were not permitted within 14 days of the
exacerbation. At recruitment, 29 patients were on maintenance nebulised colistin
or tobramycin (TOBI®) at home. These were discontinued during inpatient IV
antibiotic therapy and recommenced on discharge. Maintenance therapy did not
differ between the two treatment episodes. None had fever or engagedin physical
exercise for 48 hours prior to recruitment.
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Seven had CF-related diabetes at enrolment and one new case of diabetes was
diagnosed in the remainder over the study period. Prior to treatment, urine
dipstick was negative in all patients and none had pathological proteinuria. None
had previous episodes of acute renal failure, all had normal renal ultrasound scans
at the preceding annual review and none hadreceived organ transplantation or
were prescribed calcineurin inhibitors.
Patients gave written informed consent and the local ethics committee approved
the study protocol.
7.2.2 Methods
For each study patient renal function was compared during two consecutive
exacerbations requiring repeated treatment with IV tobramycin based on in vitro
antibiotic sensitivity patterns of their P. aeruginosaisolates.
In the 80 treatment episodes studied, all patients received 14 days IV treatment
with tobramycin plus colistin, in keeping with the UK CF Trust Antibiotic Policy
recommending that exacerbations be treated with a combination of at least two IV
antipseudomonal antibiotics (Cystic Fibrosis Trust Antibiotic Group 2002).
For each treatment episode outcome measuresincluded changes from day 0 to day
14 in U&E, CCl (measured from 24 hour urine collections), urinary levels of two
proximal tubular cell enzymes (N-acetyl-B-D glucosaminidase (NAG) and alanine
aminopeptidase (AAP)) and urinary Bz microglobulin (B2M) concentrations.
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Urinary assays were carried out weekly thereafter until recovery to pre-treatment
level. Due to large intra- and inter-individual variability of these urine enzymes and
proteins, the following thresholds were pre-defined:
- Complete recovery: urine assay back to the individual’s baseline value or
within 1 SD of the baseline group mean andno greater than double the
baseline value for each patient. Measurements outside these
boundaries represent incomplete renal tubular recovery.
- NAG results were used to categorise patients into complete vs
incomplete recovery groups, irrespective of corresponding trends in AAP
and §2M.
Laboratory methods for U&E, CCl, NAG, AAP and B2M have been described in
chapter 3 (General laboratory methods).
7.2.3 Statistical analysis
Unless otherwise specified, data are presented as means and(standard deviations)
for metric variables and proportions for categorical variables. For normally
distributed data, within- and between-group comparisons were conducted with
paired and unpaired t tests respectively. Urinary marker measurements were not
normally distributed and therefore Wilcoxon Signed Rank test was used to examine
paired baseline data and estimates of the differences between groups were
examined using the Mann Whitney U test. Trends in NAG, AAP and B2M were
analysed with Pearson’s linear correlation. Distributions of renal marker recovery
times after the first and second treatments were compared with Wilcoxon Rank
Sum test. All tests were 2 tailed and P<0.05 were consideredsignificant. Analysis
was conducted with SPSS for windowsversion 15.0.
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7.3 RESULTS
Patients’ BMI, baseline U&E and CCl were not different the two treatment
episodes(table 7.5.1, figure 7.6.1). Patients received the same dose of tobramycin
during both hospital admissions (mean of 7.9 mg/kg/day, SD 1.1, range 5.9 to 9.3 in
2-3 divided doses). Similar serum peak and trough (8.2 vs 7.9 mg/I and 0.8 vs 1.1
mg/I respectively) tobramycin levels were achieved during the two treatment
episodes. A mean of 2 (range 1-4 per patient) paired serum tobramycin levels were
collected and no toxic levels were recorded.
After the first treatment, urinary markers, but not U&E, rose significantly (table
7.5.2, figures 7.6.2, 7.6.3a, 7.6.4 — 7.6.6). The changes in NAG, AAP and B2M
correlated well (NAG vs AAP: r=0.674, P<0.0001; NAG vs §2M: r=0.768, P<0.001;
AAP vs B2M: r=0.508, P= 0.001, figure 7.6.7). The recovery rate of these markers
after the first treatment was variable. In 25 patients recovery was complete by
week 7 [median 3 weeks, range 1 to 7; figure 7.6.8]. The remainder were re-
exposed to IV aminoglycosides prior to complete tubular recovery.
Thirty four (85%) patients completed weekly follow up after the second treatment.
Repeat measurements were analyzed accounting for complete (group 1) or
incomplete (group 2) recovery of tubular markers prior to aminoglycoside re-
exposure. The interval between the two consecutive antibiotic treatments is
depicted for each groupin table 7.5.4.
In group 1, changes in U&E, the rise in tubular markers and their recovery rate were
comparableto the first episode (table 7.5.3, figures 7.6.3b-7.6.6, 7.6.9). In contrast,
group 2 patients’ serum creatinine rose significantly with the second treatment, but
it did not cross the threshold of normality (9.4% rise from baseline, p=0.037, figure
7.6.3b). Similarly, Enzymuria and proteinuria were greater than those observed in
the first treatment episode (table 7.5.3, figures 7.6.4-6) and their return to baseline
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was slowerafter the second treatment compared with group 1 (median 6 weeks;
range 1-8, P=0.0003;figure 7.6.9).
7.4 DISCUSSION
The findings of this study support the impression that IV aminoglycosides can result
in acute renal tubular injury even when serum levels are kept within the accepted
safe therapeutic range (Trollfors et al, 1980; Tan et al, 2002b; Tan et al, 2003). My
data clearly demonstrate that resolution of even mild, otherwise clinically covert,
tubular toxicity after cessation of antibiotic therapy could be protracted. Re-
exposure to aminoglycosides prior to complete tubular recovery produces
incremental tubular toxicity which may explain the previously reported cumulative
loss of renal function with frequent aminoglycoside courses (Chapter 4). The
different urinary marker signal generated by the two consecutive episodes cannot
be explained by differences in aminoglycoside exposure as similar doses and
trough/peak levels were observed.
The rise and decline of NAG after the first treatment episode is similar to that
previously reported by Glass et a/ (Glass et al, 2005) and Etherington et al
(Etherington et al, 2007). Both reports described transient rises in urinary
concentrations of NAG after a single challenge with tobramycin. Glass et al
described acute tubular injury in 22 CF children and adolescents treated with 2
weeksof tobramycin 3mg/kg tds as monotherapy. This showed evidence of almost
complete recovery after 4 weeks, a time scale not too dissimilar to that recorded
after the first antibiotic exposure in my study (3 weeks). Etherington et a/ reported
an eight-fold rise in NAG in 35 adults exposed to 14 days of IV tobramycin and one
of ceftazidime, meropenem, aztreonam or tazocin, all at doses within the UK
guidelines. Urinary NAG levels were back to baseline at a median of 52 (range 8-
123) days post treatment.
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To assess cumulative tubular damage in more detail it would be necessary to repeat
these measurements after further courses of tobramycin. In my cohort of 40
patients, the magnitude of peak NAG levels and speed ofits subsequent decay over
time depended on baseline NAG level prior to the second exposure, which wasin
turn a function of time lapsed from the first antibiotic treatment. Re-exposureto IV
tobramycin within 5 weeks accentuated acute tubular dysfunction and prolongedits
resolution whereas an interval of 14 weeks between treatments preventedthis.
Concordantwith this observation, 6 out of 10 patients who received more than one
tobramycin course in the study by Etherington et a/ (Etherington et al, 2007)
displayed succesive rises in baseline urinary NAG levels, even with a longerinterval
between treatments (median of 65 days, range 38-150).
Comparison of urinary enzymuria and proteinuria between those with and without
CFRD wasnot plausible due to the small numberof patients with CFRDin this study
compared with that of Etherington et a/ (Etherington et al, 2007).
| measured two proximal tubular cell enzymes, one localized to the lysosomes
(NAG) and anotherto the apical brush border (AAP) (Mondorf, 1982; Price, 1982).
High urinary yield of these enzymesreflects acute microstructural changes caused
by a variety of tubulotoxins (Diener et al, 1981; Price, 1982; Davey et al, 1983;
Schiavina et al, 1984; Mueller et al, 1989; dos Santos et al, 1994; Bosomworthetal,
1999). B2M was measured to assess potential functional consequences of these
structural aberrations. In normal circumstances B2M is virtually completely
reabsorbed in the proximal tubule after its filtration at the glomerulus. In the
absence of disease states increasing its production by nucleated cells, increased
urinary excretion of B2M points to impairment of tubular absorptive capacity and it
is therefore regarded a marker of tubular (as opposed to glomerular) proteinuria
(Wibell, 1978; Trollfors et al, 1980; Rybak et al, 1987; Tyner, 1999; Kinai and
Hanabusa, 2005). Clinico-pathological studies localized aminoglycoside-induced
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renal toxicity to the proximal tubule and in particular disruption of lysosomal
membrane integrity (De Broe et al, 1989; Mingeot-Leclercq and Tulkens, 1999).
Unsurprisingly therefore NAG is the most frequently studied tubular enzyme with
the most consistently reproduced reference range. Indeed, a total of eight previous
studies reported antibiotic related changes in urinary NAG in CF although a normal
range has not been agreedforthis patient group (Reed et al, 1981; Steinkampetal,
1986; Godson etal, 1988; Balla et al, 1998; Ring et al, 1998; Glass et al, 2005;
Etherington et al, 2007; Halacova et al, 2008). Hence, in my cohort, changes in NAG
signal were usedto define the extent of tubular recovery after the first exposure to
IV aminoglycosides as either complete or incomplete, irrespective of concommitent
changes in AAP and B2M. Reassuringly however, assays of the three urinary
markers correlated very well.
The significance of this transient enzymuria and proteinuria had been previously
questioned in the absence of clinically measurable functional impairment
(Steinkamp et al, 1986). For example, the insult to the renal tubules after a single
course of aminoglycosides was not sufficient to produce hypomagnesaemia,
elevated serum creatinine or diminished predicted GFR (Schwarz formula) in
previous studies (Glass et al, 2005; Etherington et al, 2007). In contrast, in my study
the greater rise in markers of tubular injury after repeated antibiotic treatment was
associated with a significant rise in serum creatinine. This confirms that the urinary
enzymes and proteins employed here serve as sensitive markers of early tubular
injury and that ultimately sufficient tubular impairment accumulates to produce
clinically overt functional derangement. This direct temporal association between
aminoglycoside-induced enzymuria and higher serum creatinine levels has not been
previously reported.
Of course, colistin, also a tubulotoxin, may be partly responsible for the observed
changes in urinary assays (Falagas et al, 2005; Falagas and Kasiakou, 2006;
Etherington et al, 2007). However, tobramycin produced muchbigger urinary NAG
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signals than colistin in a previous study (8-fold vs 2-fold rise respectively)
(Etherington et al, 2007). Therefore most of the changes observed in my experiment
are likely secondary to the aminoglycoside. Furthermore,colistin was used in both
consecutive exposures; this should minimize confounding effects of the second
antibiotic.
Based on these results, it would seem sensible, in the management of frequent
exacerbators requiring a high burden of antibiotic therapy, that alternative anti-
pseudomonalantibiotic classes are rotated incorporating “aminoglycoside breaks”/
“aminoglycoside holidays”, whilst maintaining surveillance for aminoglycoside- and
otherantibiotic-related nephrotoxicity.
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Table 7.5.2
Changesin urinary enzymesandproteinswith the first IV antibiotic treatment
(n=40)
Data presented as mean and (SD)
 
Urinary marker Day 0 Day 14 P value
NAG 0.41 ((0.57) 3.27 (2.32 <0.0001
(u/mmol)
AAP 0.83 (0.50) 25.42 (21.27) <0.0001
(u/mmol)
B2M 20.31 (11.98) 128.12 (112.19) <0.0001
(mcg/mmol)
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Table 7.5.3
Changesin urinary enzymes and proteins with treatment
Group 1: n= 25, group 2: n = 15. Data presented as mean and(SD)
 
 
 
 
marker group Treatment 1 Treatment 2
Day 0 Day 14 change Day 0 Day 14 change
0.41 3.35 2.94 0.33 3.09 2.76
1NAG (0.61) (2.51) (2.44) (0.54) (1.95) (1.94)
(u/mmol) 0.40 3.14 2.73 1.35 5.81 4.45
2
(0.52) (2.02) (1.67) (1.20) (2.52) (2.18)
P value vs
0.0003 0.011
treatment 1
0.78 26.51 26.09 0.66 24.29 23.63
1
AAP (0.53) (27.10) (25.32) (0.43) (17.56) (17.60)
(u/mmol) 0.91 22.99 22.08 7.09 42.44 35.35
2 (0.44) (12.07) (11.92) (4.84) (19.71) (16.80)
P value vs
0.0002 0.010
treatment1
19.76 130.01 110.25 21.14 134.09 112.95
1
B2M (12.61) (123.39) (117.73) (8.98) (100.61) (99.53)
(mcg/mmol) 21.22 124.98 103.76 55.29 226.36 171.07
2
(11.20) (94.60) (92.75) (30.47) (136.66) (135.43)
P value vs
0.0021 0.189
treatment 1  
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Table 7.5.4
Patient group allocation prior to the second aminoglycoside challenge
Group 1 denotes complete vs incomplete (group 2) recovery of tubular markers
prior to aminoglycoside re-exposure
 Group 1 Group 2
N 25 15
Meaninterval between 14 (11-16) 5 (3-7)
treatments in weeks (range)
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Figure 7.6.2
Changesin blood urea with treatment
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Figure 7.6.3
Changesin serum creatinine
a. by treatment
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b. by group and treatment
Dotted lines represent the local laboratory reference range
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Figure 7.6.4
Changesin urinary NAG with treatment
Group 1: n= 25, group 2:n=15
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Figure 7.6.5
Changesin urinary AAP with treatment
Group 1: n= 25, group 2:n=15
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Figure 7.6.6
Changesin urinary B2M with treatment
Group 1: n= 25, group 2:n=15
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Figure 7.6.7
Correlation between trendsin urinary markers after the first treatment
a) NAG vs AAP
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Figure 7.6.7 continued
B) NAG vs B2M
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Figure 7.6.7 continued
C) AAP vs B2M
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Figure 7.6.8
Time to recoveryof renal tubular markersafter the first antibiotic treatment. Bars
represent individual patients in whom predefined “complete recovery” thresholds
were met.
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Figure 7.6.9
Time to recovery of renal tubular markers after the second antibiotic treatment.
Bars represent individual patients for whom complete follow up data were available
(n=34). Group 1: n= 20; Group 2: n=14.
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CHAPTER EIGHT
Pilot cross over study of high dose nebulised vs.
intravenous tobramycin in combination treatment of
pulmonary exacerbationsin adult CF patients
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8.1 INTRODUCTION
Aminoglycosides are powerful antibiotics frequently used intravenously to treat
exacerbations of P. aeruginosa airwayinfection in CF patients. With the emergence
and increasing prevalence of multi-drug resistant strains (Scott and Pitt, 2004),
aminoglycosides are likely to assume a morecentral role in the management of CF
lung disease. Indeed, the commonest transmissible P. aeruginosa strain in the UK,
the Liverpool epidemic strain (LES) (Scott and Pitt, 2004) is usually only predictably
sensitive to tobramycin and colistin (Mirakhur et al, 2003). However,
aminoglycosides are renal tubular toxins and their IV use has been linked with
reports of acute renal failure in CF children (Kovesi et al, 1998; Drew et al, 2003)
and adults (Chapter 5, Bertenshaw et al, 2007; Smyth et al, 2008) . | have also
shownthat in the long term, cumulative IV aminoglycoside dosing can impair renal
function as manifest by reduced glomerular filtration rate (Chapter4).
In contrast, aerosolised delivery of these antibiotics achieves higher sputum
concentrations, while potentially minimising the risks of nephrotoxicity associated
with systemic delivery (LiPuma, 2001). Although Ring et a/ (Ring et al, 1998)
demonstrated a positive correlation between markers of renal injury and the
cumulative dose of inhaled gentamicin, the effect of inhaled tobramycin therapy
has only been studied using low doses where no renal tubular adverse effects
occurred (Steinkamp et al, 1986). To investigate these aspects further, using a
randomised crossovertrial design | carried out a pilot study comparing the impact
of high dose nebulised tobramycin with IV tobramycin on lung and kidney function
in P. aeruginosa exacerbationsin patients with CF.
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8.2 PATIENTS AND METHODS
8.2.1 Study population
| recruited 20 CF patients (mean [SD] age: 22.1 [6.9] years, forced expired volumein
1 second (FEV1): 64.7 [21.9] % predicted, body mass index (BMI): 20.2 [3.5] kg/m?,
11 males), chronically infected with multiresistant morphotypes of LES P.
aeruginosa who were admitted to the Liverpool Adult CF Unit with pulmonary
exacerbations. Chronic infection was defined as 3 or more positive sputum cultures
within the previous 12 months (Cystic Fibrosis Trust Control of Infection Group
2001), and multi-resistance as resistance to at least 2 of the 3 standard
antipseudomonal antibiotic classes (Cystic Fibrosis Trust Antibiotic Group 2002). An
exacerbation was defined as worsening respiratory symptoms accompanied by
spirometric reductions (Rosenfeld et al, 2001a). Patients with known
hypersensitivity to aminoglycosides/colistin, significant haemoptysis or new
radiographic changes, a history of Burkholderia cepacia complex isolation in the
preceding 12 months, and those who had received any aminoglycoside (IV or
nebulised) therapy during the previous 3 months or any additional
antipseudomonal antibiotic in the 2 weeks prior to randomisation were excluded.
Six had CF-related diabetes at enrolment but no new cases of diabetes were
diagnosed in the remainder over the study period. Changes to maintenance
therapy were not permitted within 14 days of the exacerbations. Nonehad fever or
engagedin physical exercise for 48 hours prior to recruitment. Patients gave written
informed consent and the local ethics committee approved the study protocol.
8.2.2 Study design
Patients were randomised to receive 14 days of either preservative-free pH-
adjusted tobramycin nebuliser solution (TNS) (TOBI®, 300 mg/5ml, Novartis, Surrey,
UK) or IV tobramycin (80 mg/2ml, Mayne Pharma Plc, Warwickshire, UK).
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TNS was administered using a Pari LC Plus™ jet nebuliser (Pari Medical Ltd, West
Byfleet, UK) and a Porta-Neb® compressor (Medic-Aid Ltd, West Sussex, UK) at a
dose of 300mg bd. Although there are no established reference values for serum
tobramycin concentration during nebulised therapy, we measured tobramycin
levels one hour after TNS dosing on days 2 and 14.
IV tobramycin wasgiven at the standard meandaily dose of 8.2 mg/kg [SD 1.5] in 2
— 3 divided doses. According to local protocols, aminoglycoside levels were
measured pre and onehour after the fourth administration and the dose adjusted
to achieve a trough level of < 2.0 mg/I and a peaklevel of 6-10 mg/l. Subsequently,
levels were measured as neededto ensure therapeutic serum concentrations.
Sputum isolates were only susceptible to colistin and tobramycin in vitro. Therefore,
all patients also received IV colistimethate sodium (Colomycin® injection, Forest
Laboratories Ltd, Kent, UK) 2 megaunits tid, in line with the UK CF Trust guidelines
advocating a minimum of 2 anti-pseudomonal antibiotics to treat pulmonary
exacerbations (Cystic Fibrosis Trust Antibiotic Group 2002).
Wheneach patient was re-hospitalised at a later date with a second exacerbation,
they received the alternative form of tobramycin and the same doseof IV colomycin
(figure 8.6.1).
The mean interval between admissions was 6.6 months [SD 4.1; range 3 — 20].
Allowing for age change, baseline patient characteristics were similar and the
remainder of their therapy was otherwise identical in the 2 inpatient episodes
(azithromycin: 8 patients, NSAIDS: 2, rhDNase: 8, IV aminophylline: 4, subcutaneous
bricanyl: 2).
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8.2.3 Outcome measures
8.2.3.1 Efficacy
Clinical evaluation and spirometry were performed and sputum samples obtained
for quantitative microbiology on admission (day 0) and on day 14 (12 hours after
the previous evening nebulised/IV dose). The primary efficacy end point of the
study was the mean change in FEV1% predicted from baseline to day 14. Changesin
forced vital capacity (FVC) % predicted, peripheral blood white cell count (WCC) and
C-reactive protein (CRP) were also noted. Impact on sputum P. aeruginosa density
and time to next exacerbation were compared between the two treatment
strategies. Patients rated their overall satisfaction with improvement during
treatment on a visual analogue scale (VAS: 0 = not satisfied — 10 = completely
satisfied), where for repeat testing patients where blinded to their previous
responses.
8.2.3.2 Safety
Safety endpoints included adverse events, incidence of TNS-induced acute
bronchospam (evaluated by measuring FEV1 before and 30 min after the first TNS
dose and defined as >10% drop in FEV1), serum tobramycin concentrations and
changesin renal function. The latter was measured before and at the end of 2 week
treatment and included serum creatinine (SCr) and magnesium (Mg**) assays, 24
hour urine collection for measurement of creatinine clearance (CCI) and total
proteinuria, and urinary levels of the proximal tubular enzyme N-acetyl-B-D-
glucosaminidase (NAG).
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8.2.4 Laboratory methods
Sputum samples were transferred on wetice to the microbiology laboratory and
processed within 48 hours of collection. Samples were cultured at the beginning
and end of treatment to assess sputum P. aeruginosa density (logio colony forming
units (cfu)/ml). Quantification of Pseudomonas counts in sputum was performed
according to methods previously described by Burns and coworkers (Burnset al,
1998). Sputa were homogenised by the mixing of equal volumes of sputum and
sputasol (Oxoid Ltd, Basingstoke, UK) in screw-toppedplastic universal containers
which were incubated at room temperature for 20 minutes with vortexing. 100 ul
aliquot of each sample was then plated on a MacConkey(Bioconnections, Leeds,
UK) and a pseudomonasselective agar plate (Pseudomonasagar base enriched with
pseudomonas CNselective supplement; Oxoid Ltd, Basingstoke, UK). The plates
were incubatedin air at 37°C for 48 hours. Subsequently the colonies grown were
counted using the Stuart Scientific Colony Counter.
For measurements of serum tobramycin levels, serum and urine creatinine
concentrations, calculation of mCCls, quantitation of 24-hour urinary protein
elimination and urinary NAG levels please refer to chapter 3 (General laboratory
methods). The effects of varied urine concentration were minimised by expressing
NAG level as a ratio of urine creatinine. Results are reported as units/mmol
creatinine.
8.2.5 Statistical analysis
Baseline demographics were compared using a paired t-test or chi-squared test.
Within group changes in pulmonary function, blood, sputum and urine tests were
assessed using a paired t-test (parametric data) or the Mann-Whitney test (non
parametric data). Treatment effect, 95% Cl, and P values were analysed using a
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paired t-test or Wilcoxon rank sum test as appropriate. Comparison of time to next
exacerbation was conducted with Kaplan Meier survival curves and a log rank test.
Results are presented as means(standard deviation (SD)), unless otherwise stated.
Analysis was conducted with SPSS for windowsversion 15.0.
8.3 RESULTS
8.3.1 Treatment efficacy
All 40 treatment episodes concluded satisfactorily and none failed to complete
therapy. The mean (SD) 14 day improvementin FEV1 % predicted was similar for
both treatments: 19.9% (11.3) with TNS and 16.4% (8.5) with IV tobramycin. Mean
difference between treatments was 3.6 (95% Cl -9.7 to 2.6, P=0.26). Figure 8.6.2
showsindividual patient FEV1 data. FVC, WCC and CRP displayed similar patterns
(table 8.5.1).
8.3.2 Effect on sputum P. aeruginosa density
Sputum before and after each treatment(i.e. 4 samples [2 pairs] per patient) were
submitted by 15 patients; sample quality in 2 prevented further quantitative
analysis. In the remaining 13 patients, baseline sputum P. aeruginosa density was
similar before the 2 treatments [TNS: 7.31 logio cfu/ml (3.11) vs IV tobramycin 6.92
(1.93), P=0.68]. Although both treatments significantly reduced sputum P.
aeruginosa counts [-2.81 logio cfu/ml (0.97), p<0.001 vs -1.56 (1.31), P<0.05],
treatment effect was greater with TNS (mean difference between treatments -1.25
logio cfu/ml, 95% Cl -2.67 to -0.33, P<0.05). Treatment-emergent superinfection
with new pathogenswasnotnotedin any of these episodes.
126
8.3.3 Time to next exacerbation
TNS therapy significantly prolonged the time to next exacerbation requiring
hospitalisation. The interval between 2 consecutive hospital admissions was 8.9 (SD
4.7) and 4.3 (SD 1.3) months for patients treated initially with TNS and IV
tobramycin respectively, x test = 12.39; HR 3.64, 95% Cl 2.62-29.6, P<0.001 (figure
8.6.3).
8.3.4 Patient appraisal of therapy
VAS scores at the end of therapy were a meanof8.1 (1.3) for TNS compared with
8.5 (1.1) for IV therapy, for an observed difference in the means between
treatments of 0.4 (95% Cl -0.34 to 1.14, P=0.29), suggesting that patients were
equally satisfied with the improvement achieved on either treatment.
8.3.5 Safety
8.3.5.1 Adverse events (AEs)
There were no AEs warranting withdrawal of therapy. The incidence of AEs was
comparable during TNS and IV tobramycin therapy. Treatment-emergent AEs were
recorded in 11 (55%) and 9 (45%) of TNS and IV tobramycin treatment episodes
respectively. Hoarseness was the most common TNS-related AE compared with
increased cough with IV therapy (table 8.5.2). Acute bronchospasm was not
observedin any of the 20 TNS treatment episodes, and neither treatment induced
acute chest tightness necessitating rescue inhaled or nebulised bronchodilator
therapy. One patient developed minor haemoptysis 2 days after starting TNS:
dosing wasinterrupted for 3 days until the haemoptysis resolved, and subsequently
recommencedwithout further complications.
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8.3.5.2 Serum tobramycin levels
No toxic drug levels were recorded on either treatment. For the IV route, mean
trough and peak serum tobramycin levels measured immediately before and 1 hour
after the 4"" dose (on day 2) were 1.2 (0.3) and 7.3 (1.5) mg/I respectively, and
paired tobramycin assays (median 2, range 1-4 per patient) showed trough and
peak levels of 1.4 (0.6) and 7.6 (1.4) mg/I respectively. Tobramycin concentrations
one hour after TNS on day 2 and day 14 were 1.4 (0.4) and 1.2 (0.7) mg/I
respectively.
8.3.5.3 Effects on renalfunction
Prior to treatment, urine dipstick was negative in all patients and none had
pathological proteinuria. All had normal renal ultrasound scans at the preceding
annual review and nonehadreceived organ transplantation.
Mean SCr wassimilar at baseline [TNS vs IV tobramycin: 82 (11.4) micromol/I vs
83.2 (12.6), P=0.75] and did not changesignificantly on either treatment. Mean %
change from baseline in SCr was 4.3% (9.4) with TNS vs 3.6% (10.4) with IV
tobramycin, for a mean difference between treatments of 0.7, 95% Cl: -6.8 to 5.4,
P=0.83.In all patients, SCr remained within the normal range(figure 8.6.4).
Similarly, Serum Mg”* did not changesignificantly during either treatment. Mean
change was -0.07 mmol/I (0.14) for TNS vs -0.09 mmol/l (0.23) for IV tobramycin,
with a mean difference of 0.02, 95% Cl -0.09 to 0.14, P=0.74. Three IV treatment
episodes but none of the TNS episodes were complicated by mild
hypomagnesaemia (0.60 - 0.69 mmo/I), without associated symptoms.
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CCI wasalso similar at baseline [TNS vs IV tobramycin: 67.9 (23.8) ml/min vs 71.6
(29.1), P=0.66]. Significant improvements in CCl were noted at the completion of
both treatments (figure 8.6.5). With TNS, mean % change from baseline in CCl was
23.9% (48.4) [P<0.05] compared with 26.1% (35.0) [P<0.05] with IV tobramycin, for
a mean difference between treatments of 2.2%, 95% Cl: -24.0 to 28.4, P=0.87.
However, IV tobramycin was associated with greater urinary protein leak than TNS
[mean difference 0.58, 95% Cl 0.30 to 0.87, p<0.001), figure 8.6.6]. Urinary levels of
NAG werelog normally distributed and rose significantly on IV tobramycin (mean
change from baseline: logio 0.74 (0.44) iu/mmol) but not TNS (logio 0.02 (0.51)
iu/mmol) with a mean difference between treatments of 0.72 (95% Cl 0.37 to 1.07,
P <0.001).
8.4 DISCUSSION
To my knowledge, this pilot study is the first to assess the utility of an aerosolised
aminoglycoside as an adjunct therapy in acute exacerbations of P. aeruginosa
infection in CF patients where quantitative microbiological measurements were
performed. The main limitation of this study is that it was not powered to
demonstrate treatment equivalence. Nevertheless, the results suggest that, when
combined with a second antipseudomonal antibiotic, high dose TNS (TOBI,
Novartis, Surrey, UK) is as effective as IV tobramycin, in the treatment of acute
pulmonary exacerbations in CF, with the added advantagesof delaying subsequent
exacerbations and less immediate renal tubular cell injury.
Previous work comparing different IV treatment regimes for tobramycin (Smyth et
al, 2005) suggested that studying 130 patients would give 80% power to show
treatment equivalence. Conversely, routine data from the Liverpool adult CF unit
indicate a standard deviation of 10% for the change in FEV1 % predicted over 14
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days antibiotic treatment. Combining these calculations, 80 patients would have to
be recruited to achieve the same powerlevel (80%) assuming that a difference of
4% or less in the mean changein FEV1 % predicted is tolerated between equivalent
regimens. This invites a multicentre study to confirm the findings of this pilot study
As expected, eradication of P. aeruginosa was not observedin any of the treatment
episodes evaluated microbiologically, since successful treatment of an exacerbation
in chronic airway infection does not dependontheeradication of the organisms but
a reduction in bacterial density (Smith et al, 1988; Regelmann et al, 1990). The
superior efficacy of TNS over IV tobramycin in this respect (a reduction in P.
aeruginosa counts of 2.81 vs 1.56 logio cfu/ml respectively) could partly explain the
longer time to next exacerbation noted after TNS therapy. These two observations
taken together also reassure me that the clinical improvement noted in the
nebuliser arm was not simply related to the concomitant use ofIV colistin. Indeed,
it has already been shownthat IV colistin used as monotherapy in treating CF
exacerbationsis less effective than in combination (Conwayet al, 1997). In keeping
with accepted CF practice (Cystic Fibrosis Trust Antibiotic Group 2002), | ensured
that all exacerbations were treated with at least two relevant antipseudomonal
antibiotics. Furthermore, | controlled the effect of the second antipseudomonal
antibiotic by ensuring that the same one was used throughout the study. To
eliminate any confounding effects of other antipseudomonal therapy, | excluded
patients whoreceived IV or nebulised antibiotics up to 3 months andoral antibiotics
up to 2 weeksprior to randomisation and no nebulised antibiotics, except those per
study protocol, were permitted throughout the study period.
The primary rationale for the use of aerosolised antibiotics in chronic bronchial
sepsis is improved targeted delivery to the site of infection whilst minimising
systemic bioavailability and associated toxicities (Mendelman et al, 1985; LiPuma,
2001; Moss, 2001). TNS (TOBI’) has excellent lung deposition with mean peak
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sputum concentrations up to 15 times higher than with IV tobramycin (Eisenberg et
al, 1997; Weberet al, 1997; LiPuma, 2001). This is very relevant to aminoglycosides
since they display concentration dependentbacterialkilling (LiPuma, 2001). It may
explain the greater impact from the inhaled antibiotic on sputum bacterial load
noted in the present study, which has not previously been reported in comparison
with IV administration in the setting of an acute CF exacerbation. The addition of
TNS to oral ciprofloxacin in pulmonary exacerbations in non-CF bronchiectasis
patients chronically infected with P. aeruginosa has already been shown to enhance
the reduction in bacterial load (Bilton et al, 2006): if similar results were reproduced
in CF, such a combination may reduce the requirement for hospitalisation and IV
therapy.
The possibility that this observation was biased by the effect of antibiotic carryover
in the respiratory secretions cannot be entirely ruled out. However, sputum
bacterial densities remained significantly reduced one week after completion of TNS
dosing in non-CF bronchiectasis (Bilton et al, 2006) and failure to culture P.
aeruginosa at the end of 28 day TNS treatment in paediatric CF patients has been
shownnot to be related to residual tobramycin in bronchial lavage fluid (Gibson et
al, 2003b). Furthermore, to minimise this effect, | collected sputa no earlier than 12
hours after the last TNS dose.
| did not measure tobramycin MICso or MICgo before or after treatment for several
reasons. Firstly, the conventional definition of drug resistance and sensitivity (ie,
MIC breakpoint of 8-16 mcg/ml) as determined by parenteral tobramycin therapy
maynotbe applicable to TNS, and indeedclinical improvement with TOBI’ has been
shownto be independent of conventional MIC category (Ramsey et al, 1999; Moss,
2001). Secondly, although long-term intermittent TNS use can confer an
incremental increase in resistance among P. aeruginosaisolates (Burns et al, 1999;
Ramseyet al, 1999; LiPuma, 2001), this is not seen when the therapyis shorter than
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28 days (LiPuma, 2001) and any acquired resistance recovers when the antibiotic
pressure is removed (LiPuma, 2001). Indeed, a return toward drug susceptibility
after each of the 1-month off-drug intervals was observed in the US inhaled
tobramycin studies (Burns et al, 1999; Ramsey et al, 1999; LiPuma, 2001).
Therefore, treatment limited to 14 days only, followed by longeroff-treatment gaps
in my study (mean 6.6 months) suggests that TNSis unlikely to render P. aeruginosa
isolates more resistant and cannot explain our observed differences in
microbiological effect. Furthermore, in a non-CF bronchiectasis study (Bilton et al,
2006), only one of 26 developed a resistant P. aeruginosa after TNS treatment. |
acknowledge that the use of high range E-test strips would have been helpful to
clarify the increase or maintenance of tobramycin MICs between treatments
(Morosini et al, 2005).
Substantial variations of peak serum levels and areas under the curve have been
observedin CF patients on inhaled tobramycin therapy (Eisenberg et al, 1997; Touw
et al, 1997; Geller et al, 2002), but systemic absorption is generally minimal and
toxicity has not been reported in randomised controlled trials. Systemic bio-
availability of 11.7% with a median serum concentration one hour after inhalation
of 0.98 mg/l and no higher than 2 mg/I are representative figures in stable CF
patients (Touw et al, 1997; Geller et al, 2002; Gibson et al, 2003b). There is a
theoretical possibility that the delivery of aerosolised aminoglycoside to the acutely
inflamed and hyperaemic airways during an exacerbation may increase therisk of
bronchospasm (Alothman et al, 2002) or enhance local drug absorption andits
systemic bioavailability. However, in this study acute bronchoconstriction was not
recorded in any of the 20 TNS episodes, and my 1 hour assays (mean 1.4 mg/l)
suggest that systemic absorption of the aerosol was not augmented during infective
exacerbations. Furthermore, in the TNS arm serum tobramycin levels were
comparable at the beginning and end of the 14 day treatment period and were
similar to concentrations previously reported in studies of maintenance TNS
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therapy in CF and non-CF bronchiectasis (Ramsey et al, 1999; Geller et al, 2002;
Scheinberg and Shore, 2005;Bilton et al, 2006).
| have previously shown that repeated IV aminoglycoside exposure in CF patients
causes renal impairment (chapter 4) and IV aminoglycosides, particularly
gentamicin, were implicated in a recent survey of acute renal failure in CF in the UK
(Smyth et al, 2008). Antibiotic choice is becoming increasingly limited in an era
characterised by rising antibiotic resistance, and the frequent need for
aminoglycosides prompted a searchfor renal-sparing alternative therapy. A recent
report suggested that once daily IV tobramycin in the treatment of CF pulmonary
exacerbations might be less nephrotoxic in children compared with thrice daily
regimens (Smyth et al, 2005). However, a similar protective effect was not seenin
adults, who displayed a higher serum creatinine after once daily therapy and the
study did not have sufficient power to exclude greater nephrotoxicity in the adult
subgroup (Smythet al, 2005). The same authors have since demonstrated reduced
tobramycin elimination rate on oncedaily therapy, postulating early renal damage
caused by the higher tobramycin boluses that could not be detected by the
biochemical assays they used (Touwetal, 2007). The Liverpool adult CF unit has
therefore not adopted once daily aminoglycoside therapy and consequently it was
not used in the control arm of the present cross overstudy.
An inherent difficulty in this subject is how best to survey for acute drug related
renal injury. Serum creatinine is not sufficiently sensitive to detect early changesin
renal function becauseits parabolic relationship with creatinine clearance (CCl) may
fail to reveal significant changes in GFR (Baker, 2002). In keeping with this, serum
creatinine in our study did not alter despite a 25% increase in CCl in both treatment
arms. Conversely, whilst CCl is helpful in the long-term monitoring of renal function
in clinically stable patients (chapter 4), its use to detect subclinical drug-induced
acute renal toxicity in acute pulmonary exacerbations may be limited by
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interventions given to reverse the hypercatabolic volume-depleted state typical of
the condition (Baker, 2002).
In contrast, measurement of proteinuria and enzymuria may serve as sensitive
indices of the early stages of renal damage (Steinkampet al, 1986; Ring et al, 1998;
Mingeot-Leclercq and Tulkens, 1999). Filtered aminoglycosides enter the proximal
tubular epithelium by endocytosis where they adhereto the lysosomal membrane,
causing it to leak and rupture (Mingeot-Leclercq and Tulkens, 1999). Even
therapeutic doses of aminoglycosides can cause proximal tubular injury resulting in
leucocyturia, proteinuria, and elevated urinary excretion of some tubular enzymes
(Mingeot-Leclercq and Tulkens, 1999), where their release is proportional to the
damage caused, long before conventional assays become deranged (Steinkamp et
al, 1986; Ring et al, 1998; Mingeot-Leclercq and Tulkens, 1999). NAG is a lysosomal
enzyme present in high concentrations in the proximal tubular cells: its large
molecular weight does not permit glomerular filtration and consequently raised
urinary concentrations indicate tubular dysfunction (Kunin et al, 1978; Bosomworth
et al, 1999). In this study, significantly lower concentrations of this biomarker were
noted on day 14 of treatment with TNS compared with IV tobramycin, even after
correcting for urinary creatinine, confirming the potential for targeted aerosol
delivery to be less immediately tubulotoxic. To my knowledge there has been only
one casereport of acute renal failure in CF in association with inhaled tobramycin
therapy (Hoffmann et al, 2002). However, in this case the preceding prolonged use
of ciprofloxacin (itself nephrotoxic) could have contributed to the renal insult with
subsequent decreased renal drug elimination leading to an inappropriately high
aminoglycoside level several hours after the last dose.
Although Steinkamp (Steinkamp et al, 1986) reported that inhaled tobramycin did
not alter urinary NAG activity in four CF patients, the doses used were low (40 to
80mg bd) and negligible amounts were detected in the serum (<1.0 pg/ml in all
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cases). Conversely, Ring (Ring et al, 1998) showed a correlation between urinary
NAG and the cumulative dose of nebulised gentamicin in 20 CF subjects: whether
gentamicin is more nephrotoxic than tobramycin is debatable. Only eight studies
(Reed et al, 1981; Steinkampet al, 1986; Godsonetal, 1988; Hugli et al, 1992; Glass
et al, 2005; Smyth et al, 2005; Etherington et al, 2007; Halacova et al, 2008) have
measured urinary NAG excretion during IV aminoglycoside therapy in patients with
CF, and different dosing regimens, laboratory assays and reporting methods make
direct comparisondifficult.
The effect on enzymuria by treatment with the IV colistin/TNS arm in this study was
minimal. Although a previous report (Etherington et al, 2007) demonstrated a small
rise in urinary NAG with IV colistin, that study combined colistin with a number of
other IV antipseudomonal agents that have been linked with enzymuria perse.
These observations need to be confirmedin larger controlled studies butif colistin
were to exert a toxic effect on this part of the nephron, this may explain the
enhancement of long term aminoglycoside-induced nephrotoxicity by colistin
therapy, previously demonstrated in chapter 4. This subject merits further
investigation.
In summary, new approaches to aminoglycoside therapy in acute CF exacerbations
are needed. Whenthis study was conducted, TNS (TOBI’) was the only high dose
aminoglycoside licensed in the UK for nebulised use in CF patients, having been
shownto be effective with a good safety profile in chronic intermittent (month on-
month off) use (Burns et al, 1999; Ramseyet al, 1999; Moss, 2002; Gibson etal,
2003b). An alternative formulation (Bramitob:tobramycin 300mg/4ml Nebuliser
Solution, Chiesi Limited, Cheshire, UK) has since been licensed for long term
aerosolised therapy in CF. My results suggest that the use of TNS (TOBI') in acute
CF exacerbations is also effective, safe and well tolerated with immediate renal
sparing properties. Larger studies are needed to confirm this effect, explore how it
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relates to long term nephrotoxicity with repeated exposure and whether the
findings of this pilot study could be reproduced with Bramitob.
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Table 8.5.2
Number(%) of patients reporting treatment emergentAE.
 
TNS IV tobramycin
aggrevated cough 4 (20) 7 (35)
increased sputum 4 (20) 4 (20)
haemoptysis 1 (5) 0 (0)
acute bronchospasm / chest tightness 0 (0) 0 (0)
hoarseness 6 (30) 2 (10)
pharyngitis 3 (15) 2 (10)
rhinorrhoea 5 (25) 3 (15)
conjunctival hyperaemia 1 (5) 0 (0)
tinnitus 0 (0) 2 (10)
dizziness 1 (5) 3 (15)
paraesthesia 1 (1) 1 (10)
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Figure 8.6.2
Changes in FEV1% predicted during the two treatmentepisodes.
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Figure 8.6.3
Effect of first treatment on the time to next exacerbation, P<0.001.
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Figure 8.6.4
Changesin serum creatinine on treatment. Dotted lines represent local laboratory
reference range.
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Figure 8.6.5
Changesin CCI on treatment. Dotted lines represent local laboratory reference
range.
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Figure 8.6.6
Changesin urinary protein leak (g/24hour) during the two treatment episodes
(mean + standard error), P<0.001.
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CHAPTER NINE
Does fosfomycin have a nephroprotective effect in CF?
Pilot cross over study of intravenous tobramycin and
colomycin with and without fosfomycin in the
treatment of pulmonary exacerbationsin adult CF
patients
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9.1 INTRODUCTION
P. aeruginosa isolates from CF patients are becoming increasingly resistant to
conventional antipseudomonal antibiotics (Pitt et al, 2003). The Liverpool epidemic
strain (LES) of P. aeruginosa, now also isolated in most other UK CF centres (Scott
and Pitt, 2003), is multi drug resistant, usually only predictably sensitive to
tobramycin (TOB) and colistin (COL) in vitro. However, a previous study presented in
chapter 4 confirmed a significant link between repeated intravenous(IV) use of
these agents in the treatment of pulmonary exacerbations in CF and increasing
nephrotoxicity. The continuing application of these antibiotics in CF, presently
unavoidable, necessitates reduction of their dose limiting renal toxicity without
compromising their concentration-dependentbactericidaleffect.
Fosfomycin (1,2-epoxypropylphosphonic acid; FOM) wasoriginally isolated from
Streptomyces fradiae and other Streptomyces species (Hendlin et al, 1969) butis
now produced synthetically. It is a unique broad spectrum bactericidal antibiotic
chemically unrelated to any other known antimicrobial agent (Forsgren and Walder,
1983). FOM hasuseful activity against P. aeruginosa (Forsgren and Walder, 1983;
Reeves, 1994), good lung tissue and biofilm penetration following IV injection
(Farago et al, 1980), and evidence from experimental animal models suggeststhatit
may attenuate the nephro- (Inouye et al, 1982; Fujita et al, 1983; Fujita, 1984;
Morin et al, 1984) and oto-toxicity (Ohtani et al, 1984; Ohtani et al, 1985) of
aminoglycosides when coadministered. Indeed its efficacy in combination IV
therapy for the treatment of multiresistant P. aeruginosa CF exacerbations was
reported recently (Mirakhur et al, 2003). However, its putative renoprotective
properties have not been evaluated in this patient group. This chapter reports the
results of a pilot prospective randomised cross over study of TOB+COL vs
TOB+COL+FOMin the treatment of pulmonary exacerbations in a cohort of adult CF
patients, paying particular attention to changesin renal function.
146
9.2 PATIENTS AND METHODS
9.2.1 Study population
| recruited 18 CF patients (mean [SD] age: 21.8 [3.4] years, forced expired volumein
1 second (FEV1): 59.3 [15.1] % predicted, body mass index (BMI): 21.2 [2.4] kg/m’,
10 males), chronically infected with multiresistant morphotypes of LES P.
aeruginosa who were admitted to the Liverpool adult CF unit with pulmonary
exacerbations. Chronic infection was defined as 3 or morepositive sputum cultures
within the previous 12 months (Cystic Fibrosis Trust Control of Infection Group
2001), and multi-resistance as resistance to at least 2 of the 3 standard
antipseudomonal antibiotic classes (Cystic Fibrosis Trust Antibiotic Group 2002). An
exacerbation was defined as worsening respiratory symptoms accompanied by
spirometric reduction (Rosenfeld et al, 2001a). Patients with known hypersensitivity
to aminoglycosides, colistin or fosfomycin, significant haemoptysis or new
radiographic changes, a history of Burkholderia cepacia complex isolation in the
preceding 12 months, and those who had received any aminoglycoside (IV or
nebulised) therapy during the previous 3 months or any additional
antipseudomonal antibiotic or non-steroidal anti-inflammatory analgesic in the 2
weeks prior to randomisation were excluded. Four had CF-related diabetes at
enrolment and no new casesof diabetes were diagnosed in the remainder over the
study period. Changes to maintenance therapy were not permitted within 14 days
of the exacerbations. None had fever or engaged in physical exercise for 48 hours
prior to recruitment.
Patients gave written informed consent and the local ethics committee approved
the study protocol.
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9.2.2 Study design
Three antibiotics, all administered IV, were used in the study:
1. Tobramycin (80 mg / 2 ml, Mayne Pharma Plc, Warwickshire, UK) at a
standard mean daily dose of 7.6 mg/kg [SD 0.8] with COL and 7.9 mg/kg [0.9]
with COL+FOMin 2 — 3 divided doses [P=0.82]. According to local protocols,
tobramycin levels were measured pre and one hour post the fourth
administration and the dose adjusted to achieve a troughlevel of < 2.0 mg/I
and a peak level of 6-10 mg/I. Subsequently, levels were measured as
neededto ensure therapeutic serum concentrations.
2. Colistimethate sodium (Colomycin®, dry powderfor injection, infusion or
inhalation. Forest Laboratories Ltd, Kent, UK) at a fixed dose of 2 megaunits
tid.
Bs Fosfomycin disodium (5 g powder for reconstitution, Idis Pharma,
Weybridge, UK) at a fixed dose of 5 g tid.
At the first exacerbation, patients were randomised in a 1:1 ration to receive 14
days of TOB+COL or TOB+COL+FOM. This is in line with the UK CF Trust guidelines
advocating a minimum of 2 anti-pseudomonal antibiotics to treat pulmonary
exacerbations (Cystic Fibrosis Trust Antibiotic Group 2002). When each patient was
re-hospitalised at a later date with a second exacerbation, they received the
alternative antibiotic combination at the same doses.
Assessment wasperformed on admission (day 1) and on day 14 and includedclinical
evaluation, spirometry, routine blood tests, 24 hour urine collections/spot urines
and sputum sampling for culture and sensitivity.
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9.2.3 Outcome measures
The primary efficacy end point of the study was the antibiotic-related change from
baseline to day 14 in urinary levels of the proximal tubular enzymes N-acetyl-B-D-
glucosaminidase (NAG) and alanine aminopeptidase (AAP). Renal indices also
included:
e blood urea
e serum creatinine (SCr) and magnesium (Mg”*) assays
e creatinine clearance (CCI) and total proteinuria/albuminuria measured from
24 hour urine collections
e urinary B2-microglobulin (B2M) levels
The two treatment strategies were also compared with regards to changes in %
predicted FEV1 and forced vital capacity (FVC), peripheral blood white cell count
(WCC) and C-reactive protein (CRP) as well as their impact on the time to next
exacerbation. Safety endpoints included adverse events and serum tobramycin
concentrations.
9.2.4 Laboratory methods
For measurements of serum tobramycin levels, serum and urine creatinine
concentrations, calculation of mCCls, quantitation of 24-hour urinary protein
elimination and urinary NAG, AAP and B2Mlevels please refer to chapter 3 (General
laboratory methods). The effects of varied urine concentration were minimised by
expressing NAG, AAP and B2M level as a ratio of urine creatinine. Results are
reported as units/mmolcreatinine (NAG and AAP) or mcg/mmolcreatinine (B2M).
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9.2.5 Statistical analysis
Baseline demographics were compared using a paired t-test or Chi-squaredtest.
Within group changes in pulmonary function, blood and urine tests were assessed
using a paired t test (parametric data) or the Mann-Whitney U test (non parametric
data). Treatment effect, 95% Cl, and P values were analysed using a t-test or
Wilcoxon rank sum test as appropriate. Comparison of time to next exacerbation
was conducted with Kaplan Meier survival curves and a log rank test. Results are
presented as means(standard deviation, SD), unless otherwise stated. P<0.05 was
consideredsignificant. Analysis was conducted with SPSS for windowsversion 15.0.
9.3 RESULTS
All 36 treatment episodes concluded satisfactorily. Table 9.5.1 shows baseline
biometric data at the start of each treatment which did not differ between the two
treatments.
The mean interval between admissions was 4.6 months [SD 2.9; range 1 — 11].
Allowing for age change, baseline patient characteristics were similar and the
remainder of their therapy was otherwise identical in the 2 inpatient episodes
(azithromycin: 6 patients, NSAIDS: 2, rhDNase: 10, IV aminophylline: 2,
subcutaneousbricanyl: 2).
9.3.1 Changesin renal function
Prior to treatment, urine dipstick was negative in all patients and none had
pathological proteinuria. All had normal renal ultrasound scans at the preceding
annual review and none had received organ transplantation or was being treated
with cyclosporine. None had previous episodesof acute renal failure.
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Urinary levels of the proximal tubular enzymes NAG and AAPafter 14 days
treatment with TOB+COL+FOM weresignificantly lower than those recorded after
treatment with TOB+COLalone (table 9.5.2). The addition of FOM to TOB+COLalso
attenuated antibiotic-induced total urinary protein leak in a 24 hour collection but
urinary albumin did not alter from baseline and did not differ between the two
treatments. Although B2M levels on the triple combination were numerically lower,
the difference observed was notstatistically significant. Except for comparable
improvements in CCl, none of the other renal indices changed significantly with
either treatment.
9.3.2 Recovery from exacerbation
The mean 14 day improvementsin all surrogate markers of exacerbation resolution
weresimilar for both treatments (table 9.5.3).
9.3.3 Sputum microbiology
Thirty one out of a possible 36 sputa were collected prior to treatment: all
harboured multiresistant P. aeruginosa isolates that were only susceptible to
tobramycin and colistin in vitro. Twenty eight isolates appeared resistant to FOM on
standarddisc diffusion tests.
P. aeruginosa eradication was not observed (29/31 remained positive, 2/31 did not
submit samples at the end of treatment, 2 of the remaining 5 were able to produce
sputum at the end of treatment, both were P. aeruginosa positive). Treatment-
emergent superinfection with new pathogens was not recorded in any of these
episodes.
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9.3.4 Time to next exacerbation
The addition of FOM did not impact on the time to next exacerbation requiring
hospitalisation. The interval between 2 consecutive hospital admissions was 4.2 (SD
2.9) and 5.0 (SD 3.2) months for patients treated initially with TOB+COL and
TOB+COL+FOM respectively; x test 0.89; HR 1.52, 95% Cl 0.59-4.41, P=0.35 (figure
9.6.1).
9.3.5 Safety
9.3.5.1 Adverse events (AEs)
There were no AEs warranting withdrawal of therapy. The incidence of AEs was
comparable during both treatments: treatment-emergent AEs were recorded in 8
(44%) and 9 (50%) of TOB+COL and TOB+COL+FOM episodes respectively (table
9.5.4).
9.3.5.2 Serum tobramycin levels
Serum tobramycin assays were similar throughout both treatments and no toxic
drug levels were recorded. Paired tobramycin assays (median 2, range 1-4 per
patient per treatment) showed mean trough and peak levels of 1.1 (0.3) and 6.7
(1.6) vs 1.1 (0.5) and 6.6 (1.8) mg/I for TOB+COL and TOB+COL+FOMrespectively.
9.4 DISCUSSION
Over the past 40 years, attention has been directed towards the evaluation of
urinary enzymes as non-invasive biomarkers of renal tubular damage. They proved
to be sensitive tools useful in the early diagnosis of acute renal injury before
conventional laboratory assays become deranged(Trollfors et al, 1980; Sethi and
Diamond, 1981; Mondorf, 1982). An elevation in urinary enzyme activity also helps
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indicate the site of primary tubular damage becauseof their localisation in brush
border (AAP) and tubular lysosomes (NAG) (Mondorf, 1982). Such tests have been
applied in studies of nephrotoxicity caused by different agents including
immunosuppressive drugs (Diener et al, 1981), contrast media (Schiavina et al,
1984; Tschakert et al, 1995), antibiotics (Gibey et al, 1981; Davey et al, 1983;
Mondorf et al, 1983; Rybak et al, 1987), lead (dos Santos et al, 1994) and cadmium
(Gatta et al, 1989; Mueller et al, 1989) exposure. Enzymuria and proteinuria have
also been usedtoinvestigate preclinical renal impairment in conditions known to
cause overt kidney disease including diabetes (Hong and Chia, 1998; Kalansooriya et
al, 2007) and glomerulonephritis (Hultberg and Ravnskov, 1981; Holdt-Lehmann et
al, 2000). Whether enzymuria predicts impending and/or chronic renal impairment
remainsto be clarified. Furthermore, no consensus has been reached as to which
diagnostic indicator has the most accurate prognostic value.
Using these assays, | was able to demonstrate that incorporating FOM in the
antibiotic treatment of CF pulmonary exacerbations afforded some protection
against the immediate proximal tubular injury caused by the TOB+COL combination.
Previously only described in animal models (Inouye et al, 1982; Fujita et al, 1983;
Fujita, 1984; Morin et al, 1984), this is the first report to reproduce the
nephroprotective properties of FOM against aminoglycoside (and possibly colistin)-
induced tubulotoxicity in CF patients. Prior studies of FOM and the humankidney
had been largely confined to its ability to attenuate the renal insult of
chemotherapy, particularly cisplatin-based regimens (Umeki et al, 1988; Hayashi et
al, 1997; Rojanasthien et al, 2001).
FOM is taken up actively into bacterial cells through two nutrient transport systems
present in various bacteria (including P. aeruginosa) and inhibits the initial step in
cell wall synthesis (Kahan et al, 1974; Reeves, 1994). However,in vitro susceptibility
testing for FOM against P. aeruginosa requires the presence of glucose-6-
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phosphate, which is not routinely incorporated into standard sensitivity testing
agars. Thus without this, sensitive strains may appear resistant (Forsgren and
Walder, 1983). Indeed, most of the P. aeruginosa isolates in our cohort were
reported to be FOM resistant. Lack of reliable and easily performed methods of
evaluating in vitro activity of FOM against P. aeruginosa is an important issue that
hampers the clinical assessment of this antibiotic. So far, the only approved
susceptibility testing method for fosfomycin is agar dilution (Clinical and Laboratory
Standards Institute 2005a) which is both laborious and time consuming. Studies
examining alternative susceptibility tests concluded that the minimum inhibitory
concentration (MIC) data for FOM against P. aeruginosa is markedly dependent on
the method used and noneof broth microdilution, disc diffusion or E-test strips are
reliable alternatives to agar dilution (de Cueto et al, 2006; Lopez-Cerero et al, 2007).
Resolution of an exacerbation does not require P. aeruginosa eradication butis
usually associated with a reduction in sputum P. aeruginosa density (Smith et al,
1988; Regelmannet al, 1990). | did not quantify sputum bacterial load before or
after antibiotic treatment. However, FOM did not prolong time to the next
exacerbation suggesting it did not potentiate the effect of TOB+COL on
Pseudomonal colony counts. Admittedly, this is somewhat speculative but there
appearsto be a dissociation betweenits antimicrobial and nephroprotective effects.
Despite this, FOM may be useful when co-administered with other antibiotics for a
numberof reasons. The vigorous inflammatory response in the CF lung encourages
P. aeruginosa to form microcolonies surrounded by negatively charged
polysaccharides (the biofilm or glycocalyx). This biofilm allows the persistence of
the organism in the face of specific antibodies and antibiotics (Hoyle and Costerton,
1991; Anwaret al, 1992). However, in vitro FOM doesnotreact with the negatively
charged glycocalyx and in vivo therefore may be better poised to penetrate the
biofilm (Kumonet al, 1994). A synergistic in vitro effect has been demonstrated in
combination with ofloxacin against P. aeruginosa growingin a biofilm (Kumonetal,
1995) and with ciprofloxacin against P. aeruginosa isolates from CF patients
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(Figueredo and Neu, 1988). This may be because FOM acts on different synthetic
pathways, demonstrating synergy against P. aeruginosa when used in combination
with a wide variety of other antibiotics including B-lactams, aminoglycosides,
macrolides and tetracyclines (Daza et al, 1977; Perea et al, 1977; Ullmann and
Lindemann, 1980; Takahashi and Kanno, 1984; Courcol and Martin, 1987; Tessier
and Quentin, 1997; Schulin, 2002).
Because FOMacts on synthetic pathways unaffected by other agents, the potential
for the developmentof cross resistance with other classes of antibiotics is reduced
(Perea et al, 1977; Woodruff et al, 1977). Furthermore, FOM has an excellent side
effects profile. Whilst the oral (calcium salt) preparations can cause gastrointestinal
side effects in 2-8% of cases (Jardin, 1990; MacGowanet al, 1990; Mayamaetal,
1993), there are no reports in the literature of significant side effects with the IV
(sodium salt) formulation. Its potential to ameliorate aminoglycoside (and perhaps
colistin)-associated nephrotoxicity demonstrated in this study adds further support
to its utility in the CF population.
| observed similar peak and trough serum tobramycin levels on both treatments,
which rules out improved aminoglycoside elimination as the underlying mechanism
for the apparent nephroprotection.
The primary toxic effect of aminoglycosides is on the lysosomal system within the
proximal tubule (Mingeot-Leclercq and Tulkens, 1999). NAG is a lysosomal enzyme
present in high concentrations in the proximal tubular cells. Furthermore, its
molecular weight (140KD) does not permit glomerular filtration. Thus, raised urinary
NAG levels have been shown to reflect proximal renal tubular dysfunction
(Bosomworthetal, 1999). Eight studies have previously described elevated urinary
NAG excretion during IV aminoglycoside therapy in patients with CF (Reed etal,
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1981; Steinkampet al, 1986; Godsonet al, 1988; Hugli et al, 1992; Glass et al, 2005;
Smyth et al, 2005; Etherington et al, 2007; Halacova et al, 2008). In addition,
Etherington et al (Etherington et al, 2007) demonstrated a much smaller and
transient rise in NAG levels after 2 week treatment with colistin at doses
recommended by the CF Trust guidelines and similar to those employed in my
study. This may explain the observation that colistin did not impair GFR with long
term use in a large cross sectional study of CF adults although it appeared to
enhancethe nephrotoxicity of tobramycin when co-administered (Chapter 4). Thus,
the mechanismsof tubular toxicity for both drugs have been postulated as similar.
Consistent with these reports, the TOB+COL combination in my study generated a
high NAG signal. The addition of FOM attenuatedthis signal, suggesting that FOM
helps preserve lysosomal membraneintegrity, as previously suggested in rat models
(Morin et al, 1978; Inouye et al, 1982; Fujita et al, 1983; Fujita, 1984; Morin et al,
1984). A similar mechanism may account for protection against aminoglycoside-
related ototoxicity.
| have found no published communications regarding urinary AAP application in CF.
Several investigators have reported significant correlations between AAP excretion
and decreasedrenal function in other patient groups (Daveyet al, 1983; Rybak etal,
1987; Holdt-Lehmannet al, 2000; Kalansooriya et al, 2007). As with other indicators
of early renal injury, elevations of AAP in urine precede increases in serum
creatinine in patients with renal toxicity (Diener et al, 1981; Gibey et al, 1981; Davey
et al, 1983). The AAPassay, as described by Jung and Scholz (Jung and Scholz, 1980),
has been consistently sensitive enough to detect differences in enzymuria between
various treatment regimens (Rybak et al, 1987; Nix et al, 1997) and different
severity groups of nondrug-related renal disease (Holdt-Lehmann et al, 2000). |
chose to use AAPas a markerin this study becauseofits specificity to the proximal
tubule cell, since this is the area in which aminoglycosidesinflict their damage.
Accordingly, observed changesin urinary AAP mirrored those of NAG.
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B2M was used for comparison purposes since it has traditionally been used in
clinical practice to detect renal tubular damage (Wibell, 1978; Stosic et al, 1989;
Viergever and Swaak, 1989; Ikeda et al, 2009). It is more of a functional assay: NAG
and AAPlevels reflect tubular structural integrity whereas B2M acts as a surrogate
marker of functional competency of the proximal tubular epithelium (Viau et al,
1986). B2M is a low molecular weight (12 KD) plasma protein synthesised by the
nucleated cells of the body and is normally filtered at the glomerulus and
completely reabsorbed by the proximal tubules where it is catabolised (Wibell,
1978). Interference with proximal tubular reabsorption, due to a variety of
tubulointerstitial diseases (Diadyk et al, 1991) and tubulotoxins (Tyner, 1999; Kinai
and Hanabusa, 2005), will cause enhanced excretion of B2M and other low
molecular weight proteins such as alpha-1-microglobulin and retinol-binding
protein into the urine (Bernard et al, 1982). Indeed, increased urinary B2M leak has
been foundto correlate with altered renal function secondary to aminoglycoside
exposure(Trollfors et al, 1980; Gibey et al, 1981; Rybaket al, 1987).
Both AAP and B2Mlevels rose significantly after TOB+COL therapy. Any contribution
from colistin is at present unconfirmed. FOM reduced AAPlevels significantly. We
could therefore hypothesise that it also preserves the apical brush bordercell
membranein the tubular epithelium in a similar mechanism to that in the lysosome.
In comparison, the impact of FOM on B2M levels was less dramatic. Large inter-
patient variability in the present study may have accounted for this apparent
discrepancy between NAG/AAPvs B2M excretion. Unlike shorter drug challengesin
animal studies (Inouye et al, 1982; Fujita et al, 1983; Fujita, 1984; Morin et al, 1984),
continued exposure to TOB/COL over two weeks may have meantthat despite the
structural preservation, functional deterioration would ultimately becomeevident,
albeit to a lesser extent. In addition, at urine pH<5.5, B2M degradesvery rapidly at
37°C andit is likely that this degradation can beinitiated in the bladder (Donaldson
et al, 1989; Blumsohnet al, 1991). | therefore did not use morning voids (which
tend to be moreacidic) and adjusted all samples to a pH of 7 immediately after
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collection but it is possible this does not entirely eliminate a confoundingeffect.
Nevertheless, there appeared to be a trend towards lower urinary B2M when FOM
was added to TOB+COL. In the absence of disease increasing B2M production (eg.
lymphoma), a rise in GFR reduces serum B2M levels, whilst saturating proximal
tubular reabsorptive capacity resulting in higher urine levels (Wibell, 1978).
HoweverCCl improved to the same extent in both armsof the study, so this can not
explain the lower B2M signal with FOM. Finally, in proteinuric states, an increased
urinary excretion of B2M may not simply reflect tubular damage but could also
result from decreased tubular reabsorption due to competitive mechanisms
(Branten and Wetzels, 1999). Although total protein leak was higher in TOB+COL,
albuminuria levels (indicator of glomerular proteinuria) were similar suggesting that
protein load arriving at the proximal tubule wasnotsignificantly different in the two
treatment arms. Furthermore, none had fever or engaged in physical exercise for 48
hours prior to recruitment as both would physiologically accentuate proteinuria.
Current monitoring of renal injury (blood urea nitrogen [BUN] and serum creatinine)
is not sufficiently sensitive to detect early changesin renal tubular function. Toxicity
is not detected until serious functional damage is evident with a large reduction in
nephron mass. Hence, despite enzymuria and proteinuria, traditional indices such
as urea, creatinine and Mg” did not change. Consistent with earlier reports and
data presented in chapters 7 and 8, CCl improved after reversal of the volume
deplete hypercatabolic state characteristic of the CF exacerbation.
Patients with CF who are chronically infected with P. aeruginosa will require
repeated courses of IV antipseudomonal antibiotics for pulmonary exacerbation.
This frequent use of a limited selection of antibiotics encourages the development
of resistance and many adult CF patients now harbour multiresistant P. aeruginosa
strains. In addition, repeated use of the same antibiotics results in patient
intolerance/sensitisation and increased toxicity, including cumulative renal
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impairment. FOM is a unique bactericidal antibiotic which can help expand the
range of antipseudomonaltherapy available for CF patients and, in my experience,
FOM appeared safe and well tolerated with valuable immediate renal sparing
effects. Whether this translates into clinically meaningful preservation of renal
function needsto beassessedin larger long-term studies.
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9.5 TABLES
Table 9.5.1 - Baseline biometric data at the start of each treatment
 
TOB+COL(N=18) TOB+COL+FOM (N=18)
Mean SD Mean SD
FEV1 % predicted 48.3 13.1 47.2 13.8
FVC % predicted 67.9 10.0 65.4 8.1
BMI (kg/m?) 21.9 2.6 21.6 2.7
Blood urea (mmol/l) 4.4 0.9 4.2 0.8
Serum creatinine (umol/I) 81.6 10.1 82.0 11.8
Serum Mg” (mmol/l) 0.90 0.15 0.83 0.17
CCI (ml/min) 84.3 21.2 81.4 19.7
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Continues onthe following page
Table 9.5.1 continued
 
TOB+COL(N=18) TOB+COL+FOM (N=18)
Mean SD Mean SD
24 hr urine protein excretion (g) 0.08 0.05 0.07 0.05
Urinary albumin (mg/mmol) 1.6 0.7 1.8 0.6
Urinary NAG (iu/mmol) 0.46 0.71 0.50 0.57
Urinary AAP (iu/mmol) 0.95 0.52 0.84 0.54
Urinary B2M (mcg/mmol) 23 13 20 9
TOB daily dose (mg/kg) 7.6 0.8 7.9 0.9
COL daily dose (megaunits) 6 - 6 -
FOM daily dose(g) N/A - 15 =  
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Table 9.5.4 - Number(%) of patients reporting treatment-emergent AE
 
TOB+COL TOB+COL+FOMAE
aggrevated cough 3(17) 3(17)
increased sputum 3(17) 4(22)
acute bronchospasm / chest tightness 2(11) 0(0)
Sore throat/hoarseness 2(11) 2(11)
reduced hearing 2(11) 1(11)
tinnitus 2(11) 0(0)
dizziness 3(17) 1(17)
Paraesthesia 1(6) 1(6)
Nausea 2(11) 3(17)
diarrhoea 1(6) 0(0)
 
Treatment episodes with any 8(44%) 9(50%)
reported AE
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9.6 FIGURES
Figure 9.6.1 - Time to next exacerbation requiring hospitalisation per treatment
group
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CHAPTER TEN
Concluding remarks
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10.1 Renal impairmentin cystic fibrosis: Is there cause for concern?
Although suppurative lung disease is responsible for most of the morbidity and
mortality in CF, expression of the CFTR gene mutation in many other organs makes
it a truly multi-system disease (Boyle, 2007). Life expectancy in patients with CF has
increased over the years. The UK CF data estimateslife expectancy is now greater
than 50 years for those born in 2000 (Dodgeet al, 2007). Complications associated
with the extended longevity of patients with CF include infection of the lung with
multi-resistant pathogens, diabetes, osteoporosis, gastric reflux and liver disease.
Treatment of these resistant pathogens introduces new challenges: they dictate
repeated use of a handful of powerful, often toxic antimicrobials (Boyle, 2007). In
addition, a long history of cystic fibrosis-related diabetes increases the prevalence
of its microangiopathic complications (Brennan et al, 2004). As a result, the focus
has turned recently toward potential, if not actual, renal complications as
highlighted by the present study. Chapters 4 and 5 demonstrate that both acute
renal failure (now termedacute kidney injury, AKI) and long term reduction in renal
reserve are a genuine concern in these patients and there is a need for better tools
to monitor renal function and innovative treatment strategies aimed at
nephroprotection.
10.2 Renal function in CF: what is already known? what did this study add? and
whatis new since?
Renal expression of the CFTR gene mutation has been well documented, yet its
exact role is uncertain. Its contribution to the risk of patients with CF developing
renal disease is unknown. However, the contribution of long-term exposure to
nephrotoxic aminoglycoside antibiotics and renally toxic immunosuppressants in CF
lung transplant recipients is well recognised (Stephens and Rigden, 2002), though
the prevalence and magnitudeofthis toxicity remained largely unmeasured.
Recently, a survey was conducted to document current Australian practices of
administration and monitoring of aminoglycosides in patients with CF (Soulsbyet al,
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2009). Eighteen out of the 28 CF units surveyed reported having identified renal
toxicity in their CF patient population that they associated with aminoglycoside use.
There was no consensusas to the best method of monitoring renal function in CF,
so the real extent of the problem is not yet fully understood. The prospective cross
sectional study presented in chapter 4 suggests significant renal dysfunction with
repetitive aminoglycoside usein adults with CFis likely. In this study between 31%
and 42% of patients had a measured creatinine clearance that was below the
normal range in our laboratory. My data indicate that lifelong treatment with
nephrotoxic agents (and/or disease progression in adults with CF — thoughit is not
possible to separate the two effects) has the potential to impact on renal function
as patients age. Whilst previous publications did not include polymyxins, |
acknowledge that the concomitantuse ofIV colistin (also a potential nephrotoxin)
may have increased the prevalence of renal impairment seen in our patient
population.
Whenthe initial screening cross sectional study was conducted,the local laboratory
lower limit of normal measured CCI (80 mls/min/1.73 m’) was used. Forty two
percent had reduced mCCl, averaging 62 ml/min/1.73 m?. More recent UK CKD
guidelines defined the thresholds of chronic kidney disease according to GFR, where
values of 60-89 ml/min/1.73 m? represent a slight decrease in GFR and lowervalues
are consistent with moderate to severe renal impairment (National Institute for
Health and Clinical Excellence, September 2008). Several patients in the study
presented in chapter 4 had only mild reductions in GFR and some may question the
relevance of this. It is noteworthy however, that | encountered a relatively high
number of episodes of ARF/AKI, some of these documented in patients who
previously had normalor only slightly reduced GFR. There have been many case
reports of aminoglycoside induced AKI in the CF literature (Samaniego-Picota and
Whelton, 1996; Drew et al, 2002; Drew et al, 2003; Kennedy et al, 2005). These
patients all received gentamicin as their aminoglycoside antibiotic. In chapter5,|
reported 8 cases of AKI in adults with CF whereall patients received tobramycin
three times a day; in some of these, creatinine clearance remained abnormal
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several months after apparent resolution of the AKI episode. AKI may occur in all
age groups. In 2007, Bertenshaw et a/ (Bertenshaw et al, 2007) surveyed the
incidence of aminoglycoside-induced AKI in patients with CF in the UK between
1997 and 2004. They found that 15 of the 21 patients identified in the study had
received gentamicin, 5 received tobramycin, and 1 patient had received both
aminoglycosides. The youngest patient was only 4 monthsold and 14 patients were
under 10 years of age. Renal function, defined crudely by serum creatinine levels,
returned to normalin all these patients on cessation of the aminoglycoside. They
concluded that AKI is increasingly recognized in patients with CF. They also
suggested there may be other factors that have an impact on renal function in the
adult CF population, for example, certain CF phenotypes may be predisposed to
renal dysfunction, and cystic fibrosis-related diabetes. In the case controlled study
subsequently conducted by the same group (Smythet al, 2008) 24 cases of AKI were
confirmed between 1997 and 2004in the UK. This case series included the cohort |
described in chapter 5. Of these 24 patients, 21 had received an aminoglycoside
antibiotic within a week of their episode of AKI. This study demonstrated more
conclusively that the use of aminoglycosides in patients with CF is a risk factor for
AKI.
It is important to note that as life expectancy increases more patients with CF
receive lung transplants. All patients receiving solid organ transplants are at risk of
renal toxicity primarily due to the immunosuppressant therapy used (Ishani et al,
2002). Ishani et a/ reported renal function decline in over 90% of lung transplant
recipients, especially in the first 6 months after their transplant, with up to 7% of
patients ultimately developing end stage renal disease (ESRD). The signal is
inconsistent however, with some reports indicating patients with CF did not appear
to be at greaterrisk of this occurring than non-CF transplant recipients and others
highlighting reduced renal survival post lung transplantations in CF compared with
other patient groups(Ishani et al, 2002; Canales et al, 2006). The majorrisk factors
for developing ESRD in this population are: lower GFR pre-transplant; a reduced
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GFR measured 1 monthpost-transplant; the use of cyclosporin alone in the first 6
months and female gender(Broekroelofs et al, 2000).
10.3 Howis renal function being monitored in the CF population at present?
In order to investigate the potential renal sparing properties of new
antibiotics/antibiotic policies, the best method to measure renal function and
monitor treatment induced changes has to be defined. Tan et al published a
literature review to establish guidelines for the monitoring of renal toxicity in
patients with CF receiving aminoglycosides, as well as best practice in relation to
dose and administration (Tan et al, 2002b; Tan et al, 2003; 2005b). They concluded
that “Adverse effects of treatment in patients with CF will become more common
unless surveillance of aminoglycoside toxicity is performed” and recommended a
series of tests that should be carried out during IV aminoglycoside therapy. These
included therapeutic drug monitoring and measurement of serum magnesium,
potassium, calcium, creatinine, and urea. Tan et al (Tan et al, 2003) subsequently
carried out a survey of CF centres in the UK published in 2003. They reported that
78% of centres were monitoring for renal toxicity but only using creatinine and
electrolytes. In a 2007 survey of 28 CF units in Australia, 96% also used plasma
creatinine as the sole method of monitoring renal function. The frequencies of
monitoring varied from daily to alternate weekly (Soulsby et al, 2009).
However, none of my 80 patients had elevated SCr outside the local reference
range, despite subnormal measured CCl in up to 40%. Interestingly, Pedersen et al
made a similar observation as early as 1987 (Pedersen et al, 1987). The authors
raised concerns regarding cumulative damage caused by exposure to multiple
courses of IV tobramycin. Their study identified that 40% of their patient population
(n=46) had an abnormal calculated creatinine clearance but none had an elevated
serum creatinine outside the normal range. However, they did not observe any
clinically obvious chronic nephrotoxicity. Similarly, acute kidney tubular injury noted
in the two cross-over studies presented in chapters 8 and 9 was not accompanied
by significant changesin SCr.
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In conclusion, a normal SCr in a CF patient is not synonymous with normal CCl nor
normal tubular function.
GFR is the most commonly accepted parameter that accurately reflects renal
function. An ideal endogenous marker for measuring GFR should be produced at a
constant rate, should be eliminated only by glomerular filtration (with no
subsequent tubular handling) and drugs should not affect the assay. Currently, GFR
is estimated by using creatinine clearance determined in one of two ways:
1. Twenty-four hour urine collection
2. By using equations based on plasmacreatinine
or using isotopic or non-isotopic clearance rates (the ‘‘gold-standard test’). All of
these methods have drawbacks as discussed in chapter6.
In this study, repeated urine collections from each patient were subjected to
rigorous validation rules as originally applied by Cockcroft and Gault and
subsequent authors (Cockcroft and Gault, 1976; Thakur et al, 1997) — (Chapters 4
and 6). However, measurement of GFR did not reflect acute tubular structural and
functional changes induced by a course of antibiotics. The data presented in
chapters 7, 8 and 9 indicate that, if anything, GFR improves in the majority of
patients after a standard 14 day course of IV therapy. Improvement in the
inflammatory hypercatabolic state and better hydration is likely to be responsible
for this.
Instead, Tan et a/ (Tan et al, 2003) recommended the use of the CGF equation for
estimating CCl in CF but this was not validated. One potential flaw with equation-
derived estimation of CCI is that patients with CF often have low muscle mass
(Miller et al, 1982) leading to a lower than normal production of creatinine and thus
low SCr levels. This can lead to over-estimation of creatinine clearance and an
underestimation of their loss of renal function. In chapter 6, | attempted to validate
several equations commonlyused for estimating CCI including both the CGF and the
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aMDRD equations. | compared 10 equations with stringently validated 24-hour
urine collections as the control. None of these equations could be used reliably to
assess renal function in patients with CF, especially as they tended to grossly
overestimate CCl, particularly in the subgroup with diminished GFR, limiting their
utility as a screening tool for renal impairment in the outpatientclinic.
It is important that there is an increased awareness of these limitations and the
need for a simple, but accurate test to be available for monitoring renal function in
CF whichis capable of identifying renal impairment earlier rather than later (Tan et
al, 2002b; Glass et al, 2005; Chapter6).
10.4 Alternative methods for measuring and monitoring renal function in CF
Thereis interest in finding less invasive and time consuming ways to measure and
monitor renal function compared to the gold-standard clearance tests. These
include quantification of urinary enzymes and proteins as described in chapters 7, 8
and 9. Since tubular dysregulation is an early event in the pathogenesis of
aminoglycoside nephrotoxicity, it seems reasonable that strategies directed at
assessing tubular structural integrity and function would yield important functional
and prognostic data. The measurementof increased levels of small proteins in urine
such as NAG, AAP, B2M, alpha 1 microglobulin, retinol binding protein, and alpha/pi
S-glutathione transferases is associated with tubular cell dysfunction. Therefore
their straightforward measurement could provide a powerful tool in patient
monitoring and ongoingclinical assessmentof renal function.
Aminoglycosides affect renal function by causing toxicity primarily in the lysosomal
system within proximal tubular cells. NAG is a lysosmal enzyme found in high
concentrations in the renal proximal tubular cells and is highly sensitive to acute
renal insults. Thus urinary NAG is a marker for tubular damage but does not
measure renal function per se; rather it demonstrates acute injury in the presence
of a variety of tubulotoxins and disease processes involving the kidneys. Eight
studies have measured urinary NAG as an indicator of acute drug-induced
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nephrotoxicity in CF (Reed et al, 1981; Steinkamp et al, 1986; Godsonet al, 1988;
Hugli et al, 1992; Glass et al, 2005; Smyth et al, 2005; Etherington et al, 2007;
Halacova et al, 2008): a consistent observation has been that urinary NAG increases
in patients receiving IV aminoglycosides but the changesare reversible and return
to baseline at follow up, although the reported follow up interval was variable. In
the TOPIC study (Smyth et al, 2005) which assessed the safety and efficacy of once
versus three times daily IV tobramycin, changes in urinary NAG were compared
between the two groups. Urinary NAGincreasedin all 107 patients who completed
the study with the increase in NAG levels being 33% lowerin those receiving once
daily dosing. Interestingly, in the TOPIC study the changes in NAG levels were only
significant in children and not in the adults although the relevance of this was not
investigated. Using NAG and other renal biomarkers | was ableto:
1. Follow longitudinally the time scale of tubular recovery after a standard 14
day IV tobramycin challenge and was able to demonstrate that a high
antibiotic pressure with shorter drug exposure-free periods lead to
incremental tubular injury, recovery of which may be slower with
consecutive treatments (chapter7).
2. Demonstrate potential renal sparing effects from the use of aerosoldelivery
of tobramycin in the treatment of acute pulmonary exacerbations without
compromising treatmentefficacy (chapter 8). Similar benefits were shownin
the cross-over study adding fosfomycin to a combination of IV tobramycin
and colistin (chapter 9).
This invites a review of our current antibiotic prescribing practices and emphasises
the need for fluent communication between CF units and their local or regional
microbiology laboratories to help interpret sputum culture results and expand
antibiotic choice. A ceftazidime-resistant transmissible strain of P. aeruginosa (the
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Liverpool Epidemic Strain [LES]) wasfirst described by the neighbouring paediatric
CF unit in 1996 (Cheng et al, 1996). This strain rapidly spread in our unit (and other
CF units in the UK (Scott and Pitt, 2004)), causing chronic infection in nearly 80% of
the Liverpool adult CF population. Reports of excess morbidity and treatment
burden from transmissible strains (Jones et al, 2002; Al-Aloul et al, 2004) lead to a
high level of anxiety among the CF physicians who were keen to treat them as
effectively as possible. Limited understanding of their phenotypic diversity and
complex susceptibility patterns at that time resulted in a unit policy that subjected
our patients to repeated courses of aminoglycosides and / or polymyxins due to the
antibiograms often, but not always, indicating resistance of LES to other
antipseudomonal antibiotics. However, the observation of several cases of acute
renal failure related to this antibiotic combination between 2000 and 2004
challenged this dogma(chapter 5). Subsequently, evidence emerged indiacting that
CF patients improve on antibiotic combinations even when their P. aeruginosa
isolates appear resistant in vitro to one or all antibiotics in that combination (Smith
et al, 2003; Aaron et al, 2005). The validity of conventional in vitro susceptibility
testing itself is questioned in the context of CF: multiple identical looking colonies of
P. aeruginosa isolated from the same sputum sample can give different
antibiograms. Routine susceptibility test results are not reproducible and
underestimate resistance (Foweraker et al, 2005). Synergy testing may help
circumvent someofthese challenges but cost, restricted availability, delayed results
(often not available until the patient has been discharged from hospital) haveall
limited its usefulness. Furthermore, in vitro antibiotic synergy results on isolates
from the same sputum sample can vary depending on the methodology used. A
recent report described poor correlation between the results of the different
methodsof synergy testing (checkerboard, time-kill curve and multiple combination
bactericidal testing [MCBT]), and none of these methods wascapable of predicting
the clinical response to treatment in all patients studied (Foweraker et al, 2009).
Lack of correlation between in vitro susceptibility results and clinical and
microbiological outcomes lead to the CF unit antibiotic policy becominglessrigid:
whilst sensitivity patterns on the antibiogram are still considered, the choice of
175
antibiotic combination is tempered against the individual patient’s previous
experience with successor failure of certain therapy, their backgroundof antibiotic
allergy or intolerance as well as their personal preference (expressed by some
patients more forcefully than others!).
Also of note is the dissociation between acute tubular injury as witnessed by
enzymuria and proteinuria and the improvement in measured CCl after a standard
14 day IV antibiotic therapy of an acute pulmonary exacerbation (chapters 7, 8 & 9).
This highlights the complex interaction between circulatory, oncotic and local
paracrine forces at the glomerular and tubular levels. GFR and_ tubular
absorptive/concentrating capacity could be measuring two different, but closely
interdependent aspects of renal function, relative injury to which, in the face of
different nephrotoxins, is also unclear. CF patients at high risk of cumulative drug
injury should be carefully monitored for tubular function as well as glomerular
performance.
10.5 Recommendations
Based on the literature review and original work contained in this thesis, | would
recommend that CF health care providers adopt the following reno-protective
strategies:
— Alternate antibiotic classes integrating aminoglycoside holidays
— If aminoglycosides have to be used:
* Consider once vs multiple daily dosing regimens
* Chooseless toxic aminoglycosides, if possible
¢ Apply regular drug level monitoring
¢ Employ vigilance with concurrent nephrotoxic agents
* Pay attention to hydration
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* Consider targeted drug delivery with nebulised
aminoglycosides to treat acute exacerbations
* Consider adding fosfomycin to aminoglycoside therapy, to
help protect tubular cell lysosomal membraneintegrity
10.6 Suggestions for future research
10.6.1 Possible different approaches to the present study
If | had a chanceto startall over again, things | would do differently:
e In the absence of a more robust and validated tool, | would endeavourto
apply radioactive agent clearance, as the gold standard reference for
assessing prevalence of renal dysfunction and monitoring long term changes
with therapy. This could be justified in stable outpatients to gauge their GFR
more accurately and remove the confounders surrounding timed urine
collections. It is less applicable howeverin the acute setting when patients
are admitted unwell and at times toxic with an exacerbation. It would not
have been possible or ethical to justify its use in the prospective studies
relating to drug treatment of acute exacerbations (chapters 8 & 9). Instead,
urine markers were more readily measuredin this situation as they did not
add much to the burdenof care the patients endured.
e | would choose a different marker of tubular proteinuria: there are now
commercial assays for measuring urine concentrations of several low
molecular weight serum proteins which leak in tubular disease because of
incomplete tubular reabsorption. Retinol binding protein and glutathione
transferases, for example, are easier to assay than B2M as their structureis
more stable and independent of urine pH (Trof et al, 2006; Bagshawetal,
2007; Coscia et al, 2008). In fact some commercial laboratories now supply
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retinol binding globulin for research purposes, extracted from humanurine
from patients with chronic renal tubular proteinuria.
° Albumin/creatinine ratio instead of measurement of 24-hour proteinuria?
Very little is published on the measurement of proteinuria in CF urine.
Drawing any conclusionis difficult due to the inconsistent reporting, lack of
clarity regarding laboratory techniques and what exactly was being
measured. Thresholds of normality depend on whether one is measuring
urine microalbumin, albumin, protein, albumin/creatinine ratio or
protein/creatinine ratio. Most hospital biochemistry laboratories now offer,
as routine service, measurement of albumin/creatinine ratio (ACR). For
adults without diabetes, significant proteinuria is an ACR of 30 mg/mmolor
more. In diabetics, microalbuminuria is measured and the normal valueis
<2.5 mg/mmolin males and <3.5 mg/mmolin females (Hofmann and Guder,
1989). Microalbumin maystill be significant in other patient groups. Thereis
clearly a continuum between microalbuminuria and
albuminuria/proteinuria.
10.6.2 Validation of new assays of renal function?
10.6.2.1 Cystatin C
Cystatin C, a cysteine protease inhibitor, is a non-glycosylated low molecular weight
protein produced by all nucleated cells. Cystatin C is freely filtered by the
glomerulus before being metabolized by the proximal tubular epithelial cells; that
is, once cystatin C is filtered it does not re-enter the circulation in its original form. It
is theoretically an ideal endogenous marker for estimating GFR as serum cystatin C
is mainly determined by glomerular filtration and is not affected by muscle mass,
sex, or age (Mussap and Plebani, 2004).
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As a simple blood test, measurement of serum cystatin C would offer significant
advantages over standard cumbersome and/or invasive methods for GFR
measurementif it correlated well. Serum concentrations of cystatin C are inversely
related to its clearance, so generally the reciprocal value of the serum cystatin C
sample is used as the comparator. Many, but notall, studies have shown that serum
cystatin C correlates more closely with the reference method used including >*Cr-
EDTA, 1251 labeled iothalamate clearance, iohexol, inulin clearance, and 9mTc- DTPA
than SCr (Dharnidharkaet al, 2002). Although cystatin C is a promising candidate as
an indirect marker for GFR not all studies have shownthatit is superior to using
calculated CCl. In a pooled analysis by Stevens et a/ (Stevens et al, 2008) they
concluded that serum cystatin C levels were nearly as accurate as SCr levels that
had been adjusted for age, sex, and race. A literature review (Zahran et al, 2007)
identified 43 studies that compared the performance of cystatin C and SCr for
estimating GFR. Fourteen of these studies were in patients who had received a
kidney transplant and 70% of the studies favoured cystatin C over SCr. The other 29
studies were in patients with identified kidney disease: none showed superiority of
SCr over serum cystatin C and, 60% of them favoured serum cystatin C. A further 11
studies were identified that directly compared SCr-based equations with cystatin-C-
based equations: cystatin C performed better. This review showedthat cystatin C
was not uniformly better in all patient groups but it may be a preferred option in
certain patient populations. In a study not included in the above review, Perkins et
al (Perkins et al, 2005) monitored renal function in patients with type 2 diabetes
over 4 years. Cystatin C was compared with iothalamate clearance. Perkins et a/
concluded that cystatin C could accurately detect trends in renal function over time
in this patient group. This study may be relevant as many adult CF patients also
have diabetes. Halacova et a/ (Halacova et al, 2008) used cystatin C to assess GFRin
patients with CF who weretreated with IV amikacin. Cystatin C appeared to be a
better marker of GFR than either using SCr or CCI (calculated using a
pharmacokinetic computer programme, MW/PHARMversion 3.3.0). Recently, the
potential role of cystatin C has been specifically explored in patients with CF by
Beringer et a/ (Beringer et al, 2009). Nineteen patients with CF had their renal
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function measured using iothalamate clearance as the gold standard.
Simultaneously, blood samples were taken to measure creatinine and cystatin C
levels. Cystatin C was not only more precise at estimating renal function but also
had greater sensitivity and specificity when compared to two creatinine-based
equations (CGF and aMDRD). They concluded that there might be a role for cystatin
C in measuring renal function in patients with CF.
The advantage of using cystatin C over conventional equations is that no other
patient data are required.
10.6.2.2 Tobramcyin clearance
It has been hypothesized that tobramycin clearance itself could be used as a
predictor of renal function in patients with CF. Smith et a/ (Smith et al, 2006)
reported the role of tobramycin clearance as an indirect measure of GFR in nine
children with CF. Unfortunately, they found that there was little correlation
between GFR measured using an isotopic technique and the values for tobramycin
clearance determined using the ALADDIN method for therapeutic drug monitoring.
Similarly, Levy et al (Levy et al, 1984) found no correlation between measured
creatinine clearance and tobramycin renal clearance. This could be dueto a variety
of factors including the small numbers of patients in these studies and the fact that
approximately 20% of tobramycin is reabsorbed after filtration thus possibly
explaining the observation that the predicted values of tobramycin clearance were
lower than the measured values of GFR (Matthews et al, 2004). In contrast,
tobramycin clearance was found to correlate well with measured creatinine
clearance in 18 adult patients with CF (Touwet al, 1994). The evidence is therefore
conflicting over the actual relationship of tobramycin clearance to GFR. Many
centres now use computerized programmes for therapeutic drug monitoring of
tobramycin and therefore would have access to tobramycin clearance values for
each admission and the capacity to monitor changes in those values. As this
information is readily available, it would seem to be an area that could be
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investigated further to determine the true value of tobramycin clearance as an
indirect measure of GFR.
10.6.3 Interaction between CFRD andrenal function
| did not find a significant interaction between CFRD and antibiotic-related kidney
toxicity in the regressional analysis of the cross sectional data presented in chapter
4. However, In the 36 patients with CFRD included in the study by Etherington et al
(Etherington et al, 2007), baseline urinary NAG levels were elevated at the start of
IV tobramycin treatment in 27 patients and remainedso at their routine follow-up
clinic appointment. This suggests that patients with CFRD may already haverenal
impairment. Mechanisms of this are currently unknown and deserve further
attention. The improved survival of CF patients means they live longer with CFRD,
increasing the risk of developing microangiopathic complications akin to those seen
in the non CF diabetics (Sullivan and Denning, 1989; Westall et al, 2004). In the
absence of histological confirmation, microalbuminuria is a sensitive marker of early
diabetic nephropathy. In a case control study, a higher prevalence of
microalbuminuria in the CFRD group compared with non-CF type 1 insulin-
dependent diabetics was described, even after correcting for blood pressure and
level of glycaemic control (van den Berget al, 2008) but interestingly Etherington et
al found a normal albumin/creatinine ratio in those with and without CFRD
(Etherington et al, 2007). This may reflect the influence of other, as yet
undetermined, CF-related factors on renal function which require further study.
10.6.4 Adequately powered multicentre studies
Collaborations are essential to retest the concepts presented in this thesis with
sufficient power. As mentioned in chapter 8, 80 to 130 patients are required in a
parallel group study to show equivalence between two antibiotic treatment
strategies with 80% power, using FEV1 % predicted as the primary end point and
urinary NAG as the secondary. As experience is shared and data accumulates,it is
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conceivable that sufficient data will be available to define reference ranges for the
CF population with respect to GFR, tubular enzymesand cystatin C. It may even be
possible to draft a CF-specific equation for GFR estimation replacing generic ones
such as CGF. This would allow for a non invasive tool to help deliver individualised
patient-tailored therapy.
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